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Abstract 
Transplantation of foreign tissues into genetically dissimilar recipients, called an 
allograft, results in an inflammatory immune response against the allograft, 
necessitating suppression of the rejection response. However, current 
immunosuppressive drugs broadly supress the immune system and have number of 
associated side-effects. More selective, alternative therapies such as inhibition of T 
cell migration to sites of allograft are for this reason of great interest. CXCR3 is a 
chemokine receptor highly expressed on activated Th1 and CD8+ T cells, with 
elevated expression in patients undergoing allograft rejection and animal models of 
allograft rejection and autoimmune disease.  
Due to the clinical application of islet transplantation for use in patients with diabetes 
we investigated the efficacy of a novel anti-CXCR3 mAb in models of islet 
transplant, autoimmune diabetes and islet transplant into autoimmune diabetic 
recipient mice. We hypothesised that transient blockade of CXCR3 signalling would 
delay islet allograft rejection and alter diabetes incidence. 
As anticipated inhibition of CXCR3 signalling impaired chemotaxis of CXCR3 
expressing cells and prolonged islet allograft survival in models of islet transplant. 
This was associated with reduced CD8+CD44 expression and reduced CD8+ effector 
and memory T cells. An increased frequency of Treg was also seen in islet allograft 
recipients. Further, Islet allograft survival was prolonged in autoimmune diabetic 
allograft recipients, a finding yet to be shown within the literature.  
The role of CXCR3 in diabetes is ambiguous; with some prior studies indicating 
accelerated diabetes onset, while others show a delay. Of note treatment with our 
anti-CXCR3 antibody showed no change in diabetes incidence or pathology. In 
particular recruitment of Tregs from the pancreas to the pancreatic lymph node was 
unaffected, in contrast to previous literature showing impaired Treg migration and 
resultant accelerated diabetes onset. 
Therefore transient antibody targeting of CXCR3 signalling with our antibody shows 
promise for use in allograft, in particular in islet allograft with safety in models of 
diabetes. 
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Chapter 1. General Introduction 
 
The role of CXCR3 in type 1 diabetes and islet 
transplantation 
  
  General Introduction 
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Overview  
The immune system is highly mobile, this key element of its function is determined 
by the secretion and response to a large family of small proteins called 
“chemokines”, taken from the Greek –kinos or movement. The involvement of 
chemokines and their receptors in recruitment of immune cells to sites of 
inflammation is well established
8
. In particular recruitment of T cells to sites of 
inflammation under conditions of damage or infection is crucial for clearance of 
infection and resolution of inflammatory processes
9,10
. Under conditions of 
inflammation in the autoimmune as well as the allogeneic rejection response, 
recruitment of immune cells is unwanted and results in damage to either self-tissue or 
to allogeneic replacement tissues, respectively
11,12
. Additionally, chemokines play an 
important role in immune cell development and homeostasis, dictating the flow of 
immune cells from the bone marrow to peripheral sites for further development
13,14
. 
The immune system plays a key role in many known pathologies, making targeting 
the immune system an appealing therapeutic strategy for intervention
15
. However 
cellular based therapies suffer numerous caveats. For instance current therapeutic 
approaches that target T cells by depletion or by impairing their activation result in 
systemic suppression of the immune system and are often not T cell specific resulting 
in toxicities in other tissues
16-20
. For these reasons other approaches need to be 
explored. Targeting chemokine signalling pathways, which are primarily involved in 
migration of activated T cells towards inflammation, is one appealing therapeutic 
strategy to intervene in these inflammatory responses
3,21-26
. In this thesis we will 
develop this concept further and explore in a series of in vitro and in vivo models, the 
potential for targeting one such chemokine ligand-receptor system, namely the 
CXCR3–CXCL9/10/11 family. 
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Type 1 Diabetes Mellitus 
Classification and Epidemiology 
Diabetes mellitus (DM) is a heterogeneous metabolic disorder characterised by 
hyperglycaemia, which can be subdivided into several distinct subtypes based on the 
pathogenic processes leading to this hyperglycaemia. Of these the two major 
subtypes include type 1 and type 2 diabetes mellitus. Type 2 diabetes mellitus (T2D) 
is a heterogeneous group of disorders characterised by varying degrees of insulin 
resistance, impaired insulin secretion and increased glucose production and accounts 
for approximately 85% of individuals with diabetes. Type 1 diabetes mellitus (T1D) 
is characterised by insulin deficiency, typically due to autoimmune beta cell 
destruction (type 1A) although a small proportion of individuals lack markers 
indicative of autoimmune disease (type 1B).  Of all individuals with diabetes, 
individuals with T1D account approximately 10%
27-30
.  
Diabetes mellitus currently affects an estimated 382 million people, 8.3% of adults, 
with estimates for 2035 predicting a rise to 592 million individuals affected by the 
disease globally
29
. Australia in particular, has an estimated diabetes prevalence of 
7.4%, with approximately 7.7% of these individuals having T1D and one of the 
highest incidence rates of T1D in children globally (22.3 cases per 100,000 
children)
29,31,32
. 
Symptoms 
In individuals with T1D the insulin-producing pancreatic beta cells, within the islets 
of Langerhans, are destroyed through an autoimmune process. Due to the importance 
of insulin secretion in glucose metabolism the loss of insulin results in a number of 
symptoms. Under physiological conditions the pancreatic islets produce both insulin 
and glucacon, which act in concert to regulate blood glucose levels. Insulin secretion 
triggers glucose uptake and storage as glycogen by insulin sensitive tissue such as the 
muscle and liver. In contrast glucagon mediates glycogenolysis, gluconeogenesis and 
ketone body formation by liver and lipolysis by adipocytes in order to breakdown 
glucose stores
27,28,33
. The lack of insulin produced in individuals with T1D results in 
impaired glucose uptake by liver and muscle and dysregulated, elevated glucagon 
levels. If left untreated this results in elevated blood glucose (hyperglycaemia) and 
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symptoms of polyuria, polydipsia and polyphagia, volume depletion, tachycardia, 
hypotension and metabolic acidosis. In extreme cases, if unchecked, hyperglycaemia 
can result in coma and be fatal
27
. In addition to these acute symptoms, chronic 
hyperglycaemia results in an increased risk of severe micro and macro-vascular 
complications including; retinopathy, nephropathy, neuropathy, ischaemic heart 
disease, stroke and peripheral vascular disease
28,30
.  
Genetic and Environmental Susceptibility  
Type 1 diabetes (T1D) results from the interaction of environmental factors within 
genetically susceptible individuals. A role for genetics in T1D is demonstrated by the 
high concordance rate seen within monozygotic twins, which are genetically 
identical, showing between 22.7 to 70% concordance, particularly where T1D 
develops early in life i.e. within the first 10 years. This rate is much higher than that 
seen for dizygotic twins (0-13%) indicating an important genetic component for early 
diabetes, but also highlighting an environmental component, as genes do not account 
for 100% of disease susceptibility
34-37
. The increased risk of T1D in individuals with 
first degree relatives who have T1D provides further evidence for the role of 
genetics
36
. Moreover individuals without diabetes who have first degree relatives 
affected by TID, have significantly greater levels of autoantibodies against islet 
antigens (insulin (IAA), glutamate decarboxylase (GADA), and the protein tyrosine 
phosphatase-like protein IA-2 (IA-2A)), with 31% found to have at least one positive 
autoantibody compared to none in controls who had no first degree relatives with 
T1D
38
. Islet autoantibodies are strong predictors of T1D risk with higher 
autoantibody titer, presence of particular epitopes and IgG subclasses in patient 
serum correlating to increased risk of diabetes development
39
. In addition these 
individuals have worse beta cell function and reduced insulin sensitivity showing 
heritability of the disease
38
.  
T1D is a polygenic disease with at least 50 loci associated with susceptibility to the 
disease
40
, of these the largest contribution comes from the so called Insulin-
Dependent Diabetes Mellitus (IDDM) 1 locus. Linkage of this region to the human 
leukocyte antigen (HLA) class II major histocompatibility complex (MHC) allele 
accounts for over 50% of the genetic risk of developing T1D
40
. Many other non-
HLA genes show strong genetic linkage associated with TID susceptibility, such as 
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IDDM2 a polymorphic locus near the human insulin gene and IDDM12 a 
polymorphism of the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) gene
41-
43
.  
In addition to the genetic component of T1D susceptibility a number of 
environmental factors have been suggested to contribute to disease development, 
though to date this aspect of T1D is not well understood. Of the suggested 
environmental factors birth route via caesarean birth has been shown to increase the 
incidence of T1D, possibly to due lack of exposure to the vaginal microbiome of the 
mother, leading to an altered gut microbiota
44
. Diet has also been suggested to 
contribute to T1D development with early exposure to cows milk leading to an 
increased incidence of T1D. Shorter duration of breastfeeding and earlier exposure to 
cow milk proteins are both thought to alter the gut microbiome which plays an 
important role in development of oral and peripheral tolerance
45,46
. Further, exposure 
to some infectious agents, such as enteral viruses, has been linked to an increased 
diabetes incidence
47
.  However controversy surrounds many of these proposed 
environmental triggers due to a number of conflicting studies
44-46,48-51
. As such more 
research is needed to determine with more certainty the roles of these environmental 
triggers in T1D development. 
Human Pathogenesis and Natural History 
T1D results from an autoimmune destruction of the insulin-producing pancreatic beta 
cells, found within the islets of Langerhans. In 1965 a pivotal article by Gepts et. al., 
noted the presence of a lymphocytic infiltrate, now termed insulitis, and significantly 
reduced number of insulin-secreting beta cells in the pancreatic islets upon autopsy 
of patients with T1D. However glucagon (alpha), somatostatin (delta) and pancreatic 
polypeptide secreting cells were unaffected in these individuals
52,53
. This led Gepts 
and colleagues to propose that; “the islet inflammation may be secondary to a viral 
infection or represent an immunological autoimmune process”52.  
Much research has been since conducted to test the hypothesis that T1D is an 
autoimmune condition. Key studies that support this notion are those which have 
identified islet cell autoantibodies against insulin (IAA), glutamate decarboxylase 
(GADA) and the protein tyrosine phosphatase-like protein IA-2 (IA-2A) in people 
with T1D as well as murine models
54-56
. In addition the identification of islet specific 
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T cell clones, including those against insulin and Islet-specific glucose-6-
phosphatase catalytic subunit-related protein (IGRP) further support the idea that 
T1D exhibits an autoimmune atiology
57,58
. In line with these findings T cell 
suppression using prednisone and anti-thymocyte globulin (ATG) or cyclosporine 
were found to delay onset of T1D
59,60
.  
The major leukocytes found within the islet infiltrate are CD8 cytotoxic T cells 
(CTL) and B cells, with a small proportion of CD4 T cells and macrophages 
occasionally present
11,61-63
. Within the affected pancreas all cells of the islet hyper-
express MHC I and secrete interferon (IFN)-α and this appears to precede insulitis, 
suggesting a role for the islets themselves in the initial activation of an immune 
response against the beta cells
61-65
. Beta cells are also able to secrete chemokines 
(e.g. CXCL10) involved in recruitment of both CD8+ and CD4+ T to the islet, 
providing further evidence for a beta cell specific role in the immune response
66
. 
Collectively these data indicate a role for T cells in the pathogenesis of the disease, 
but most significantly support the concept that T1D has an autoimmune aetiology
54-
60
.  
Study of the natural history of the disease in humans has been limited by its reliance 
on specimens obtained from autopsy of deceased patients with T1D. However our 
current understanding of the pathogenesis of TID has evolved over time with initial 
models suggesting a linear decline in beta cell mass and onset of overt diabetes with 
only 10% residual beta cell mass. These models have now been expanded to 
encompass a relapsing-remitting decline in beta cell mass and onset of overt diabetes 
occurring with variable beta cell mass remaining (40-50% in some individuals)
40,52,67-
69
. The pancreatic pathology also suggests a heterogeneous and lobular distribution 
of affected islets with some islets heavily infiltrated while other neighbouring islets 
are unaffected. Beta cells may also be classified based on insulin content as insulin 
deficient islets (IDI) or insulin containing islets (ICI)
53,65
. The medical significance 
of these patterns is unknown. 
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Animal Models 
Due to the limited availability of human pancreas specimens our current 
understanding of T1D has been heavily reliant on experimental animal models, of 
which the non-obese diabetic (NOD) mouse has been extensively studied. The NOD 
mouse shares a number of important features with the human disease although a 
number of differences should also be noted (reviewed by
70-72
). As for patients with 
T1D, NOD mice show destruction of the pancreatic beta cell with loss of insulin 
production and hyperglycaemia
70
 (Figure 1.1). There is a strong genetic component 
to diabetes in the NOD mouse, with a significant contribution by the MHC and other 
loci that overlap with human loci involved in T1D
73,74
. Further to this, there is also a 
strong environmental influence on disease susceptibility, which appears to relate to 
infection and diet. As an example of this environmental susceptibility, the 
‘cleanliness’ with respect to viral load of the NOD colony is known to significantly 
affect disease penetrance in this model
70,75
. Increased viral load results in a decreased 
diabetes incidence in the NOD colony while specific-pathogen-free mice show a 
greater diabetes incidence
75
.   As understood for T1D, NOD mice also show islet 
specific autoantibodies and T cell autoreactivity against beta cell specific antigens 
(insulin and IGRP) with disease driven by CD4+ and CD8+ T cell cytotoxicity, 
which in the later stages requires the presence of B cells
76-80
. NOD mice also show 
beta cell replication and a type 1 IFN signature early in disease progression, as in the 
human disease
63,77,81-83
.  
The age of onset and staging of disease in the NOD mouse differs from that seen in 
individuals with T1D, with insulitis beginning at 4 weeks of age and overt diabetes 
developing from 12 to 30 weeks of age in 80% of female mice. In comparison, onset 
of overt TID in humans is variable and can present at any age starting from infancy 
into old age
68,71
. The NOD mouse also shows a clear female gender bias, with 80% 
of female but only 10-40% of males developing diabetes, another aspect of the NOD 
disease not seen in humans
72,75
. The inbred nature of the NOD strain also means 
study of this model is representative of a single case study of diabetes, rather than the 
heterogeneous human population
68,71
. Finally NOD mice are able to survive 1-2 
months with hyperglycaemia without requirement of insulin for survival, which is 
not seen in humans and results from their resistance to ketoacidosis
75
. 
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Within the NOD model disease development can be divided into 4 major stages 
based on age and immune infiltrate. Initial infiltrate from 4-6 weeks of age consists 
primarily of antigen presenting cells (APC), as well as CD4+ T cells, found in 10-
30% of islets and accompanied by a type 1 IFN signature. From around 8 weeks of 
age up-regulation of chemokines (e.g. CXCL9, CXCL10, CXCL11, CCL4, CCL5, 
CCL2, CCL22) and adhesion molecules (ICAM-1, VCAM-1), as well as a 7 fold 
increase in T cells, and CD11c+ cell infiltration occurs, with 50-60% of islets 
showing predominantly peri-insulitis
77
. At 11-12 weeks, the point at which 
development of overt diabetes is first seen, a 3 fold increase in marginal zone B cells 
is evident
1,77,81
. An important role for B cell presentation of beta cell antigen, in a 
MHC class 1-restricted manner, to cytotoxic CD8+ T cells for their activation and 
proliferation has been identified
1
. Together this results in progressive beta cell loss 
Figure 1.1: Comparison of Human T1D and NOD diabetes. 
Left; H&E stained islets infiltrated with immune cells (blue) from a pre-diabetic NOD 
mouse and a person  with T1D and pancreas transplant showing recurrent autoimmunity, 
with two neighbouring islets, one heavily infiltrated and one without infiltrate, courtesy of 
S. Pilgrim, Sydney (top) and G. Burke, Miami, (bottom) 
Middle; Insulin stained islets from a diabetic NOD mouse showing heavily infiltrated islets 
(blue) and residual insulin positive cells (brown) and from a healthy person showing an 
islet without infiltrate and insulin positive staining (brown) courtesy of S. Pilgrim, Sydney 
(top) and S. Bonner Weir, Cambridge, Massachusetts (bottom) 
Right; T cell infiltration (green) of an islet from a NOD mouse showing residual insulin 
staining (red) and T cell infiltration (αCD3, brown) of an islet from a person with T1Ds, 
courtesy of S. Grey, Sydney (top) and T. Kay, Melbourne (bottom) 
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and onset of overt diabetes. This time point is associated with a cytotoxic related 
gene profile
77
. Development of diabetes in the NOD mouse is dependent on both 
CD4+ and CD8+ T cells and a breakdown of regulatory and tolerance mechanisms is 
thought to contribute to disease development in the NOD mouse
72,84-88
.  
A number of other models of diabetes exist, briefly these include; the BB rat, which 
develops insulitis and spontaneous diabetes, characterised by hypoinsulinaemia, 
hyperglycaemia, glycosuria, ketonaemia and ketosis. However unlike human or 
NOD diabetes the BB rat displays lymphopenia
89,90
. Models of experimentally 
induced diabetes are also used, one such model is the RIP-LCMV model. In this 
model mice transgenically express the Lymphocytic choriomeningitis (LCMV) viral 
glycoprotein (GP) under the control of the rat insulin promoter (RIP). This does not 
itself result in diabetes but leads to beta cell specific expression of the LCMV GP 
and upon infection of mice with LCMV leads to generation of GP specific CD8+ T 
cell clones, which recognise and destroy GP expressing beta cells leading to 
hyperglycemia
90-92
. 
Therapies 
Currently no cure for diabetes exists and the primary treatment involves 
administration of exogenous insulin typically via multiple daily injections or a pump 
system, which aims to maintain euglycaemia artificially
93
. While most individuals 
with T1D are able to maintain blood glucose levels (BGL) with regular 
administration of insulin, it is an imperfect solution and requires constant monitoring 
to maintain euglycaemia, preventing hyper- or hypoglycaemia
27,93
. The risk of 
complications in individuals with diabetes is significantly reduced through tight 
management of blood glucose, although fear of hypoglycaemia prevents many 
individuals from maintaining optimal glycaemic control
27,93-96
. 
Hypoglycaemia is a severe complication of insulin therapy, characterised by 
palpitations, trembling, sweating, hunger and confusion due to low blood glucose 
levels
97
. Many individuals are able to recognise and respond appropriately to these 
symptoms. However individuals with hypoglycaemic unawareness lack the 
physiological response to hypoglycaemia and have an impaired ability to 
appropriately manage their blood glucose levels. In addition to those with 
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hypoglycaemic unawareness a small group of individuals with diabetes show 
significant variability in their blood glucose level, which is poorly managed by 
exogenous insulin, known as ‘brittle diabetes’. Individuals suffering these more 
extreme episodes make up approximately one third of individuals with T1D and 
suffer recurrent episodes of severe, disabling hypoglycaemia, increasing the risk of 
complications and mortality
27,97-99
. These individuals with hypoglycaemic 
unawareness and brittle diabetes have a significantly reduced quality of life and 
diminished ability to carry out everyday tasks and it is in these individuals that islet 
transplant is advised
27,98,100-102
.  
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Islet Transplantation 
Transplantation 
Transplantation is a medical procedure involving the transfer of organs from a donor 
into a recipient, primarily to replace damaged or absent organs. The evolution of 
modern transplantation began as early as the 2
nd
 century B.C. with incomplete 
accounts of skin autograft performed by Sushruta followed in the 16
th 
century A.D by 
the better documented works of Tagliacozzi
103,104
. In the 1940s the role of the 
immune system in failure of transplants was recognized when skin grafts received by 
burns patients from unrelated donors underwent a process of inflammatory necrosis, 
while skin grafts from the patient themselves successfully engrafted
105,106
. This anti-
graft immune response was termed ‘rejection’ and was followed in the mid-1970s 
with drugs able to suppress the rejection response. These immunosuppressive drugs 
revolutionised the practice of transplantation, impairing the host immune response 
against the donor tissue and allowing successful engraftment of allogeneic tissue
107
. 
Today the use of transplantation is much more widespread, with significant 
improvements in immunosuppressants and surgical techniques leading to higher rates 
of graft and patient survival. A number of organs and tissues are transplantable today 
including; heart, liver, kidney, pancreas, lung, skin and pancreatic islets among 
others. There are however two major caveats to transplantation; firstly the 
availability of donor organs and secondly the immune response to foreign 
tissues
106,107
.  
Allograft Immune Response – A role for T cells 
Transplant of tissues between genetically dissimilar individuals of the same species 
is termed an allograft, with foreign tissues recognised by the recipient immune 
system and rapidly destroyed, leading to organ/tissue rejection. This occurs due to 
the introduction of MHC antigens on the surface of donor cells, designated HLA in 
humans, which differ to those of the recipient
108,109
. These are expressed on all cells 
of the body, with MHC class II molecules expressed by professional APC, primarily 
dendritic cells (DC), macrophages (MØ), monocytes and B cells and MHC I 
expressed ubiquitously on all nucleated cells
109
. The recognition of these genetic 
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MHC variants, termed ‘mismatches’, between the donor and recipient result in a T 
cell mediated immune response against the donor tissue leading to acute allograft 
rejection responses
110
.  
Antigen Presentation (Signal 1) 
Cell mediated immune reactions involve T cells, which can be subdivided into CD4+ 
and CD8+ T cells based on their expression of cluster of differentiation (CD)4 and 
CD8 surface glycoproteins. CD4 and CD8 T cells recognise antigen presented by 
either MHC II or MHC I, respectively, via their T cell receptor (TCR)(Signal 
1)
108,109
. In the transplant setting this interaction between the MHC molecules and 
TCR can occur through direct, indirect or semi-direct antigen presentation and 
represents the first signal of T cell activation. Indirect presentation requires uptake 
and processing of donor expressed MHC into peptides and presentation by recipient 
APCs. Direct presentation involves transfer of donor derived APCs within graft 
tissue, which migrate to the recipients draining lymph nodes and are recognised, via 
their MHC expression, as foreign by recipient T cells
109,111,112
. A more recently 
proposed pathway, the semi-direct pathway of allorecognition, involves uptake of 
intact donor MHC by recipient APC and presentation of the intact allogeneic MHC 
on the surface of recipient APCs
112,113
. The direct and semi-direct pathways of 
recognition are unique to the allograft setting, where foreign MHC II and MHC I are 
introduced with the graft tissue
112-114
. 
T cell Co-stimulation (Signal 2) 
Cell mediated immune reactions also require a second costimulatory signal for 
activation (Signal 2). This involves binding of T cell expressed CD28 to CD80/CD86 
(B7.1/B7.2) expressed by APCs, in addition to a number of other costimulatory 
signals such as CD40-CD40L (CD154). Together with MHC interactions these 
signals activate T cells resulting in expansion and differentiation of antigen activated 
T cells
115-118
 
Cytokine and Chemokine Milieu (Signal 3) 
In addition to TCR and co-stimulation, CD4+ T cells are driven to differentiate into 
effector lineages depending on the cytokine milieu and the cytokine receptors 
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induced during activation
119
. Within the allograft immune response damage at the 
site of the allograft releases pro-inflammatory cytokines and chemokines that 
contribute to T cell activation, differentiation and migration of T cells (signal 
3)
8,16,120-124
. Some of the triggers leading to this damage include mechanical injury 
and infection. Ischemia reperfusion injury, which results from storage, transport, 
transplantation and reperfusion of the organ also results in release of danger 
associated molecules (e.g. DAMPs), damaging the organ
125
. 
The CD4+ T helper (Th) cell subsets involved in allograft rejection include; Th1, 
Th17 and CD4+ regulatory T cells, Foxp3+Treg
126-128
.  
These 3 signals result in activation of antigen specific T cell subsets, which are able 
to both directly damage or provide help to other immune cell subsets, mediating 
allograft rejection and offer attractive therapeutic targets for the prevention of 
allograft rejection. 
T cell Effectors and Immune Regulation 
T cell subsets differentiate based on different environmental cues, signal 1-3 above 
and are characterised by their expression of different transcription factors, cytokines 
and chemokines. Differentiation of the Th1 subset is driven by interleukin (IL)-12, 
IFN-γ, activation of Signal Transducer and Activator of Transcription (STAT) 4 and 
the transcription factor T-bet
123,129,130
. Activated Th1 highly express CXCR3 and 
IFN-γ and are associated with allograft rejection123,131. Alternatively Th cells may 
become Th17 cells, which differentiate in response to Transforming growth factor 
(TGF)-β and IL-6 and release IL-17 and IL-6. Their exact role in allograft rejection 
remains uncertain, although the ratio of Th17 to Tregs appears to predict allograft 
dysfunction and production of IL-17 enhances local inflammation
132-137
. Regulatory 
CD4+ T cells (Tregs) are characterised by expression of the transcription factor 
forkhead box P3 (Foxp3). These may be thymically derived or induced from naïve 
CD4+ T cells in the periphery upon exposure to TGF-β138,139. Tregs are essential to 
peripheral tolerance and can control allograft responses. Indeed, in experimental 
models that allow allograft survival many have found expanded Tregs to be essential 
for this phenomenon. For instance, studies indicate an increased ratio of Tregs to 
CD3+ T cells positively correlates with allograft function. Treg transfer was also able 
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to induce antigen-specific tolerance in allograft models
119,140-144
. The suppressive 
activity of Tregs is attributed to multiple mechanisms but close proximity to the cell 
targeted for regulation appears to be key. Mechanisms of regulation include; 
impaired T cell activation and maturation via IL-10 and TGF-β secretion, inhibition 
of pro-inflammatory transcription factors, cytolysis and cell contact mediated 
inhibition of T cell co-stimulation via CTLA-4
139,145-148
.  
 
Islet Allograft Success and Immunosuppressive Therapy 
The allograft immune response is a major factor hindering the application of islet 
transplantation. However recent improvements in islet isolation techniques as well as 
the introduction of the Edmonton Protocol of immunosuppressive therapy have 
significantly improved islet allograft success rates
101,149,150
 and from 1999 to 2012 a 
total of 864 allogeneic islet transplants were performed (figure 1.2)
151
.  
Although islet allograft success rates have improved from initial transplantation 
outcomes to those seen in 2010, discussed below, a number of issues including; the 
availability of HLA matched donor organs, the risk of surgical complications, 
particularly for pancreas transplant, and most importantly the need for life-long 
treatment with immunosuppressant drugs to prevent graft rejection exist
16,100
. The 
current immunosuppressant regimens required to maintain allograft function broadly 
supress immune function, resulting in a number of side-effects
16,17
. These include; an 
increased susceptibility to infections, development of cancer
18
 and toxic effects of 
the drugs such as nephrotoxicity
19
 and impaired beta cell function (diabetogenic 
drugs)
20
. These toxic side effects may also damage the replacement organ resulting in 
impaired function
152
. In addition current immunosuppressive therapy appears to 
impede development of long-term immunological tolerance
153
.  
These issues limit pancreas and islet cell allograft to the most serious cases
100,154
. 
Islet transplant is also not performed in children or those individuals with diabetes, 
where the benefits of transplant for the individual are outweighed by the requirement 
for life long immune suppression
16,154
. However earlier transplantation in these 
individuals has the potential to improve glycaemic control and may minimise long-
term complications.  
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The advent of the Edmonton protocol, by Shapiro et al., in 2000 revolutionised the 
course of islet transplant with 7 out of 7 patients achieving insulin-independence
149
. 
This drug regimen was corticosteroid free, using an IL-2 receptor antagonist for 
induction together with the mammalian target of rapamycin (mTOR) inhibitor 
(sirolimus/rapamycin) and a calcineurin inhibitor (CNI) (tacrolimus) for 
maintenance
149
. The Collaborative Islet Transplant Registry (CITR) indicates rates of 
51% insulin-independence at 1 year, 36% at 2 years and 27% at 3 years for 
transplants performed from 1999-2002. Transplants performed from 2007-2010 
showed significantly improved insulin-independence rates of 66%, 55% and 44% at 
1, 2 and 3 years post-transplant, respectively. The period from 2007-2010 has also 
seen the use of a T-cell depleting antibody in addition to an antibody that blocks 
activity of the inflammatory cytokine tumour necrosis factor (TNF)-α (etanercept) 
and involves maintenance therapy with an mTOR inhibitor or an inosine 
monophosphate dehydrogenase inhibitor (mycophenolic acid) combined with a 
CNI
149,150
.  
 
 
 
Although a number of individuals are no longer insulin-independent by the 3
rd
 year 
post transplant, islet graft survival (C-peptide ≥0.3 ng/mL) remains in 83% of 
individuals and over 90% of transplanted individuals remain free of severe 
hypoglycaemic and life-threatening events 5 years post-transplant
150
. While insulin-
Figure 1.2: Islet Transplantation 
Collection, isolation and infusion of pancreatic islets from a donor into the portal vein of 
an islet transplant recipient with T1D. Bright field image of human islets curtesy of S. 
Grey and islet transplant image adapted from
7
. 
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independence is as yet suboptimal the improvements seen in blood glucose control 
and absence of hypoglycaemia in individuals who had unmanageable glucose prior to 
transplant, significantly improves their quality of life and manageability of their 
diabetes
101,102,155,156
.   
Current Immunosuppressants 
Immunosuppressant therapies target the 3 main steps in T cell activation; TCR/MHC 
interaction (signal 1), co-stimulation (signal 2) and cytokine & chemokine signalling 
(signal 3), while others exert their function via the depletion of T cells
15,119
.  
Firstly, Tacrolimus and Cyclosporine A function through blockade of nuclear factor 
of activated T-cells (NFAT), impairing T cell activation via inhibition of calcineurin 
(signal 1). However these drugs, also known as CNIs, cause significant 
nephrotoxicity, hypertension and impaired beta cell function
15,157,158
. Sirolimus 
(rapamycin) is an mTOR inhibitor, which also impairs cell cycle, proliferation and 
activation, although mediates this in a calcineurin independent manner
159
.  Co-
stimulatory blockade (signal 2) is targeted by CTLA-4-Ig (Abatacept and Belatacept) 
and anti-CD40 (5C8), which inhibits interactions of CD80/CD86 with CD28 and 
CD40 with CD40L, respectively
160-162
. 
Cytokine signalling (signal 3) is also targeted by a number of drugs. Etanercept 
antagonises TNF signalling, reducing the pro-inflammatory effects of this cytokine 
on the immune system
163
. Basiliximab & Dacilizumab are directed against IL-2Rα 
and impair T cell proliferation and activation
164,165
.  
Finally drugs which deplete T cells include; OKT3, an anti-CD3 antibody and 
aletuzumab, a CD52 targeting antibody. Anti-thymocyte globulin (ATG), a 
polyclonal-immunoglobulin preparation with multiple antibody specificities is raised 
in rabbits or horses against human thymocytes for T cell depletion via complement-
dependent cell lysis
119,166-168
. Importantly use of T-cell depleting antibodies are 
associated with increased cancer risk
167
.  
Each of these drugs have adverse side effects that limit their use, as outlined briefly 
in table 1.1
15
. 
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In addition to inhibiting these stages of T cell activation, the targeting of immune cell 
migration is another attractive strategy. Recruitment of immune cells into sites of 
inflammation is essential in allograft and autoimmune destruction, with local 
production of chemokines causing migration of cells expressing their cognate 
receptors. Therapeutic strategies directed against chemokine receptors preferentially 
expressed by the alloreactive and autoreactive T cells mediating disease may prove 
useful in the design of novel anti-inflammatory therapies. 
Table 1.1: Immunosuppressant Side-effects 
Drug Molecular Target 
(pathway/receptor) 
Primary 
Target Cell 
Population 
Side-effects 
Cyclosporine  TCR activation/Calcineurin-
dependent deposphorylation 
of NFAT 
T lymphocytes Nephrotoxic, 
hypertension,  
Tacrolimus TCR activation / 
Calcineurin-dependent 
deposphorylation of NFAT 
T lymphocytes Nephrotoxic, 
diabetogenic, 
hypertension 
Sirolimus mTOR/complexes with 
FKBP blocking mTOR 
activation 
T lymphocytes Hyperlipidaemia, 
peripheral oedema, 
myelosuppression 
OKT3 Apoptosis of CD3 
expressing cells via Ab 
binding, prevents T cell 
activation 
T lymphocytes 
(mature) 
Cytokine storm, 
pulmonary oedema, 
thrombocytopenia 
Alemtuzumab Binds to CD52 causing 
antibody-dependent cellular-
mediated lysis 
(mature B & T 
cells, NK 
cells, 
monocytes, 
dendritic cells 
Thrombocytopenia, 
fever, hypotension 
Basiliximab T cell differentiation/ 
proliferation/Binds IL-2 
receptor α chain (CD25) and 
competes with IL-2 for 
binding 
T lymphocytes 
(activated) 
Fever and chills 
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Chemokines  
Chemokines are a family of 8-12 kDa peptides, which induce directional migration 
of leukocytes in both physiological and pathological settings. These molecules are 
released by many different cells, both of immune and non-immune origin, in order to 
recruit immune cells into sites of inflammation. Chemokines can be subdivided into 
4 different classes based on cysteine number and spacing. The largest group, 
cysteine-cysteine (CC) chemokines, have the first 2 cysteines in adjacent positions 
and cluster on chromosome 17q11 & q12. The second largest group, CXC 
chemokines, have the first 2 cysteines separated by an intervening amino acid, 
clustering on chromosome 4q12-4q13 and 4q21. Finally the last two groups, 
containing either two highly related or a single unique chemokine, are the C and 
CX3C chemokines respectively. These chemokines consist of either 2 cysteine 
residues (C) or two cysteine residues separated by 3 amino acids (CX3C)
8,169
.  
Each of these chemokines also bind to G protein coupled chemokine receptors, 
which show redundancy with a single receptor able to bind multiple different 
chemokines, although this does seem to be restricted by subclass i.e. CC chemokines 
typically don’t bind CXC receptors. Chemokine receptors have 7 transmembrane 
spaning domains flanked by an acidic extracellular N-terminal and an intracellular C-
terminal
8,170-173
.  
Within the chemokine-chemokine receptor system, in addition to redundancy and 
cross-over between chemokine-receptor targets there is also overlap in the functional 
targets of each chemokine with multiple chemokine-chemokine receptors responsible 
for migration of a single cell type e.g. T cells. Broadly CC chemokines target 
monocytes and granulocytes while CXC chemokines target neutrophils, however 
both families have particular chemokines responsible for directing T cell migration. 
This T cell effect can also be broken down into those chemokines targeting Th1 
(CCR5 and CXCR3) and those targeting Th2 (CCR3 and CCR4) responses
8,131,169
. 
Mechanistically chemokines mediate migration of different cells expressing their 
cognate receptor along a concentration gradient. Upon inflammation, endothelial 
cells of blood vessels up-regulate cellular adhesion molecules (e.g. ICAM-1, VCAM-
1), these adhesion molecules are able to bind to molecules on the leukocytes 
travelling within the circulatory system, slowing leukocytes, which roll across 
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endothelial surfaces. In addition exposure to inflammatory stimuli results in 
endothelial cell expression of proteoglycan bound chemokines, causing activation of 
firm adhesion by integrins and high affinity binding of chemokine receptor 
expressing leukocytes. This synergistic binding both activates leukocytes and causes 
extravasation out of the circulatory system, where cells may then travel along a 
chemokine gradient towards the site of inflammation (figure 1.3)
8,174-176
. In addition 
chemokines are important in spacial and temporal localisation of immune cells 
within lymphoid organs, allowing appropriate T and B cell activation
13
. 
 
 
 
 
 
 
T cells are critical immune cells in the inflammatory reaction. Therefore studying the 
chemokines and receptors which govern their recruitment is important in 
understanding lymphocyte infiltration and also for the development of T cell targeted 
therapies. One of the chemokine receptors shown to be highly expressed in a number 
of cancers, autoimmune diseases and in allogeneic transplantation is CXCR3, a 
chemokine receptor primarily upregulated on activated CTL and Th1 cells
21,177-182
. 
Manipulating the ability of cells to migrate into the islet allograft, or potentially the 
pancreas in pre-diabetic individuals via inhibition of this chemokine receptor is an 
appealing therapeutic concept. 
Figure 1.3: Leukocyte Chemotaxis 
1) Endothelial cells and leukocytes within the circulation become activated by 
inflammation and chemokine exposure up-regulating adhesion molecules (e.g. ICAM-1) 
and their ligands (e.g. integrin) 
2) Fast moving leukocytes are slowed by binding of adhesion molecules and roll along the 
endothelial surface 
3) Slow moving leukocytes firmly adhere to the endothelial surface 
4) Leukocytes transmigrate out of the circulation and migrate along chemokine gradients 
towards inflammation and injury. 
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CXCR3  
CXCR3 is a G-protein coupled receptor (GPCR) composed of a 7 transmembrane 
domain flanked by an intracellular carboxyl (C)-terminal and an extracellular N-
terminus both of which are involved in chemokine mediated receptor activation
2,183
. 
CXCR3 is located on the X chromosome (Xq13)
184
. Up-regulation of CXCR3 
expression occurs in the presence of inflammatory signals with T cell expression 
dependent on the presence of T-bet and IFN-γ signalling and non-persistent T cell 
receptor (TCR) triggering
184-186
. 
CXCR3 exists as 3 alternatively spliced isoforms in humans, the most studied 
CXCR3-A consists of a 368 amino acid sequence of 40kDa, which binds the 3 
classic CXCR3 chemokines; monokine induced by gamma interferon (MIG or 
CXCL9), interferon-induced protein of 10kDa, (IP-10 or CXCL10) and interferon-
inducible T cell alpha chemoattractant, (I-TAC or CXCL11). The CXCR3-B isoform 
has a longer C-terminal domain and in addition to binding the 3 classic chemokines, 
binds platelet factor 4 (CXCL4) with high affinity
183,187,188
. The affinity of binding 
differs for the CXCR3-A and CXCR3-B isoforms. CXCL11 has the highest affinity 
for CXCR3-A with CXCL10 followed by CXCL9 having lower affinity. However 
CXCL4 has highest affinity for CXCR3-B followed by CXCL11, CXCL10 and 
CXCL9
187-190
. Finally, the alternate isoform (CXCR3-alt) differs from CXCR3-A in 
its C-terminus, lacking several transmembrane spanning domains and binding only 
CXCL11
191
.  
CXCR3 Expression 
These CXCR3 isoforms perform differential functions with CXCR3-A expression on 
immune cells important in recruitment to sites of inflammation, as well as for their 
activation and proliferation
2,187,192-194
. However, interestingly CXCR3-B seems to be 
predominantly expressed on cells of the vascular endothelium facilitating angiostatic, 
apoptotic and anti-proliferative functions
5,187,195-197
. CXCR3 is also implicated in 
cancer with higher expression of CXCR3-A and reduced expression of CXCR3-B 
thought to predict poor overall survival due to greater proliferative and migratory and 
reduced apoptotic and angiostatic action
193,195,198
. In mice only the CXCR3-A 
isoform has been identified with high sequence homology (86%) to human 
CXCR3
199
. It is responsible for facilitating chemotactic, proliferative, angiostatic and 
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apoptotic functions of CXCR3, supporting an important biological role for this 
receptor
5,199
.  
CXCR3 is expressed on immune cells with a particularly high expression on 
activated and memory CD4+ Th1 and CD8+ CTL with expression also seen on 
Natural Killer (NK), Natural killer T cells (NKT), B cells and DC
21,177,200-202
. This 
has also been shown in C57BL/6 mice using an anti-CXCR3 monoclonal antibody 
with 23% of CD3+CD4+, 43% of CD3+CD8+ and 34% of CD4+Foxp3+ T cells and 
on 59% of CD4+CD44+ T cells and 85% of CD8+CD44+ T cells
200
.  
CXCR3 Chemokines 
The 3 characteristic CXCR3 chemokines are transcribed in response to IFN-γ, IFN-α, 
IFN-β and TNF-α, triggering calcium mobilisation, and activation of signalling 
pathways involving;  phosphatidylinositide 3-kinases (PI3K)/Protein kinase B (Akt) 
as well as p65 nuclear factor kappa-light-chain-enhancer of activated B cells (NFκB) 
or c-Jun N-terminal kinase/ Janus kinase (JAK)/STAT-1
189,203-208
.  
Importantly the expression of these chemokines relies on different cytokines and 
signalling through different promoters, resulting in temporally and spatially different 
expression patterns for the 3 chemokines and accounting for the various roles of 
CXCR3. CXCL9 production is dependent only on IFN-γ mediated signalling, while 
CXCL10 and CXCL11 production are induced by IFN-γ, IFN-α, IFN-β and TNF-α4. 
All of the CXCR3 chemokines can be produced through the common promoter NF-
κB. Additionally the CXCL9 promoter contains an IFN-response element (γIRE-
1)
208
, the CXCL10 promoter contains an IFN-stimulated response element (IRSE)
205
 
and the CXCL11 promoter contains an IFN-regulatory factor 1 (IRF1)
209
 each of 
which can also induce these CXCR3 chemokines.  
While IFN-γ is responsible for the transcription of these chemokines it is also 
essential in up-regulation of CXCR3 expression
185
. This results in recruitment of 
CXCR3 expressing immune cells, CD4+ Th1, CD8+ cytotoxic T cells and NK cells, 
in response to CXCL9, CXCL10 and CXCL11 release. These cells in turn secrete 
further IFN-γ increasing chemokine secretion and immune cell recruitment resulting 
in an inflammatory amplification loop and exacerbation of inflammation
5
 (Figure 
1.4). 
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Receptor Structure  
CXCR3 signalling and internalisation are activated by chemokine binding through 
alternate receptor domains. For this reason a number of studies have investigated the 
importance of these domains in activation and internalisation of the human CXCR3 
receptor with absence resulting in impaired or abrogated ligand binding and 
consequently reduced downstream signalling, calcium mobilisation, actin 
polymerisation and chemotaxis as well as receptor internalisation
2,183
. 
Briefly, using a pre-B cell leukaemia cell line transfected to express human CXCR3 
a number of regions of the extracellular N-terminus have been shown to play an 
essential role in chemokine binding and receptor activation, while the intracellular C-
Figure 1.4: CXCR3 in immune cell migration 
1. Upon insult/injury/infection inflammatory cytokines (IFN-α, IFN-β and TNF-α) are 
produced locally. 2. This triggers CXCL10 release fromendothelial and other tissue resident 
cells 3. CXCL10 forms a concentration gradient and recruits circulating Natural Killer (NK) 
and CD4+ Th1 cells into the target tissue. 4. NK and Th1 cells secrete IFN-γ, stimulating 
resident cells, including local dendritic cells (DCs) to 5. increase chemokine (CXCL9 & 
CXCL10) release. 6. These chemokines recruit CD8+ CTLs into the target tissue, 7. which also 
produce IFN-γ, stimulating chemokine production and amplifying the inflammatory response. 
Adapted from
4,5
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terminal domain and 3 cytoplasmic loops are involved in CXCR3 internalisation 
(figure 1.5, human CXCR3-A).  
 
 
 
 
 
 
CXCL9, CXCL10 and CXCL11 require conservation of N-terminal residue R216 of 
the second extracellular loop, tyrosine phosphorylation of Y29 and Y27 and charged 
residues D112 and D278 for optimal binding. Charged residues D282 and E293 are 
also required for CXCL9 and CXCL10, while the proximal 16 amino acids and 
residues R197 and R212 of the second extracellular loop are necessary for CXCL10 
and CXCL11 binding but non-essential for CXCL9.  
Figure 1.5: Snakeplot structure of Human CXCR3-A amino acid sequence 
Including transmembrane conformation and residues of importance to receptor activation 
and signalling as well as internalisation: 
Red: location of anti-CXCR3-9C5 binding, also contains Y27 and Y29, essential in 
chemokine binding and receptor activation 
Green: S245 necessary for CXCL11 migration, actin polymerisation and integrin 
dependent adhesion, LLL motif necessary for CXCL11 receptor internalisation and 
migration 
Blue: D112 & D278 for binding and activation by CXCL9, CXCL10 and CXCL11, D282 
and E293 for binding and activation by CXCL9 and CXL10. Adapted from
6
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The intracellular C-terminus of human CXCR3 is necessary for CXCL9 and 
CXCL10 internalisation, dependent on serine/threonine phosphorylation of the C-
terminal and for CXCL11 internalisation, dependent on conservation of the third 
intracellular loop. A DRY (aspartate-arginine-tyrosine) motif in the third 
transmembrane domain is necessary for CXCL9, CXCL10 and CXCL11 induced 
chemotaxis and calcium mobilisation, while the C-terminal LLL motif is also 
necessary for chemotaxis in response to CXCL9, CXCL10 and CXCL11 but not 
calcium mobilisation or receptor internalisation
183
.  
Signalling Pathways 
Activation of signalling pathways by CXCR3 depends on the ligand as well as the 
receptor isoform, G-protein and cell type involved leading to primarily 
chemotactic/proliferative or apoptotic/angiostatic effects
187,203
. Upon ligand binding, 
GPCRs signal through G proteins α, β and γ causing activation of the regulatory α 
subunit and dissociation of the catalytic β, γ subunits210.  
Using a number of in vitro studies it has been identified that human CXCR3 signals 
primarily through the pertussis toxin (PTX) sensitive G-protein, Gαi. However the 
actions of CXCR3-B have been found in some cases to facilitate PTX insensitive 
activation, with proliferation of CXCR3-B transfected cells unaffected by PTX
187,203
. 
Conversely the CXCR3-B selective chemokine CXCL4 was shown to mediate PTX 
dependent signalling in T cells
203
. For this reason it is thought that signalling of the 
CXCR3-A isoform occurs through Gαi, while CXCR3-B generally signals through 
Gαs187,194,203. Ligand driven human CXCR3 receptor activation stimulates a number 
of signalling pathways with all 4 CXCR3 ligands able to activate calcium 
mobilisation and signalling through Extracellular signal-regulated kinases (ERK)1/2 
(Ras/Raf/Mek), Mitogen-activated protein kinase (MAPK) and PI3K/Akt 
pathways
194,203
. Ligation with CXCL11 stimulates the most rapid and sustained 
response for CXCR3-A and similarly CXCL4 is the dominant stimulator of CXCR3-
B
187,194,203
. However CXCL4-CXCR3B signalling shows significantly lower calcium 
mobilisation and does not result in internalisation or chemotaxis
203
.  
In human derived T cells it was found that although CXCL11-CXCR3 ligation 
induced MAPK and PI3K/Akt signalling neither pathway was responsible for 
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chemotaxis, instead this occurred through Phospholipase C (PLC) and F-actin 
polymerisation
194
. It was also found that while ERK signalling was in part 
responsible for human CXCR3 mediated chemotaxis it also displayed a pattern of 
biphasic activation associated with mitogenic and proliferative activity
196
. CXCR3-B 
mediates apoptotic and anti-proliferative functions though a number of pathways 
including inhibition of the anti-apoptotic gene heme-oxygenase 1 (HO-1), via 
MAPK, and blockade of ERK1/2 signalling. Increased survival and proliferation of 
human breast cancer cells was seen upon inhibition of CXCR3-B
195
. Human CXCR3 
ligation has also been shown to phosphorylate a number of molecules downstream of 
the TCR (ZAP-70, LAT and PLCγ1), which suggests cross-talk between these two 
molecules and possibly a co-stimulatory role of CXCR3 in T cell activation
203,211
. 
Studies conducted in mice have identified only the CXCR3-A isoform, which 
therefore must regulate the opposing functions seen for CXCR3-A and CXCR3-B in 
humans. In vivo and in vivo studies using C57BL/6 wild type (WT) and CXCR3-/- 
mice have shown CXCR3-B-like functions with CXCL9 found to inhibit VEGF 
induced angiogenesis, proliferation and migration. This occurred via reduced PLCγ 
and ERK phosphorylation reducing angiogenesis and fibrosis in endothelial and 
stellate cells from fibrotic mouse livers
212
. In contrast CXCL10 expression in cardiac 
allografts, of WT and CXCL10-/- B6/129 (C57BL/6x129Sv/J (H-2
b
)) mice, was 
essential for immune infiltration of allograft, mediating CXCR3-A-like functions
213
.   
Due to the varied roles of CXCR3 it has been identified as a potential therapeutic 
target in a number of disease processes, most importantly cancer, transplantation and 
autoimmunity
178-182,214,215
. Due to the potential benefits of reduced immune cell 
trafficking to sites of inflammation in autoimmune and allogeneic conditions, such as 
Type 1 diabetes and islet transplantation, investigation of CXCR3 mediated immune 
cell migration is of great interest. A number of studies have investigated CXCR3 as a 
therapeutic target with deletion or use of antibodies against CXCR3 and its 
chemokines showing beneficial effects for some but not all studies
216,217
.  
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Experimental Models  
CXCR3 in Inflammation  
The role of CXCR3 in health and disease is highly complex, orchestrating a number 
of processes from recruitment of immune cells
22
 to wound healing
218
 and viral 
clearance
219,220
. Under normal immune conditions CXCR3 is important in the anti-
viral immune response. One in vivo study investigated this effect using vaginal 
infection of C57/BL6 WT and CXCR3-/- mice with HSV-2 revealing a role for 
CXCR3 in CD8+ T cell cytotoxicity, T-bet, perforin and granzyme B expression
219
. 
Further, in vivo models using OT-I TCR transgenic WT and CXCR3-/- mice on a 
STOCK Tg(CAGDsRed*MST)1Nagy/J background were infected with vaccinia 
virus revealing impaired ability of immune cell invasion and contact-dependent 
interactions with virally infected cells, leading to poor viral clearance in CXCR3-/- 
mice
220
.  
A model using adoptive transfer of P14 LCMV-specific T cells, comprised of WT & 
CXCR3-/- cells, into C57BL/6 recipient mice followed by infection with LCMV lead 
to reduced development of short-lived effector T cells when transfected with 
CXCR3-/- cells. Further, co-localisation of CD8+ virus specific T cells and antigen 
presenting cells in the splenic marginal zone of irradiated C57BL/6 mice was 
impaired when mice were adoptively transferred with C57BL/6 WT & 
Rag2−/−CXCR3−/−OT-I bone marrow and infection with vaccinia virus (VV)-OVA. 
Together these models suggest an import role for CXCR3 in T cell-APC co-
localisation and subsequent T cell development
221,222
. In addition in vitro studies 
using OVA specific CD8+ T cells from IRF-9-/- C57BL/6 mice suggest that CXCR3 
signalling via a type 1 IFN dependent pathway preferentially affects proliferation and 
activation (CD25 and CD69 expression) of naïve (CD44
low
) CD8+ T cells
192
.  
Activated Th1 and CD8+ CTL cells highly express CXCR3
22
, which is necessary for 
their recruitment to sites of infection but is also involved in deleterious effects seen 
under conditions of disease and uncontrolled inflammation, e.g. autoimmunity. For 
this reason the roles of CXCR3 signalling in numerous models of inflammatory 
disease have been investigated using either antibody blockade or deletion of CXCR3 
signalling, via administration of anti-CXCR3 antibodies or gene deletion.  
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Inhibition of CXCR3 signalling reduces immune cell chemotaxis to inflamed sites, 
such as; the dermis, lymph nodes and prostate and is also involved in migration in 
response to renal ischemia reperfusion injury, arthritic pathology and experimental 
allergic encephalomyelitis (EAE)
3,22-25
.  
Lymphocyte recruitment is reduced in rats following anti-CXCR3 antibody 
administration in a Mycobacterium butyricum induced arthritis model
3
 as well as in 
Ischemia reperfusion injury in Sprague–Dawley rats, using temporary left renal 
occlusion, following treatment with the CXCR3 antagonist TAK-779
24
. The 
antagonist TAK-779 also reduces immune cell infiltration of the prostate in a 
NOD/LtJ mouse model of Experimental autoimmune prostatitis, using immunization 
with a mixture of prostate antigens in CFA
23
. Further antagonism of CXCR3 using 
SCH546738 in experimental autoimmune encephalomyelitis (EAE), induced by 
immunization of C57BL/6 mice with pertussis toxin and myelin peptide (MOG 35-
55) in CFA, lead to reduced disease severity and delayed onset
25
. Disease severity 
and immune cell recruitment to the colon are also reduced in an experimental IL-10-
/- C57BL/6 mouse model of colitis following administration of anti-CXCL10 Ab
223
. 
Finally, CXCR3-/- C57BL/6 mice had reduced recruitment to sites of inflammation 
in models of collagen-induced arthritis, Complete Freunds adjuvant (CFA) induced 
LN inflammation and TLR agonist (poly I:C and LPS), Con A and OVA induced 
dermal inflammation
22
. In addition within this model of dermal inflammation over 
90% of Th1 and CD8+ CTL expressed CXCR3
22
.  
In contrast to the beneficial effect seen in these studies, a further study looking at the 
effects of an anti-CXCL10 antibody found no significant difference in recruitment or 
disease severity in multiple models of inflammatory disease. These models included; 
collagen induced arthritis induced in DBA/1 mice, EAE induced in SJL/J mice using 
immunization with a myelin protein (proteolipid protein) in incomplete Freunds 
adjuvant and inflammatory bowel disease (IBD) induced by CD4þ CD45RBHi T cell 
transfer from female CB6 F1 mice to female CB17 scid/scid mice. Of note however, 
initial in vivo studies on CD8+ T cell chemotaxis found inhibitory effects of the 
antibody occurred only at high doses (1000ug i.p.), while all further experimental 
studies used significantly lower doses (8-500ug i.p.)
224
.  
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In addition to expression on effector T cells, CXCR3 is expressed on a subset of Th1 
Tregs. These Tregs are induced in response to Th1 conditions and upregulate 
CXCR3, under the control of T-bet, and regulatory markers (IL-10, TGF-β, 
Granzyme, CTLA-4, GITR, CD103). These Treg show superior ability to suppress 
Th1 mediated inflammatory disease
225
. In models of CXCR3 deficiency in both the 
NOD and C57BL/6 mouse CD25+Foxp3+Treg were found to accumulate in the 
spleen and draining lymph nodes with reduced ability to infiltrate the inflamed 
pancreas an liver, respectively
217,226
. However other studies have indicated no impact 
of CXCR3 blockade or deficiency on Treg migration to sites of inflammation with 
improved disease outcomes
124,200,227
. One study found impaired migration of Th1 and 
CTLs in CXCR3 deficient mice, while migration of Treg to the inflamed dermis was 
unaffected
22
.  
Taken together the role of CXCR3 on regulatory T cells appears to be variable with 
an important role for migration of Th1 specific Treg and suggesting redundancy or 
use of alternative chemokine receptors for recruitment of other Treg subsets. Given 
the number of studies showing beneficial results for inhibition of CXCR3 in 
inflammatory diseases, it is likely that other subsets of Treg, which are less 
dependent on CXCR3, are involved in Th1 mediated diseases. 
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CXCR3 in Diabetes 
A number of human studies of patients with T1D show increased expression of 
CXCR3 and its ligand CXCL10, with elevated expression correlating with recent 
onset of overt diabetes
214,228-234
. Elevated expression of CXCR3 has also been 
suggested to be a good predictor of diabetes development in high risk first degree 
relatives
178
.  
CXCR3 and its’ ligands, particularly CXCL10 are involved in both immune cell 
recruitment to the pancreas and in impaired beta cell survival or proliferation
66,124,235
. 
The beta cells, originally thought of as innocent bystanders in the immune mediated 
attack, are now known to express CXCR3 and CXCL10 following initial 
inflammatory insult. CXCL10 acts in an autocrine/paracrine manner through toll-like 
receptor (TLR)-4, rather than CXCR3, to enhance Akt driven apoptotic signals, 
impair insulin secretion and reduce beta cell viability resulting in decreased beta cell 
mass, independent of insulitis
66,124,235
. CXCL9 is also expressed by islet vascular 
endothelial cells rather than beta cells and contributes to immune cell recruitment
235
.  
Investigation into the role of these chemokines in in vivo models of diabetes using 
virally induced RIP-LCMV transgenic mice revealed a role for CXCR3 in the 
recruitment of T cells into the pancreas. Following infection with LCMV, 
development of LCMV specific CD8+ T cells occurs, which are recruited to the 
pancreas where LCMV-GP is expressed. In CXCR3 deficient C57BL/6 mice this 
recruitment of immune cells into the pancreas was significantly impaired and 
consequently diabetes onset was also significantly delayed in this model
124
. However 
these results were not replicable in further studies in RIP-LCMV transgenic mice. 
Little to no delay in onset of diabetes or insulitis was evident in C57BL/6 RIP-
LCMV mice deficient in CXCR3 (B6.129P2-Cxcr3tm1Dgen/J) or CXCL10 
(B6.129S4-Cxcl10tm1Adl/J) or in C57BL/6 RIP-LCMV mice following treatment 
with an anti-CXCL10 mAb or CXCR3 antagonist NIBR2130236,237.  
Within the NOD mouse CD4+ T cells and CD4+Foxp3+ regulatory T cell migration 
are dependent on CXCR3 expression
217
. In CXCR3 deficient NOD mice 
accumulation of CD4+Foxp3+ Treg in the pancreatic lymph node and loss of 
pancreatic infiltration were evident, resulting in enhanced diabetes incidence
217
. Of 
note disease penetrance and diabetes incidence in this model was quite low. 
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Additional studies in the NOD mouse used deletion of the inflammasome component 
NLRP3 (nucleotide-binding oligomerisation domain leucine rich repeat and pyrin 
domain-containing protein), which is involved in Th1 cell activation, proliferation 
and migration into the pancreatic lymph node and pancreas. This study found that 
NLRP3 deficiency altered chemokine-chemokine receptor expression with increased 
CXCR3 and CCR5 in the spleen but reduced expression of the chemokine-receptors 
and their chemokines in the pancreas. Together this lead to impaired migration of 
activated Th1 cells into the pancreas, though no change in the migratory ability of 
Tregs was noted
238
.  
Overall, data on the effect of CXCR3 blockade or deletion within the diabetes 
literature is variable. Some studies show that reduced CXCR3 expression provides an 
inhibitory effect on autoreactive infiltrating T cells, reducing disease incidence. In 
contrast other studies show that CXCR3+ Tregs are essential in prevention of the 
disease and loss of this chemokine receptor prevents their migration, increasing 
diabetes incidence upon CXCR3 gene deletion. 
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CXCR3 in Allograft 
Within the context of allograft transplantation the chemokine receptor CXCR3 and 
its chemokines are upregulated in kidney, heart and lung donor organs and are also 
expressed by pancreatic islets
66,179,180,182,239,240
. Xenograft models of kidney or islet 
transplant from pig to non-human primate also indicate an upregulation of CXCR3 
and its chemokines during allograft rejection
241-243
. 
Using a model of BALB/c (H-2
d
) murine cardiac allograft into C57BL/6 or 
C57BL/6x129Sv/J (H-2
b
) mice expression profiles of CXCR3 and its ligands show 
upregulation of CXCR3 and CXCL10 by cardiac endothelial cells within 24hrs
213,216
. 
Donor derived CXCL9 expression has also been shown to increase at 24 hours upon 
exposure to IFN-γ secreting memory CD8+ T cells following A/J (H-2a) cardiac 
allograft into C57BL/6 (H-2
b
) mice
244
.  This is followed by expression of CXCL9, 
CXCL10 and CXCL11 by the cardiac endothelium and infiltrating macrophages and 
lymphocytes at day 3 and persisting to day 7 when rejection typically occurs. mRNA 
expression of chemokines; CCL3, CCL4, CCL5, CXCL2 CXCL9, CXCL10 and 
CXCL11, as well as their receptors; CCR1, CCR2, CCR5, CXCR4 and CXCR3 were 
all increased in wild type BALB/c (H-2
d
) cardiac allografts into C57BL/6 or 
C57BL/6x129Sv/J (H-2
b
) recipients
213,216
. For cardiac allograft from BALB/c (H-2
d
) 
mice into C57BL/6x129Sv/J (H-2
b
) mice the number of CXCR3 expressing cells was 
shown to increase steadily over the course of allograft rejection, with NK cell 
infiltrate peaking at day 3 and CD3+ cell infiltrate progressively increasing until 
graft loss at day 7
213
. Importantly models using cardiac allograft of WT BALB/c 
hearts into C57BL/6 CXCR3 deficient recipient mice or transplantation 
C57BL/6x129Sv/J CXCL10 deficient donor hearts into WT BALB/c hosts show 
significant prolongation of graft survival (~60 and 40 days, respectively) and reduced 
immune cell infiltration of cardiac allografts. This indicates that in cardiac allografts 
the initial release of donor derived CXCL10 chemokine drives chemotaxis of 
recipient immune cells expressing CXCR3 to the graft
213,216,245
. Monoclonal 
antibodies against CXCR3 or CXCL10 also prolonged BALB/c cardiac allograft 
survival when transplanted into C57BL/6 or C57BL/6x129Sv/J recipients. This was 
characterised by intact myocardium and vasculature and reduced CD4+ and CD8+ T 
cell infiltration, albeit to a lesser extent than seen in knockout models (~20 and 14 
days, respectively)
200,213,216
.  
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In addition to cardiac allografts, skin allografts from C56BL/6 (H-2
b
) donors were 
also shown to upregulate CXCR3 and its chemokines CXCL9, CXCL10 and 
CXCL11 when transplanted into MHC mismatched BALB/c (H-2
d
) recipients, 
compared to isografts. Treatment of skin allograft recipients with an anti-CXCL11 
antibody did not alter pro-inflammatory cytokine expression (INF-γ, TNF-α) or 
proliferation within the allograft. However a reduction in immune cell infiltration of 
the graft and prolonged survival was seen in anti-CXCL11 treated compared to 
untreated mice
246
. C57BL/6 CXCR3 deficient MHC mismatched skin allografted 
into BALB/c (H-2
d
) recipients also resulted in prolonged allograft survival compared 
to wild type allograft recipients
245
.  
Biopsies from rejecting human lung allografts also showed high expression of 
CXCL10 by infiltrating and alveolar macrophages, as well as epithelial cells, which 
were obtained from patient bronchiolar lavage fluid (BAL) samples. BAL was highly 
chemotactic for CXCR3 expressing, IFN-γ+ T cells (Th1 and CTL), which was 
inhibited by anti-CXCR3 or anti-CXCL10 antibodies
240
. A model of lung allograft 
rejection in mice, used transfer of a C57BL/6 CXCR3-/- or WT CD8 T cell clone 
specific for OVA antigen (OT-I), into C57BL/6 CC10-OVA mice expressing OVA 
antigens on the cells lining their airway. The mice transferred with CXCR3-/- CD8 T 
cells displayed significantly improved graft survival and reduced lung infiltration 
compared to those transferred with WT CD8 T cells. Interestingly a significantly 
increased number of Tregs were recruited to the lung, in a CCR6 and CCR7 
dependent but CXCR3 independent manner. The study proposed that under normal 
circumstances both CD8+ T cells and Tregs are recruited to the lung, however the 
ratio of Teff:Treg is insufficient to prevent rejection. The reduction in Teff cells 
recruited to the lung in this CXCR3-/- model, paired with increased Treg 
accumulation, appear sufficient for the prevention of rejection
247
. 
The role of CXCR3+ cells were also characterised in a model of graft versus host 
disease (GVHD) with CD8+ T cell transfer from C3H.SW (H-2Db CD45.2+) mice 
into irradiated B6/SJL(H-2Db CD45.1+) recipients Disease was inducible by both 
CXCR3+ and CXCR3- cell transfer, although CXCR3- cells were found to 
upregulate CXCR3 upon APC stimulation to mediate this effect. These 
CXCR3+CD8+ T cells showed higher expression of cytotoxic markers (TNF-α, IFN-
γ, Granzyme B, FasL and Annexin B) with an increased ability to lyse target cells 
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and mediate GVHD, compared to CXCR3- CD8+ T cells. GVHD was prevented in 
this model upon anti-CXCR3 mAb administration for 21 days, but not when 
administered for 7 days. This is thought to be due to the ability of CXCR3-CD8+ T 
cells to upregulate CXCR3 at the earlier time point but not later in disease 
progression
248
. 
Although CXCR3 has been found to have an important role in allograft rejection, 
redundancy within the chemokine system exists and as such loss of CXCR3 does not 
confer complete protection on its own. However, in combination with inhibition of 
other chemokine receptors, such as CCR5, which is also responsible for T cell 
chemotaxis, improved allograft survival was evident. WT BALB/c (H-2
d
) cardiac 
allograft into B6;129P-Cmkbr5tm1Kuz (H-2
b
) CCR5-/- recipient mice or WT 
B6;129PF2/J recipient mice treated with an anti-CXCR3 mAb resulted in allograft 
survival of 29-34 days. However when CCR5-/- mice were treated in combination 
with an anti-CXCR3 mAb, 100% of WT BALB/c (H-2
d
) cardiac allografts showed 
long term survival for over 100 days
249
. Interestingly, while graft infiltration was 
significantly reduced, an increased frequency of graft infiltrating Tregs were present. 
These cells play a crucial role in long-term graft survival, as indicated by graft loss at 
post-operative day (POD) 22 upon depletion of these cells
249
. Use of a small 
molecule antagonist, TAK-779, which targets CCR5 and CXCR3, was also shown to 
improve cardiac (C57BL/6 H-2
b
 > BALB/c H-2
d
) and islet (C57BL/6 H-2
b
 > 
C3H/HeJ H-2
k
) allograft survival, although mean survival times were increased only 
by ~5days compared to controls, rather than long-term survival seen with the 
previous study. Immune cell recruitment and expression of inflammatory 
chemokines (CCL3, CCL2 and CCL5) and cytokines (TNF-α, IFN-γ, IL-4 and IL-
10) were all reduced with preserved cardiac allograft morphology
250
. 
A role for islet allograft survival has also been shown in a number of studies. 
However, typically these studies focus on cardiac allograft, with minimal data on the 
islet allograft. It is important to note that although similarities within allograft 
rejection exist, tissue specific differences, such as for vascularised vs. non-
vascularised grafts are important considerations. In support of this, differential 
functions of the chemokine receptor CCR2 have been shown, via MHC mismatched 
allograft from WT BALB/c (H-2
d
) donors into WT or CCR2-/- C57BL/6 (H-2
b
) 
recipients. Using these models CCR2 was shown to have an important early role in 
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islet allograft rejection but no significant role was seen for cardiac allograft 
rejection
251
. Studies on BALB/c (H-2
d
) or C3H/HeJ (H-2
k
) donor islet allograft into 
C57BL/6 (H-2
b
) recipients show promising results with administration of an anti-
CXCR3 mAb or the TAK-779 antagonist, found to prolong mean islet allograft 
survival from 12.5 to 25 days or 22 to 28 days, respectively. Further, histology from 
treated mice indicates a reduced immune cell infiltration of the islet allograft
200,250
. 
The study in 2003 by Baker et al. on the role of CXCR3 and its ligand CXCL10 in 
islet allograft represents a more in depth investigation of the role of this signalling 
pathway in islet allograft. Using either CXCR3 deficient or anti-CXCL10 antibody 
treated C57BL/6 (H2
b
) recipients of A/J strain (H2K
a
) islets grafted under the kidney 
capsule, Baker et al. found a significant prolongation of graft survival for both 
treatment groups (~20days) compared to controls (~12.7days). Further investigation 
revealed that although graft chemokine expression (CCL5, CCL3 and CXCL10) was 
not different for treated compared to controls a significant reduction in CD8 T cells 
was evident (both mRNA and graft histology) as well as reduced markers of NK 
cells, CD4 T cells and macrophages (CD19, CD4, F4/80)
252
.  
Fully MHC-mismatched BALB/c (H-2d) to C57BL/6 (H-2b) cardiac allograft 
survival is also further enhanced by synergistic effects of CXCR3 inhibition and low 
dose immunosuppressive therapy (rapamycin or cyclosporine A) resulting in 
permanent engraftment of 100% of cardiac and 80% of islet allografts
200,216
.  
Taken together this indicates that although the role of CXCR3 in islet allograft 
rejection has not been extensively studied, its roles in immune cell migration into 
sites of allograft are well characterised. In particular inhibition of CXCR3 signalling 
has been shown to significantly prolong islet allograft survival. 
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Thesis Aims 
Inflammation is a naturally occurring process, responsible for clearance of infections 
and dead or damaged tissues and initiation of tissue repair. However an inflammatory 
disease represents a condition where inflammation is not controlled, characterised by 
continuous recruitment of immune cells to target sites resulting in collateral damage 
to local tissues. In the context of autoimmune disease this inflammation is 
misdirected specifically at self-tissue, while in allogeneic transplantation 
inflammation occurs against non-self-tissue. In both circumstances T cells are 
recruited to sites of inflammation and play a critical and unwanted role in tissue 
damage. Chemokines and their receptors are necessary for recruitment of T cells, as 
well as other cells involved in the autoimmune and alloimmune inflammatory 
processes, making them an appealing therapeutic target to intervene in these 
inflammatory responses. 
The current landscape of available immunosuppressants is limited by their broad 
action, impairing the response against auto- and allo-antigens, as well as those 
responses to viral infection and cancer. In addition many of these drugs display 
adverse side effects or toxicity towards tissues such as the kidney
16-20
. For this reason 
much research is currently being conducted to identify new therapeutic targets as 
alternatives to current immunosuppressive therapy.  
One such approach would be to impair lymphocyte migration to sites of 
inflammation via chemokine receptor blockade. To test this idea we have developed 
a novel anti-CXCR3 monoclonal antibody, targeting a conserved epitope found in 
mice, non-human primates and humans. Due to the long-term risks associated with 
current immunosuppressant regimens, which limit the use of islet transplantation to 
individuals with severe, unmanageable T1D, we determined the efficacy of this 
antibody in mouse models in the context of islet allograft and T1D, for use clinically 
in islet transplant into patients with type 1 diabetes. 
In addition to a clinical application in islet transplantation we were interested in 
targeting CXCR3 broadly in inflammatory responses as a T cell targeting therapy
3,23
. 
Historically these therapies directed at T cells, such as tacrolimus and ATG
15
, have 
shown promise in the clinic and due to the importance of CXCR3 in regulating 
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proliferation, activation and migration of T cells we believe this will be another 
encouraging target
15,188,192,197,253-255
. Mouse models of islet allograft transplantation 
and diabetes will also offer insight into the efficacy of our antibody broadly in 
inflammation. The conserved nature of our antibody in mice and humans also makes 
results generated in the mouse model more readily translatable for clinical 
application by humanising the antibody
254
. 
The chemokine receptor CXCR3 is highly expressed on Th1 and CTLs and has been 
shown to play an important role in recruitment of these cells into sites of 
inflammation
21,177,187,194
. Previous literature has also shown that expression of 
CXCR3 correlates with both onset of diabetes
214,228-234
 and allograft 
rejection
66,179,180,182,239,240
. CXCR3s’ involvement in allograft rejection is well 
established in mouse models
200,216
. However the role of CXCR3 signalling in the 
development of diabetes is less clear
124,217,235,236
. Importantly CXCR3 signalling has 
been found to promote allograft loss in a number of mouse models
200,216
. In contrast 
the incidence of diabetes in the NOD mouse following deletion of CXCR3 was 
increased. This was attributed to an impaired ability of regulatory T cells to migrate 
into the diabetic NOD pancreas
217
. As yet studies on temporal CXCR3 blockade in 
the NOD mouse have not been performed, although the possibility of differential 
effects for deletion versus antibody blockade have been highlighted in studies of 
other molecules
256-259
. Finally, as islet transplantation is a treatment for patients with 
T1D, it is of interest to test the efficacy of targeting CXCR3 for islet transplantation 
in the NOD model. We note that no previous literature has investigated a role for 
CXCR3 in this context. 
Therefore the aims of this thesis were; 
 To characterise the in vivo effects of our novel anti-CXCR3 monoclonal 
antibody, particularly on T cell chemotaxis. 
 To characterise the efficacy of this anti-CXCR3 antibody in a model of 
BALB/c to C57BL/6 MHC mismatched islet allograft. 
 To characterise the efficacy of this anti-CXCR3 antibody in a model of 
autoimmune type 1 diabetes using the NOD mouse model. 
 To characterise the efficacy of this anti-CXCR3 antibody in a model of 
mismatched islet allograft into NOD autoimmune diabetic recipients.  
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Materials 
Table 2.1. Buffers/Reagents 
Buffer Components Manufacturer 
FACS buffer 0.5% bovine serum albumin 
(BSA) 0.2% Sodium azide  
1x Dulbeccos Phosphate 
Buffered Saline (DPBS) to 1L 
Gibco BRL 
Sigma-Aldrich 
MACS Buffer 0.5% BSA,  
2mM ethylenediamin tetra 
acetic acid (EDTA)  
DPBS to 1L 
 
Gibco BRL 
Sigma-Aldrich 
 
Invitrogen 
Red Blood Cell Lysis 
Buffer 
0.15M Ammonium chloride 
10mM potassium bicarbonate 
0.1mM Disodium EDTA 
Triple distilled water to 1L 
pH 7.2-7.4 
Merck 
Merck 
Merck 
 
Chemotaxis buffer 49% HBSS (phenol red)  
 49% RPMI (L-glut, Pen/strep)  
 2% FBS 
 
Invitrogen 
 
Serum Free Islet 
Isolation Media 
(M199-) 
10.6g Medium 199 (with 
Hanks salts and L-glutamine) 
0.35g sodium bicarbonate  
dH2O to 1L 
Sigma-Aldrich 
 
Sigma-Aldrich 
 
Islet isolation media 
(M199+) 
100mL heat inactivated bovine 
calf serum (BCS) 
M199- to 900mL 
Gibco 
Liberase Liberase-Enzyme Blend-RI 
30μL Liberase + 0.5μL 
Thermolysin 
Sterile M199- to 3mL per 
mouse 
Roche T-Flex, 
Indianapolis, IN, USA 
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Avertin 2.5%  2-2-2 tribromoethanol 
 2-methyl-2-butanol 
Saline 0.9% 
Sigma-Aldrich 
Fisher 
Baxter 
Alloxan 0.04g alloxan tetrahydrate 
2mL sterile water for injection 
Sigma-Aldrich 
Streptozotocin (STZ) 0.02g streptozotocin  
0.1% TBS-T 0.12% Tris Base 
0.87% Sodium Chloride 
0.1% Tween20 
Millique Water to 1L 
Ajax Finechem 
Ajax Finechem 
Ajax Finechem 
CFSE culture media 10% FCS, 1:100 L-glutamine  
1:100 Pen-strep  
1:2000 β-mercaptoethanol 
(@1000x 55mM)  
1:100 Sodium pyruvate 
(@100x 100mM)  
1:100 HEPES (@1M)  
RPMI-1640 to 500mL 
Invitrogen 
Invitrogen 
GIBCO 
 
Invitrogen 
 
Invitrogen 
Invitrogen 
CFSE staining buffer 1% FCS 
DPBS 
Invitrogen 
Invitrogen 
CFSE quenching 
buffer 
20% FCS 
DPBS 
Invitrogen 
Invitrogen 
Rapamycin Vehicle 
(used with rapamycin 
stock in DMSO) 
0.2% Carboxymethyl cellulose 
0.25% Polysorbate 80 (tween) 
0.9% NaCl solution to 100ml 
Sigma-Aldrich 
Sigma-Aldrich 
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Methods 
Mice 
6-10 week old C57BL/6 mice and BALB/c mice were obtained from Australian 
BioResources (Moss Vale, NSW Australia) for use as allograft recipients and donors, 
respectively or for use in in vivo MLR experiments. C57BL/6 mice were also used 
for antibody characterisation experiments.  
C57BL/6 recipient mice selected for islet allograft were treated with Alloxan 
(110mg/kg) two days prior or Streptozotocin (STZ)(180mg/kg) five days prior to 
islet cell transplantation, to chemically induce diabetes, and blood glucose levels 
monitored for onset of hyperglycaemia (BGL>15mmol/L). Following transplant both 
C57BL/6 and NOD allograft recipients were monitored daily for elevated BGL for 
the first week followed by monitoring 2-3x/week. BGL >15mmol/L for 2 
consecutive days indicated rejection of transplanted islet grafts and mice were 
euthanised.  
6-8 week old female non-obese diabetic (NOD/Lt or NOD/ShiLtJ) mice were 
obtained from Australian BioResources (Moss Vale, NSW Australia) or Walter and 
Eliza Hall Institute (Parkville, Victoria Australia). Mice were monitored for weight 
and blood glucose level (BGL) using a Free Style Lite Blood Glucose Monitoring 
System, once per week until BGL reached above 8mmol/L at which point twice 
weekly monitoring was employed. Mice were monitored for onset of diabetes, 
classified as blood glucose level (BGL) >15mmol/L for 2 consecutive days, at which 
point mice were euthanised. For studies using pre-diabetic mice, NOD mice were 
euthanised at 12 weeks of age.  NOD islet allograft experiments used NOD mice 
with BGL>8mmol/L as recipients of BALB/c islet allograft (4 donors:1 recipient).  
RAG-/- mice were obtained from Animal Resource Centre (ARC, Perth Australia) 
for use in cell transfer experiments.   
All animal experiments were performed with approval from Garvan/St Vincents 
Hospital Animal Ethics Committee (AEC) and mice housed in static micro-isolator 
cages. 
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Islet Isolation and Transplantation 
Islet Isolation 
Cannulations were performed by S. Walters or N. Zammit. Donor mice were injected 
with 400μL avertin solution and a midline incision performed to expose the 
peritoneal cavity (pancreas and liver) and heart cut to stop blood flow. Distension of 
the pancreas was performed by clamping the pancreatic/bile duct followed by careful 
insertion of a 30G needle into the bile duct and perfusion with 3mL Liberase-
Enzyme Blend into the pancreas. Pancreas was carefully excised and put into 
prepared 50mL Falcon tubes on ice. This was repeated for each donor mouse to give 
a ratio of 3 donor mice per 1 recipient mouse for C57BL/6 and RAG-/- recipients or 
4 donor mice per 1 recipient mouse for NOD recipients with 1 50mL Falcon tube per 
recipient mouse. 
Pancreata were digested at 37°C in a water bath for 10 minutes. Tubes were then 
removed directly onto ice, resuspended in 30mL islet isolation media (M199+), 
shaken and vortexed to dislodge acinar tissue from islets followed by centrifugation 
at 1250rpm for 3min. The supernatant was discarded and cells washed twice more. 
Cell pellets were resuspended again, filtered through a 425 micron sieve (US 
standard sieve, A.S.T.E. E.11 specifications dial MFG, Co. Chicago, II, USA) and 
centrifuged as above. Supernatant was discarded and tubes containing pellet left 
upside down briefly to drain excess supernatant. Pellets were then resuspended in 
10mL Ficoll-paque plus (Amersham) followed by addition of a further 10mL Ficoll. 
Ficoll was then overlayed with a further 10mL serum free islet isolation media 
(M199-) and centrifuged on a density gradient at 2830rpm for 22min with no 
acceleration or brake. Supernatant, containing separated islets, was then poured into 
clean tubes, divided in two and topped up to 50mL before centrifuging at 1250rpm 
for 3min. Here supernatant was discarded and cell pellets transferred to a single 
Falcon tube. The cell pellet was then divided between 1.5mL Eppendorf tubes 
depending on the number of recipients and pellet aspirated into a section of thin 
tubing in preparation for transplantation. All prior steps were done on ice at 4°C 
unless otherwise stated. 
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Islet Transplantation 
S. Walters or N. Zammit conducted all islet transplants. Following isolation of islets 
recipient mice were prepared for transplantation and maintained under light 
isoflurane anaesthesia (1.5-2% isoflurane in O2) for the duration of the transplant 
using a Bains paediatric circuit. Briefly mice were placed on a heat mat to maintain 
body temperature and the area over the left kidney shaved and sterilised using 
alcohol wipes. The tubing containing the islet pellet was attached to a Hamilton 
syringe and tubing trimmed leaving pellet close to the end of the tubing. A small 
incision was made over the kidney and kidney brought into the wound through gentle 
blunt dissection, allowing access to the capsule. A small nick was made at the 
inferior renal pole of the kidney capsule allowing the tubing to be inserted and pellet 
gently released towards the superior renal pole. Mice were administered 0.2mL 
ketoprofen analgesic (0.5mg/kg) and 0.5-1mL saline for rehydration into the surgical 
site. The inner and outer skin layers of the incision were then sutured, wound closed 
with surgical staples and betadine antiseptic applied. Mice were left to recover in a 
fresh cage with heat lamp and heat pad till fully awake. Blood glucose was 
monitored on days 1-7 and every second/third day thereafter until rejection occurred 
(BGL>15mmol/L).  
Antibody 
The anti-CXCR3 antibody (clone 9C5) was supplied by the Mackay Laboratory 
(Monash University), produced by Dr Remy Robert. Briefly the mouse IgG1 
antibody was generated through immunisation of mice deficient for the CXCR3 
receptor (CXCR3-/- mice) with a murine pre-B cell line (L1.2) transfected with the 
receptor of interest (CXCR3 transfected cells). Following immunisation, antibody 
clones were isolated and selected for strong reactivity against mouse CXCR3 
(mCXCR3). The clone used in this study recognises a highly conserved region of the 
CXCR3 N-terminus and efficiently binds human, mouse and marmoset lymphocytes. 
Fluorescent conjugation of αCXCR3-9C5 antibody was performed for use in 
antibody characterisation assays (internalisation and competitive binding). For this 
an Allophycocyanin (APC) Conjugation Kit (Abcam) was used and conjugation 
performed according to protocol provided. Briefly 6μL APC modifier reagent was 
added to 60μL αCXCR3-9C5 at 2μg/μL antibody and resuspended gently. This mix 
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was then transferred into the lyophilized APC conjugation mix, gently resuspended 
and left standing in the dark for 3hrs at room temperature (20-25°C). Finally APC 
conjugate was resuspended with 6μL APC Quencher reagent and stored at 4°C until 
required. This procedure was also performed for IgG Isotype control antibody. 
Antibody Treatments 
Allograft 
C57BL/6 mice received 2mg/kg αCXCR3-9C5 monoclonal antibody intravenously 
(i.v.), unless otherwise stated. Allograft recipient mice, C57BL/6 or NOD, received 
2mg/kg αCXCR3-9C5 once per week from the day of allograft for 9 weeks or until 
loss of allograft, respectively. Alternatively allograft recipient mice received 2mg/kg 
i.v. Isotype (IgG) control antibody once per week from the day of allograft until loss 
of allograft, as a control for αCXCR3-9C5 treated mice. Additional groups received 
2mg/kg i.v. αCXCR3-9C5 or Isotype in combination with sub-therapeutic 
rapamycin, administered i.p. at 0.1mg/kg for 7 days in C57BL/6 allografts
260
 or 
0.5mg/kg for 7 or 14 days in NOD allografts. An untreated control group was also 
used in NOD allograft experiments. 10x Rapamycin stock (LC laboratories, Woburn, 
MA, USA) (in DMSO) was diluted in vehicle solution for 50μL i.p.  
Type 1 Diabetes 
NOD mice were treated with 1mg/kg αCXCR3-9C5 monoclonal antibody i.v. unless 
otherwise stated. Mice received 1mg/kg i.v. αCXCR3-9C5 once every 4 days from 6 
weeks of age (6W) or 8 weeks of age (8W) until study end point was reached, at 
12weeks of age or onset of overt diabetes. An Isotype (IgG) antibody was 
administered to an additional control group using the same regimen or mice were 
untreated as controls. 
CD25 Depletion – PC61 
C57BL/6 islet allograft recipient mice, receiving 2mg/kg αCXCR3-9C5, were also 
treated with 200μg purified rat anti-mouse CD25 IgG mAb (clone PC61, Bioexpress) 
via i.v. tail vein injection. The antibody was confirmed via flow cytometry to deplete 
the CD4+CD25+ T cell compartment, containing the CD25+Foxp3+ regulatory T 
cell subset
261
. 
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Cell Population Analysis 
Lymphocyte Isolation 
Lymphocytes were isolated from spleen, pooled lymph nodes (axillary and inguinal), 
pancreatic lymph node and blood. Splenocytes were homogenised in a 50x9mm petri 
dish using two frosted glass slides (Menzel-Glaser, Braunschweig, Germany) and 
centrifuged at 1250rpm for 3min. Supernatant was discarded and pellet resuspended 
in 2mL red blood cell lysis buffer (RCLB) for 2min to deplete erythrocytes. Lysis 
was quenched by addition of FACS buffer and cells washed twice. Blood samples 
were collected, through tail bleed in live mice or cardiac puncture in euthanised 
mice, in 200μL or 2mL Heparinised saline (10UI/mL Pfizer), respectively. Blood 
samples underwent red blood cell lysis to deplete erythrocytes leaving lymphocytes 
and washed as above. Lymph nodes and thymus were homogenised as above with no 
red blood cell lysis and cells washed twice to remove fat. All cell suspensions were 
filtered using a 70μm nylon mesh filter (BD), counted using typan blue (0.4% 
Sigma) and a haemocytometer (Blood samples excluded) and resuspended at 
1x10
7
cells/mL, unless otherwise stated. All steps were performed on ice at 4°C 
unless otherwise stated. 
Splenocyte isolation for culture and antibody characterisation were performed as 
above in azide free MACS buffer rather than FACS buffer under aseptic conditions 
and used a 2mL syringe plunger to homogenise cells through a 70μm nylon mesh 
filter (BD). 
Flow Cytometry 
Isolated lymphocytes were resuspended at a concentration of 4x10
7
cells/mL and 
2x10
6 cells per 50μL plated out per well in FACS buffer for each staining condition 
in a 96 well-V bottom plate (Greiner Bio-One)(Table 2.2). Antibody staining was 
performed at a final dilution of 1:200 unless otherwise specified (Table 2.3). 
Following incubation in the dark at 4°C for 30min the plate was centrifuged and 
supernatant removed. Cells stained for Natural killer and B cell markers as well as 
those from internalisation, competitive binding or CFSE assays were resuspended in 
200μL FACS buffer and passed through a 70μm filter into 5mL microtubes (BD 
Biosciences). Cells stained for T cell markers were resuspended in 
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fixation/permeabilisation buffer (fixation/permeabilisation concentrate and diluent 
1:3 dilution, eBioscience) for at least 2 hours followed by incubation with Foxp3 
antibody resuspended in 1x permeabilisation buffer (eBioscience) in the dark at 4°C 
for 30min. Following the final antibody incubation T cells were washed and filtered 
as above into 5mL microtubes before flow cytometry was performed on a LSRII 
SORP flow cytometer with FACSDiva software (BD Bioscience). Data was analysed 
using FlowJo (TreeStar Inc, Ashland Oregon USA). Light scatter gating was 
performed on all samples to include live lymphocytes and exclude doublet cells, dead 
cells and debris unless otherwise specified. 
CFSE Proliferation Assay/Mixed Lymphocyte Reaction 
Total lymphocytes were isolated from the spleen as above in MACS buffer under 
sterile conditions and cells washed twice and resuspended at 1x10
7
cells/mL in warm 
CFSE staining buffer. The cell suspension was transferred to a fresh 15mL Falcon 
tube wrapped in aluminium foil. CFSE (carboxyfluorescein succinimidyl ester; 
Sigma-Aldrich) was prepared from stock (10μM) for in vivo (1μL of 10μM CFSE 
stock) studies. On a dry portion of a fresh 15mL tube 1μL CFSE per 1x107cells/mL 
was placed and cells quickly inverted and vortexed to ensure even distribution of 
CFSE stain before incubation at 37°C for 10min. Staining was quenched by adding 
5mL ice cold CFSE quenching buffer and incubating for 3 min. Cells were 
centrifuged and washed twice more with ice cold CFSE quenching buffer before 
performing a final cell count using trypan blue exclusion.   
In vivo cell transfer experiments were performed using cells from C57BL/6 mice and 
transferred into sub-lethally irradiated BALB/c mice. BALB/c mice were irradiated 
with a single irradiation dose of 2.7Gy using an X-RAD 320 Biologic Irradiator 
(Precision X-ray). 48 hours later mice were intravenously injected with 2x10
7 
CFSE 
labelled whole spleen cells. Mice also received either 2mg/kg anti-CXCR3-9C5 i.v. 
immediately following cells or were untreated as controls. Mice were euthanised and 
splenocytes isolated 72hrs later for flow cytometry.   
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Antibody Characterisation 
Chemotaxis Assay 
This was carried out by the Mackay Laboratory, briefly a murine pre-B cell line 
transfected with human CXCR3 (L1.2 hCXCR3) was incubated with a range of 
concentrations of αCXCR3-9C5, from 0μg/mL to 20μg/mL, for 10min at 37°C. 
Following incubation with αCXCR3-9C5, 500,000 cells of each antibody 
concentration were suspended in 75μL chemotaxis buffer and loaded into the top 
chamber of individual HTS transwell plates (Corning; 5μm pore size, 96 well #3387-
8EA). Human chemokine; CXCL9, CXCL10 or CXCL11 (Prepotech) diluted to 
30nM in 240μL chemotaxis buffer were added to the bottom chamber of each HTS 
transwell plate and incubated at 37°C for 4 hours. Following incubation 200μL of 
cells from the bottom chamber were resuspended in 100μL FACS buffer + 2%PFA 
and left overnight. Cells were read on the HTS plate reader on BD LSR flow 
cytometer and the degree to which αCXCR3-9C5 inhibited migration expressed as a 
percentage inhibition, compared to 0μg/mL αCXCR3-9C5, for each concentration of 
αCXCR3-9C5 for hCXCL9, hCXCL10 and hCXCL11. 
Receptor Internalisation Assay 
Following isolation of splenocytes in MACS buffer, cells were resuspended at 2x10
6 
cells/50μL in duplicate for each time point (0, 10, 20, 30, 60, 120 and 180 minutes) 
of the internalisation assay. Cells were resuspended with 1μl (2μg/μL) APC-
conjugated αCXCR3-9C5 for each time point or APC-conjugated IgG Isotype in 
50μL MACS buffer and incubated at 4°C for 30min to allow for antibody-receptor 
binding. Isotype treated cells and αCXCR3-9C5 treated 0 time point cells remained 
at 4°C for all further steps. For all other time points cells were incubated at 37°C for 
the allocated time (0, 10, 20, 30, 60, 120 and 180 minutes) followed by removal onto 
ice and quenching with 500μL ice cold PBS. Cells were washed twice followed by 
fixation in 1:1 PBS and 4% formaldehyde. Once all time points were collected cells 
were washed with cold PBS twice and stained for flow cytometry (table 2.2). All 
steps were performed in azide free conditions. 
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Competitive Binding Assay 
Following isolation of splenocytes in MACS buffer, cells were resuspended at 
2x10
6cells/50μL in duplicate. Cells were incubated for 30 minutes at 4°C in azide 
free conditions with 0.2μg APC-conjugated αCXCR3-9C5, APC-conjugated Isotype, 
PerCpCy5.5-conjugated CXCR3-173 or PerCpCy5.5-conjugated Isotype antibody. 
Cells were then washed twice with MACS buffer followed by a further round of 
staining with 0.2μg antibody for 30 minutes at 4°C. Cells stained initially with APC-
conjugated αCXCR3-9C5 or APC-conjugated Isotype were stained with 
PerCpCy5.5-conjugated CXCR3-173 or PerCpCy5.5-conjugated Isotype antibody. 
Cells stained initially with PerCpCy5.5-conjugated CXCR3-173 or PerCpCy5.5-
conjugated Isotype were stained with APC-conjugated αCXCR3-9C5 or APC-
conjugated Isotype antibody. Cells were then stained for flow cytometry (table 2.2).  
Antibody Titrations 
In order to determine frequency and dose of αCXCR3-9C5 appropriate for the NOD 
and C57BL/6 mouse strains antibody titration experiments were conducted. C57BL/6 
mice were injected with a range of doses of αCXCR3 9C5 (0, 1mg/kg, 2mg/kg, 
5mg/kg and 10mg/kg) on day 0 and followed for 10 days with tail vein blood 
collected throughout the 10 days. NOD mice were injected with 1mg/kg αCXCR3-
9C5, 1mg/kg Isotype or untreated as controls on day 0 and followed for 6 days with 
blood taken throughout the 6 days. Blood samples were processed and analysed by 
flow cytometry to determine CXCR3 expression on T and B cells for each 
concentration and time point (table 2.2). 
Adoptive Transfer 
Adoptive transfer experiments were performed on RAG-/- recipients of BALB/c islet 
allografts 14 days post allograft. Transferred splenocytes were harvested from long 
term surviving (>100days) C57BL/6 recipients of BALB/c islet allografts, treated 
with a combination of αCXCR3-9C5 (2mg/kg i.v. 1/week for 9 weeks) and sub-
therapeutic rapamycin (0.1mg/kg i.p for 7 days). Alternatively, spleens from 
untouched C57BL/6 mice were used as controls.  
Splenocytes were isolated under aseptic conditions and total T cells isolated via 
magnetic separation using a Pan T cell kit (Miltenyi Biotec, Auburn, CA). 
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Subsequently CD25- effector T cells were isolated through positive depletion of 
CD25+ cells using a CD25 Microbead kit (Miltenyi Biotec, Auburn, CA) following 
manufacturers instructions. Magnetic separations were performed to a purity of 
>95% using AUTOMACS (Miltenyi Biotec, Auburn CA), assessed by flow 
cytometric analysis.  
Whole T cells or CD25 depleted effector T cells (2x10
6
 cells) were then adoptively 
transferred into Rag-/- recipient mice via tail vein i.v. 
Histology 
At designated end points mice were euthanized using CO2 and tissues collected. 
Pancreata were collected from NOD mice. Kidneys were collected from long term 
surviving islet transplant recipient mice. 
Tissues were collected into labelled cassettes stored in 10% formaldehyde for 2 days 
followed by transfer into 70% ethanol and paraffin embedding (performed by TKCC 
Histopathology Facility). Sections of 5μm were cut using a Microtome (Leica, 
Wentzler, Germany), mounted onto slides and allowed to air dry overnight. Kidney 
sections were mounted on 20 slides with sections 1-20 at the top of each slide 
followed by sections 21-40 at the base of each slide allowing better visualisation of 
islet graft site. Pancreas sections were mounted with sections on slides 1-8 
contiguous, 9-16 contiguous and 17-24 contiguous (2-3 sections per slide) with a 
~150μm section discarded between each set of 8 slides, to prevent recounting the 
same islet.  
H&E 
For kidney sections slides 1, 10 and 20 were stained using H&E to identify the 
optimum slide to visualise remaining islet grafts. Pancreas sections slides 1, 9 and 17 
were stained for H&E to allow grading of insulitis. H&E was performed using an 
autostainer (Leica autostainer XL) and coverslipper (Leica CV5030) provided by 
TKCC Histopathology Facility. 
Briefly insulitis in the NOD sections was graded on a 5 point scale using Leica 
microscope (Leica DC 200 camera, Leica Microsystems) and software to visualise 
each islet at 100-200x magnification. Degree of insulitis was graded as; 0; no 
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infiltration, 1; periductal/peri-insulitis, within the pancreas, localised around but not 
within the islet, 2; circumferential, <25% of the islet infiltrated, 3; invasive, 25%-
50% of the islet infiltrated, 4; destructive, >75% of the islet infiltrated
262
. A 
minimum of 70 islets were counted per mouse over the 3 histological levels and 
expressed for each grade as a percentage of total islets scored for each group. 
Insulin Staining 
In order to determine degree of insulin production by islets remaining within the islet 
allograft, slides contiguous with H&E stained sections were deparaffinised using the 
autostainer (Leica autostainer XL). Insulin staining was performed using the DAKO 
EnVision + System-HRP (DAKOCytomation) with 100μL reagent per tissue section 
and incubations at room temperature in the dark maintaining sections under moist 
conditions.  
Once deparaffinised, tissue sections were treated with 0.3% H2O2 (DAKO; 
Peroxidase block) for 5min and washed twice with 1x PBS. Tissue sections were 
incubated for 1 hour with insulin primary antibody (Promega #4590; 1:100 rabbit 
anti-mouse insulin antibody in DAKO antibody diluent; Cell signalling). Slides were 
washed twice with 1x PBS and incubated for 30min with secondary, polymer-HRP 
anti-rabbit antibody (DAKO). Slides were washed three times followed by 
development with DAB and substrate buffer (DAKO; 1 drop DAB/mL substrate) for 
2min keeping timing consistent for all slides. Slides were washed thoroughly with 
dH2O and counterstained (Leica autostainer XL) and cover slipped (Leica CV5030). 
Foxp3+ Staining 
In order to determine infiltration of pancreata and islet grafts by Foxp3+ regulatory T 
cells, Foxp3 staining was performed on sections contiguous with those used to stain 
for H&E and/or insulin. Slides were deparaffinised using the autostainer (Leica 
autostainer XL) followed by antigen retrieval using a pressure cooker (DAKO 
Cytomation, Pascal, California Inc. S2800). Briefly, slides were placed in an antigen 
retrieval box containing citrate buffer (DAKO; 10mM, pH 6, 1:10 with dH2O) and 
heated in a pressure cooker (125°C for 30sec, 95°C for 10sec) followed by cooling 
the antigen retrieval box with cold running water. Following antigen retrieval tissue 
sections were washed with dH2O, treated with 0.3% H2O2 (DAKO; Peroxidase 
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block) for 10min and washed twice with TBS-T. Tissue sections were treated with 
protein block (DAKO) and incubated for 1 hour. Protein block was flicked off and 
briefly washed with TBS-T followed by incubation for 2 hours with Foxp3 primary 
antibody (eBioscience; rat anti-mouse purified Foxp3, clone FJK-16s, 1:100 in 
DAKO antibody diluent; Cell signalling). Slides were washed three times with TBS-
T and incubated for 30min with secondary, biotin anti-rat antibody (Jackson 
Laboratories; biotin SP-conjugated affinity purified F(ab’) fragment goat anti-rat 
IgG, Fc with spacer, 1:1000 in DAKO antibody diluent; Cell signalling). Slides were 
washed three times with TBS-T and incubated for 30min with the ABC Vectastain 
kit (Elite PK6100) in PBS. Slides were washed thoroughly with TBS-T followed by 
development with DAB and substrate buffer (DAKO; 1 drop DAB/mL substrate) for 
30sec keeping timing consistent for all slides. Slides were washed thoroughly with 
dH2O, counterstained (Leica autostainer XL) and cover slipped (Leica CV5030). 
Statistics 
Data was analysed using GraphPad Prism version 6.04 for Windows (GraphPad 
Software, La Jolla California USA, www.graphpad.com). Kaplan-Meir survival 
curve analysis using a Log-rank (Mantel Cox) test was performed to determine 
changes in allograft survival or diabetes onset. Holm-Sidak multiple comparison t 
tests were perfomed followed by further analysis using unpaired t test (Mann-
Whitney) or one-way ANOVA on select results. Results were considered statistically 
significant when the p value was less than 0.05 
Table 2.2: Flow Cytometry Staining Conditions; 
Stains Antibodies 
T cells (C57BL/6 and 
NOD) 
CD4, CD8, CD25, Foxp3, CD44, CD62L, CXCR3 
NK & B cells (NOD only) B220, CD21, CD23, CD3, NKp46, CXCR3 
CFSE Staining CD4, CD8, CD44, CD62L, CXCR3, CFSE (521nm) 
Antibody Titration B220, CD4, CD8, CD25, Foxp3, CXCR3 
Internalisation Assay CD4, CD8, APC-CXCR3-9C5/Isotype, PerCpCy5.5-
CXCR3-173/Isotype 
Competitive Binding 
Assay 
CD4, CD8, APC-CXCR3-9C5/Isotype, PerCpCy5.5-
CXCR3-173/Isotype 
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Table 2.3: Antibodies for Flow Cytometry 
Antibody Clone Flurochrome Final Dilution Manufacturer 
CD4 RM4-5 Pacific Blue 1:200 BD Pharmingen 
CD8 53-6.7 Pe-Cy7 1:200 eBioscience 
CD44 IM7 APC-Cy7/FITC 1:200 BD Pharmingen 
CD25 7D4 FITC 1:200 BD Pharmingen 
CD62L MEL-14 PE 1:200 BD Pharmingen 
Foxp3 FJK-16s APC 1:200 eBioscience 
B220 RA3-6B2 APC-Cy7 1:200 Biolegend 
CD21 7G6 FITC 1:200 BD Pharmingen 
CD23 B3B4 PE 1:200 BD Pharmingen 
CD3 145-2C11 APC 1:200 eBioscience 
NKp46 29A1.4 Pe-Cy7 1:200 eBioscience  
NK1.1 PK136 FITC 1:200 BD Pharmingen 
IgM II/41 APC 1:200 BD Pharmingen 
CXCR3 CXCR3-173 PerCp-Cy5.5 1:100 Biolegend 
IgG Isotype (for 
CXCR3-173) 
HTK888 
Armenian 
hamster IgG 
PerCp-Cy5.5 1:100 Biolegend 
CXCR3 αCXCR3-9C5 APC 1:100 Abcam kit 
IgG Isotype (for 
CXCR3-9C5) 
IgG APC 1:100 Abcam kit 
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Chapter 3. Characterising αCXCR3-9C5 
The chemokine receptor CXCR3 is involved in the recruitment of immune cells to 
sites of inflammation
3,24,200,263
. Targeted blockade of immune cell recruitment to sites 
of inflammation has clinical potential for preventing conditions like autoimmunity 
and transplant rejection. For this thesis I will explore the efficacy of a novel 
monoclonal antibody against CXCR3 in animal models of autoimmunity and 
transplant rejection. 
αCXCR3-9C5 Impairs Chemotaxis of CXCR3 transfected cells  
This antibody was generated by Remy Robert in the Mackay lab. The CXCR3 
antibody was raised in a CXCR3-/- mouse against a highly conserved epitope found 
in the mouse, marmoset and human CXCR3 sequence (figure 3.1a). The antibody 
clone, CXCR3-9C5, binds a region of the CXCR3 sequence critical for chemokine 
binding
2
, as shown for the human CXCR3-A sequence (Figure 3.1b). As a result it 
was expected that administration of the anti-CXCR3-9C5 (αCXCR3-9C5) antibody 
would inhibit chemotaxis of a murine pre-B cell line transfected with human 
CXCR3-A (L1.2 hCXCR3) to express the CXCR3 receptor. The efficacy of this 
antibody in inhibition of CXCR3 induced chemotaxis was determined by incubating 
CXCR3 transfected cells with αCXCR3-9C5 (0-100μg/mL) and measuring the 
change in the ability of these cells to migrate across a membrane towards human 
CXCR3 chemokines; hCXCL9, hCXCL10 and hCXCL11. A strong inhibitory effect 
on chemotaxis of transfected cells in response to increasing doses of αCXCR3-9C5 
for human (h)CXCL9 was seen, with ~90% inhibition at a concentration of 20μg/mL. 
In addition chemotaxis in response to hCXCL10 and hCXCL11 showed 50-60% 
inhibition at a concentration of 20μg/mL αCXCR3-9C5 (figure 3.1c). These data 
show the efficacy of the mAb αCXCR3-9C5 in blockade of CXCR3 dependent 
chemotaxis. 
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Effects of αCXCR3-9C5 on CXCR3 expression and cell stability  
We next investigated CXCR3 receptor expression and internalisation following 
αCXCR3-9C5 treatment of target cells to determine the effects of αCXCR3-9C5 
ligation on cell stability. For this we investigated if αCXCR3-9C5 ligation mediated 
neutralisation of the receptor or depletion of bound cells or internalisation of the 
chemokine receptor. 
In order to examine receptor expression on splenocytes the αCXCR3-9C5 antibody 
was fluorescently conjugated followed by incubation with isolated splenocytes to 
determine CXCR3 expression by flow cytometry. A second flurochrome conjugated 
Figure 3.1: αCXCR3-9C5 antibody binds a conserved epitope and impairs 
Lymphocyte Chemotaxis 
(a) Amino acid sequence of CXCR3 with a highly conserved region of the extracellular N 
terminal across a number of species. Figure includes the highly conserved region against 
which the αCXCR3-9C5 mAb was raised (red). (b) Snakeplot structure of human CXCR3-A 
amino acid sequence including transmembrane conformation and location of anti-CXCR3-
9C5 binding on the N terminal (red). This region contains Y27 and Y29 (black), essential 
in chemokine binding and receptor activation2,3. (c) Chemotaxis assay showing inhibition 
of Murine pre-B cell line transfected with Human CXCR3-A (L1.2 hCXCR3) chemotaxis for 
increasing doses of αCXCR3-9C5 from 0μg/mL to 20μg/mL for human (h)CXCL9, hCXCL10 
and hCXCL11. 
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CXCR3 antibody sold commercially (CXCR3-173) was used to validate CXCR3 
expression. Upon treatment of splenocytes with αCXCR3-9C5 or CXCR3-173, 
binding to the CXCR3 receptor on CD4 and CD8 T cells was found to be comparable 
for both antibodies (figure 3.2a). This CXCR3-173 monoclonal antibody was raised 
against a similar epitope of CXCR3 as αCXCR3-9C5 (figure 3.2b)200. 
 
 
 
 
 
 
Receptor internalisation and competitive binding assays 
Receptor internalisation and competitive binding assays were then performed (see 
figure 3.3 for schematic representation) in order to determine the mechanism by 
which αCXCR3-9C5 elicits its inhibitory effect on ligand binding and chemotaxis.  
Receptor internalisation was examined through incubation of splenocytes with 
αCXCR3-9C5 antibody for varying times (0, 10, 20, 30, 60, 120, 180 minutes) at 
37°C, in azide free conditions, followed by fixation and staining for flow cytometry 
(figure 3.4a). In comparison to isotype treated cells, those incubated with αCXCR3-
9C5 showed binding for both CD4+ and CD8+ T cells indicating specificity of 
binding to CXCR3. No significant difference in the degree of binding was seen 
following incubation with αCXCR3-9C5 at any time, suggesting the αCXCR3-9C5 
antibody clone was not affecting basal CXCR3 expression on these cells and was not 
Figure 3.2: Equivalent Binding of CXCR3+ T cells by αCXCR3-9C5 and commercially 
available CXCR3-173 antibody. 
(a) Lymphocytes incubated with either CXCR3-173 (commercially available) or αCXCR3-9C5 
at 4°C were found to bind comparable frequencies of CXCR3+CD4+ and CXCR3+CD8+ T cells, 
by flow cytometry. Mean+/-SEM data from 2 replicate experiments performed in duplicate. 
(b) Both antibodies were raised against the extracellular N-terminal domain of the CXCR3 
receptor, targeting similar and overlapping epitopes of the CXCR3 receptor. 
 
                                                                                         Characterising αCXCR3-9C5 
55 
 
inducing receptor internalisation. Due to the use of fixation however, the possibility 
of detecting internalised receptor poses a potential caveat. 
Following incubation with αCXCR3-9C5 at 37°C, cells were also treated with the 
alternate CXCR3-173 antibody to validate this result. However CXCR3-173 was 
unable to bind those cells pre-treated with αCXCR3-9C5 (figure 3.4b). Binding of 
CXCR3-173 to cells pre-treated with isotype rather than αCXCR3-9C5 showed a 
similar frequency of binding to CD4+ and CD8+ T cells compared to binding by 
αCXCR3-9C5. This result, combined with the overlapping peptides against which 
the two antibodies were raised, suggested competitive binding between the 
antibodies for a similar epitope on the CXCR3 receptor and as such competitive 
binding was investigated further. 
 
 
 
 
In order to clarify the ability of CXCR3 to be bound by the two antibodies 
splenocytes were incubated at 4°C in azide free conditions with either antibody alone 
(αCXCR3-9C5 or CXCR3-173 alone) or sequential incubation of cells with 
αCXCR3-9C5 followed by CXCR3-173 or incubation with CXCR3-173 followed by 
αCXCR3-9C5. Firstly this did not affect the frequency of CD4+ or CD8+ T cells 
Figure 3.3: Internalisation and competitive binding assay. 
Schematic representation; order of antibody application for each in vitro assay. 
Splenocytes, represented by blue cells, αCXCR3-9C5 fluorescently labelled (red) and 
CXCR3-173 fluorescently labelled (grey). 
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detected through flow cytometry (figure 3.4c) suggesting that the antibody is not 
causing T cell depletion. Incubation with each antibody alone showed binding of 
significantly more CXCR3 expressing cells compared to isotype, as expected, with a 
slightly lower frequency of CD4+ T cells bound by CXCR3-173 than αCXCR3-9C5 
(figure 3.4d). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4: αCXCR3-9C5 competitively binds CXCR3 receptor but does not cause 
internalisation or lymphocyte depletion. 
Internalisation Assay; Incubation of splenocytes at 37°C, azide free, with CXCR3-9C5 
antibody for 0, 10, 20, 30, 60, 120 and 180 minutes or isotype control antibody and analysis 
of CXCR3+CD4+ and CXCR3+CD8+ T cell binding by flow cytometry for (a) CXCR3-9C5 
binding (b) or  CXCR3-173 binding post incubation with CXCR3-9C5.  
Competitive binding assay; Incubation of splenocytes with αCXCR3-9C5 or CXCR3-173 
alone or sequentially with CXCR3-173 staining prior to or followed by αCXCR3-9C5 
staining, or isotype control expression. (c) The frequency of CD4+ and CD8+ T cells. (d) 
Expression of CXCR3 for isotype, αCXCR3-9C5 and CXCR3-173 treated CD4+ and CD8+ T 
cells, (e) binding of αCXCR3-9C5 or (f) binding of CXCR3-173 to CD4+ and CD8+ T cells 
treated with either antibody alone or sequentially. 
Mean+/-SEM p<0.05*, p<0.01**, p<0.001***, data from 2-3 replicate experiments 
performed in duplicate. 
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Incubation of cells with CXCR3-173 did not affect binding of cells by αCXCR3-
9C5, regardless of whether CXCR3-173 was applied prior to or post αCXCR3-9C5 
(figure 3.4e). However binding of cells by CXCR3-173 was impaired when cells 
were incubated with αCXCR3-9C5 following initial treatment with CXCR3-173 and 
to an even greater extent when stained with αCXCR3-9C5 prior to incubation with 
CXCR3-173 (figure 3.4f).  
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Summary & Conclusions 
CXCR3 is an important chemokine receptor, particularly for activated CD4+ and 
CD8+ T cells and natural killer cells
21,22,188,200,201
. Here we characterise a novel 
αCXCR3-9C5 antibody raised against a conserved epitope of CXCR3 found in a 
number of species including mice and humans. This monoclonal antibody targets an 
epitope containing residues critical for chemokine binding and as a result impairs 
chemotaxis of CXCR3 transfected cells in a concentration dependent manner to the 
three CXCR3 ligands, CXCL9, CXCL10 and CXCL11
2
. In addition ligands with 
higher affinity to CXCR3, CXCL10 and CXCL11, showed a lower level of 
chemotactic inhibition compared to the lower affinity chemokine CXCL9
189,190
. 
These results show no change in CXCR3 expression in internalisation assays with 
αCXCR3-9C5, suggesting that αCXCR3-9C5 does not induce receptor 
internalisation. However, due to the fixation of cells following αCXCR3-9C5 
treatment this data may represent surface and internal CXCR3 expression. Future 
experiments using biotinylated αCXCR3-9C5 followed by staining post incubation 
with fluorochrome conjugated streptavidin and with no fixation would be expected to 
clarify this. 
Results also did not indicate depletion of T cells with no change in the frequency of 
CD4+ of CD8+ T cells following αCXCR3-9C5 treatment compared to isotype 
control, as well as compared to CXCR3-173, known to neutralise but not deplete 
CXCR3 expressing cells
200
. This result is in agreement with previous literature 
showing minimal effector function of mouse IgG1 antibodies for both antibody-
dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity 
(CDC)
264
. However, further in vivo investigation will be required to clarify cell 
depletion through these pathways. This can be achieved briefly by incubating 
effector cells with the αCXCR3-9C5 mAb followed by addition of complement 
(CDC) or NK92 (a cell line with characteristics of NK cells)(ADCC) which lyse the 
target effector cells. Lysis can then be measured using absorbance to determine 
lactate dehydrogenase release. 
When looking at our αCXCR3-9C5 antibody in relation to the commercially 
available CXCR3-173 we found that the degree of chemotactic inhibition for 
CXCL10 found with αCXCR3-9C5 showed a similar efficacy, ~50-60% inhibition at 
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20μg/mL, as the CXCR3-173 antibody200.  In contrast, CXCR3-173 showed only 
minor (~25%) inhibition for CXCL11 and no effect on chemotaxis in response to 
CXCL9, while αCXCR3-9C5 resulted in a higher level of chemotaxis inhibition for 
CXCL11 (~50%) and CXCL9 (~90%) at concentrations of 20μg/mL. Both 
antibodies were found to neutralise rather than deplete T cells upon binding
200
. 
Studies of the CXCR3 receptor structure by Colvin et al. revealed that 
phosphorylation of residues Y29 and Y27 is essential for chemokine binding by 
CXCL9, CXCL10 and CXCL11
2
. The region targeted by αCXCR3-9C5 
encompasses these residues (figure 3.1 & 3.2). Further the proximal 16 amino acids 
of the CXCR3 N-terminal, which are targeted by CXCR3-173 but not αCXCR3-9C5, 
are important for CXCL10 and CXCL11 but not CXCL9 binding, this difference in 
binding sites may account for the distinct effects of the two antibodies
2
.  
 
Finally these results strongly suggest competitive binding between the αCXCR3-9C5 
and CXCR3-173 antibodies. These antibodies were raised against overlapping 
peptides of the CXCR3 receptor with binding assays showing impaired binding of 
CXCR3-173 in the presence of our αCXCR3-9C5 antibody. The ability of αCXCR3-
9C5 to bind to T cells was not significantly affected by the presence of CXCR3-173, 
either administered prior to or post incubation with αCXCR3-9C5. In contrast the 
ability of CXCR3-173 to bind T cells, both pre-incubated with αCXCR3-9C5 or 
where αCXCR3-9C5 was administered following CXCR3-173 was significantly 
impaired. This suggests that CXCR3-173 was displaced by αCXCR3-9C5, due to 
steric hindrance or a higher binding affinity for this shared epitope, resulting in 
competitive binding
265,266
. Due to the competitive binding of αCXCR3-9C5 and 
CXCR3-173 for this shared epitope of the CXCR3 receptor, fluorescently labelled 
CXCR3-173 expression represents CXCR3 receptor not bound by αCXCR3-9C5. 
Thus comparisons between αCXCR3-9C5 treated and untreated cells for expression 
of CXCR3-173 could be used to determine the frequency of cells bound by 
αCXCR3-9C5. This also allows the expression of free, functionally available 
CXCR3 to be determined and was used in further experiments as a measure of 
αCXCR3-9C5 binding and free CXCR3 expression. 
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Chapter 4. αCXCR3-9C5 in the Islet Allograft Model 
The chemokine receptor CXCR3 has been shown to be highly upregulated in a 
number of inflammatory conditions in humans including; cancer, autoimmunity and 
allograft rejection
178,179,181,182,239
. Due to its known role in recruitment of 
lymphocytes we sought to investigate the role of CXCR3 in a mouse model of islet 
allograft transplantation. Islet allograft rejection is both a well-established and well-
studied model for human transplant rejection
267-269
. This model has also gained 
further importance due to the emergence of clinical islet transplantation as a 
treatment for individuals with brittle diabetes and hypoglycaemic 
unawareness
102,149,155
.  
A number of studies have investigated the effects of CXCR3 blockade and deletion 
in mouse models of allograft transplantation (skin, cardiac, GVHD and also in islets) 
showing improved allograft survival due to impaired recruitment of immune cells to 
the foreign tissue
44,200,216,246,252
. This prompted us to investigate the role of αCXCR3-
9C5 antibody in a BALB/c (H2
d
) to C57BL/6 (H2
b
) MHC mismatched islet allograft 
model allowing us to determine the efficacy of this new antibody in an established 
model. 
Peripheral Immune cell characterisation of CXCR3 Expression  
Initial studies of the efficacy of different doses of αCXCR3-9C5 antibody in 
C57BL/6 mice were conducted to determine the effect of αCXCR3-9C5 treatment on 
the peripheral lymphocyte populations. Using this information we also determined 
the ideal dose and timing regimen of αCXCR3-9C5 treatment for mice receiving an 
islet allograft transplant or for untouched mice. 
These experiments were conducted on 10 week old C57BL/6 mice, intravenously 
(i.v.) administered 1mg/kg, 2mg/kg, 5mg/kg or 10mg/kg doses of αCXCR3-9C5 on 
day 0 followed by tail bleed on days 2, 4, 8 and 10 post i.v. Untouched C57BL/6 
mice were used as controls. The peripheral blood frequency of B cells and CD4+, 
CD4+Foxp3+ (Treg) and CD8+ T cells and their respective binding by CXCR3-173, 
as an indication of free CXCR3 unbound by αCXCR3-9C5, were determined via 
flow cytometry. No significant changes in peripheral lymphocyte (B or T cell) 
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frequencies were evident with administration of αCXCR3-9C5 regardless of dose or 
time post administration (figure 4.1 & 4.2).  
The frequency of CXCR3-173 binding to CXCR3 was significantly decreased in 
mice treated with αCXCR3-9C5 with a similar reduction in binding seen for all doses 
of αCXCR3-9C5 (1mg/kg-10mg/kg) administered. For this reason statistical 
comparisons were performed between the lowest dose (1mg/kg) of αCXCR3-9C5 
and controls, unless otherwise stated. Administration of CXCR3-173 showed 
minimal binding to B cells regardless of αCXCR3-9C5 administration for all doses 
and time points examined, indicating a very low expression of CXCR3 on B cells, 
unaffected by αCXCR3-9C5 (figure 4.1a). CXCR3 expression on T cell subsets 
showed reduced binding by CXCR3-173 compared to control expression for 
CXCR3+CD4 (figure 4.1b), CXCR3+CD4Foxp3+ (figure 4.2a) and CXCR3+CD8 
(figure 4.2b) T cells, This indicates a reduced frequency of free CXCR3, unbound by 
αCXCR3-9C5. 
A significant reduction in CXCR3-173 binding was evident for CD4+ T cells at day 
2 (figure 4.1bi) and day 8 (figure 4.1biii) between control and all αCXCR3-9C5 
doses. However due to variability at day 4 only control and the 2mg/kg αCXCR3-
9C5 dose were found to differ significantly (figure 4.1bii). On day 10 no significant 
difference was found between control and 1mg/kg αCXCR3-9C5 treated peripheral 
blood CD4+ T cell CXCR3-173 binding, indicating a loss of efficacy at this time 
point (figure 4.1biv).  
Analysis of CXCR3-173 binding for CD4+Foxp3+ (figure 4.2a) and CD8+ T cells 
(figure 4.2b) revealed significant reductions at all time points compared to controls. 
This lead us to consider all doses equally effective at blocking CXCR3 function in 
vivo for up to 8 days, with loss of efficacy for CD4+ T cells at this point. For this 
reason administration of multiple doses of αCXCR3-9C5 antibody at 2mg/kg on a 
weekly basis (every 7 days) to consistently block the CXCR3 receptor was 
considered optimal for further experiments. 
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Figure 4.1: αCXCR3-9C5 Antibody Titrations – C57BL/6 
Analysis of peripheral blood lymphocyte expression of CXCR3, determined using CXCR3-
173 by flow cytometry. Mice were treated with 1mg/kg, 2mg/kg, 5mg/kg or 10mg/kg 
αCXCR3-9C5 i.v. on day 0 or untouched as controls for (a) B cells and (b) CD4+ T cells on 
day (i) 2, (ii) 4, (iii) 8 and (iv) 10. Expressed as percent lymphocytes (n=3 mice/group). 
Mean+/-SEM p<0.05*, p<0.001***. 
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Figure 4.2: αCXCR3-9C5 Antibody Titrations – C57BL/6 
Analysis of peripheral blood lymphocyte expression of CXCR3, determined using 
CXCR3-173 by flow cytometry. Mice were treated with 1mg/kg, 2mg/kg, 5mg/kg or 
10mg/kg αCXCR3-9C5 i.v. on day 0 or untouched as controls for (a) CD4+Foxp3+ 
Tregs and (b) CD8+ T cells on day (i) 2, (ii) 4, (iii) 8 and (iv) 10. Expressed as percent 
lymphocytes (n=3 mice/group). Mean+/-SEM p<0.05*, p<0.01**, p<0.001***, 
p<0.0001**** 
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αCXCR3-9C5 in C57BL/6 Islet Allografts 
Once an appropriate timing and dosage had been determined in C57BL/6 mice we 
investigated the expression of CXCR3 in the spleens of untouched control C57BL/6 
and control C57BL/6 recipients of an islet allograft.  
Islet allograft survival follows a typical pattern of initially elevated blood glucose, 
due to chemical treatment with alloxan/STZ to induce diabetes. This is followed by a 
sharp decline in blood glucose back to euglycaemia upon islet allograft. Mice were 
monitored for an initial reduction in blood glucose, back to euglycaemic levels, 
followed by a rise in blood glucose i.e. hyperglycaemia. This model is able to 
physiologically mimic what would happen clinically. In the islet allograft model 
euglycaemia indicates that the islet allograft is functionally able to produce insulin 
and restore blood glucose. This is then followed by a gradual loss of function, 
measured by a rise in blood glucose level (BGL), over the course of immune 
mediated destruction and allograft loss (see figure 4.3d). Islet allograft survival was 
determined as the number of post-operative days maintaining euglycaemia before 
onset of hyperglycaemia (BGL>15mmol/L) indicating loss of allograft.  
Islet allograft was performed using diabetic C57BL/6 (H2
b
) recipient mice, 
chemically induced using alloxan (110mg/kg) or STZ (180mg/kg), transplanted with 
MHC mismatched BALB/c (H2
d
) islets under the kidney capsule (figure 4.3). These 
mice were then either left untreated as controls or administered 2mg/kg i.v. 
αCXCR3-9C5. An additional group of C57BL/6 mice, which did not receive islet 
allograft transplant, remained untouched, with the exception of αCXCR3-9C5 
administration (2mg/kg i.v) as indicated. 
Initial experiments aimed to characterise the expression of CXCR3 and effects of 
administration of 2mg/kg i.v. αCXCR3-9C5 on levels of free CXCR3 and changes in 
the frequency of T cell populations. These experiments used either αCXCR3-9C5 
treated C57BL/6 mice (αCXCR3-9C5 treated untouched recipients) which were 
untouched or islet allograft recipients (αCXCR3-9C5 treated islet allograft 
recipients) compared to untreated control mice (untouched controls or control islet 
allograft recipients). 
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Further investigation of the effects of αCXCR3-9C5 on islet allograft survival 
employed 4 treatment regimens from the day of transplant. These included; once 
weekly i.v. injections of 2mg/kg Isotype control antibody or αCXCR3-9C5 antibody 
with no other treatment or Isotype or αCXCR3-9C5 antibody in combination with 
sub-therapeutic doses of the immunosuppressant rapamycin, at 0.1mg/kg, i.p., every 
day for the first week following transplant
260
 (see figure 4.3c). 
 
 
 
 
 
Basal and Islet Allograft CXCR3 Expression 
In order to determine the proportion of cells expressing CXCR3 in untouched and 
islet allograft recipient mice, flow cytometry was performed on isolated splenic T 
cells.  
Figure 4.3: Allogeneic Experimental Model 
Overview of C57BL/6 experimental model including a) BALB/c to C57BL/6 Islet allograft 
schematic, b) timing of treatments and endpoints, chemical induction of diabetes with 
alloxan 48 hours prior to first treatment dose with isotype or αCXCR3-9C5 mAb with or 
without rapamycin and receipt of MHC mismatched BALB/c islet allograft c) treatments 
received by Islet allograft recipients for determination of efficacy of αCXCR3-9C5 mAb on 
graft survival, d) schematic of typical BGL over the course of rejection. 
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Basal expression of CXCR3 on T cell subsets within the spleens of control 
untouched mice (unfilled black) was determined based on isotype antibody 
expression (grey line with gating based on grey dashed line) (figure 4.4). The median 
of the values for proportion of CXCR3 positive cells were determined for untouched 
control mice with 8.5% of CD4+, 21.9% of Treg and 24.7% of CD8+ T cells found 
to express CXCR3. The median of the values for proportion of CXCR3 positive cells 
for control islet allograft recipient mice (unfilled black) was also determined at day 4 
post-transplant compared to isotype antibody expression (grey line with gating based 
on grey dashed line) (figure 4.4). This revealed upregulation of CXCR3 expression 
on T cells isolated from the spleens of control islet allograft recipients compared to 
untouched control mice with 15.5% of CD4+, 33.4% of CD4+Foxp3+ and 28.1% of 
CD8+ T cells expressing CXCR3. CXCR3 expression for CD4+, Tregs and CD8+ T 
cells were also determined for αCXCR3-9C5 treated untouched and islet allograft 
recipient mice on POD 4, determined via CXCR3-173 binding. CXCR3 expression 
was detected on each T cell subset following treatment with 2mg/kg αCXCR3-9C5 
(grey shaded, dashed line) at a reduced level compared to control treated mice. 
Mean, median and range values are given for each group in Table 4.1. 
 
  
 
Figure 4.4: C57BL/6 CXCR3 Expression Profiles 
Representative histograms of C57BL/6 splenic T cell subsets (CD4+, CD4+Foxp3+Treg 
and CD8+) showing median for proportion of CXCR3+ staining for untouched C57BL/6 
and islet allograft recipient C57BL/6 mice at 4 days post-transplant. Isotype mAb 
(grey line) compared to untreated control (unfilled black) or αCXCR3-9C5 treated 
(grey shaded, dashed line) CXCR3 expression (n=2-6 mice/group). 
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Untouched 
Control 
Untouched 
αCXCR3 
Islet Allograft 
Transplant 
Control 
Islet Allograft 
Transplant 
αCXCR3 
CD4+CXCR3+ Mean 8.8225 4.48 19.52 5.64 
  Median 8.545 3.855 15.5 5.64 
  Range 11.6-6.6 9.79-1.86 38.9-4.16 6.16-5.12 
CD4+Foxp3+ 
CXCR3+ 
Mean 25.975 5.76833333 28.5 18.35 
  Median 21.95 3.47 33.4 18.35 
  Range 49.3-10.7 18.6-1.7 39.4-12.7 22.3-14.4 
CD8+CXCR3+ Mean 25.075 3.455 23.49666667 15.025 
  Median 24.7 1.94 28.1 15.025 
  Range 29.1-21.8 10.7-1.55 34.2-8.19 20.6-9.45 
  n= 4 6 3 2 
 
 
 
αCXCR3-9C5 Binds CXCR3 and Reduces Memory and Effector CD8+ T cells    
The proportion of cells expressing free unbound CXCR3 on CD4+, Treg and CD8+ 
T cell subsets was next determined for C57BL/6 mice, which received 2mg/kg, IV, 
αCXCR3-9C5 or were left untreated as controls, at day 4 and day 8 post treatment. 
This was also performed for an additional group of mice which received an islet 
allograft transplant followed by treatment with 2mg/kg, IV, αCXCR3-9C5 or left 
untreated as controls and expression determined at day 4 and day 8 post treatment.  
Initial analysis revealed little change in raw cell counts at day 4 or between 
untouched groups. Initial raw counts of the total number of splenocytes in control 
transplant recipients showed a large but non-significant decrease at day 8 (figure 
4.5). Of note these mice were treated with STZ to chemically induce diabetes prior to 
receipt of an allograft (see summary & conclusions). Although this change was non-
significant compared to αCXCR3-9C5 treated islet allograft recipients it did impact 
upon determination of changes in cell populations by flow cytometry. As a result 
both total number and frequency were assessed for allograft recipients (figure 4.9-
4.12), while only total splenocyte number was analysed for untouched mice (figure 
4.6-4.9).  
Table 4.1: C57BL/6 CXCR3 Expression Profiles 
Mean and median values as well as range of C57BL/6 splenic T cell subsets (CD4+, 
CD4+Foxp3+Treg and CD8+) proportion of CXCR3+ staining for untouched C57BL/6 and 
islet allograft recipient C57BL/6 mice at 4 days post-transplant (n=2-6 mice/group). 
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The total number of CD4+, CD4+Foxp3+ or CD8+ T cells found in untouched 
C57BL/6 mice either treated with αCXCR3-9C5 or untreated controls was not 
different between groups at either day 4 or day 8 post-treatment (figure 4.6a, 4.7a, 
4.8a). 
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Analysis of the number of cells expressing free unbound CXCR3, via CXCR3-173 
binding, for each T cell subset suggested a trend toward reduced expression for 
Figure 4.5: Untouched and transplant recipient mice total splenocyte counts 
C57BL/6 mice were treated i.v. with 2mg/kg αCXCR3-9C5 or untreated as controls, of these 
a cohort of mice were received a BALB/c islet allograft under the kidney capsule 
(transplant) while another group did not (untreated). Mice were then assessed for total 
splenic lymphocyte counts at day 4 and 8 post i.v. (n=2-6 mice/group) 
Figure 4.6: αCXCR3-9C5 treatment in untouched C57BL/6 mice – CD4+ T cells  
Untouched C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5, were assessed by flow 
cytometry for splenic lymphocyte populations at day 4 and 8 post i.v. Splenocytes were 
expressed as cell number for (a) CD4+ T cells and (b) CD4+CXCR3+ showing binding of 
free CXCR3, determined via CXCR3-173 binding. Mean+/- SEM p<0.05* (n=2-
6mice/group). 
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CD4+, CD4+Foxp3+ and CD8+ T cells at day 4 compared to untreated controls, 
although small group sizes prevent statistical analysis (figure 4.6b, 4.7b, 4.8b). When 
the number of cells expressing free CXCR3 was determined at day 8 post αCXCR3-
9C5 administration a significant decrease was evident for CD8+ T cells but not 
CD4+ or CD4+Foxp3+ T cells, compared to untreated controls (figure 4.8b).  
0
5 0 0 0 0 0
1 0 0 0 0 0 0
1 5 0 0 0 0 0
#
 C
D
4
+
F
o
x
p
3
+
 S
p
le
n
o
c
y
te
s
0
2 0 0 0 0
4 0 0 0 0
6 0 0 0 0
8 0 0 0 0
#
 C
D
4
+
F
o
x
p
3
+
C
X
C
R
3
+
S
p
le
n
o
c
y
te
s
* *
U n to u c h e d  C o n tro l 4  d a y
U n to u c h e d  C X C R 3 -9 C 5  4  d a y
U n to u c h e d  C o n tro l 8  d a y
U n to u c h e d  C X C R 3 -9 C 5  8  d a y
a b
 
 
 
 
0
2 .01 0 6
4 .01 0 6
6 .01 0 6
8 .01 0 6
#
 C
D
8
+
 S
p
le
n
o
c
y
te
s
0
2 0 0 0 0 0
4 0 0 0 0 0
6 0 0 0 0 0
#
 C
D
8
+
C
X
C
R
3
+
 S
p
le
n
o
c
y
te
s
U n to u c h e d  C X C R 3 -9 C 5  4  d a y
U n to u c h e d  C o n tro l4  d a y
U n to u c h e d  C X C R 3 -9 C 5  8  d a y
U n to u c h e d  C o n tro l 8  d a y
*
*
a b
 
 
 
 
Figure 4.8: αCXCR3-9C5 treatment in untouched C57BL/6 mice – CD8+ T cells 
Untouched C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5, were assessed by flow 
cytometry for splenic lymphocyte populations at day 4 and 8 post i.v. Splenocytes were 
expressed as cell number for (a) CD8+ T cells and (b) CD8+CXCR3+ T cells showing 
binding of free CXCR3, determined via CXCR3-173 binding. Mean+/- SEM p<0.05* (n=2-
6mice/group). 
Figure 4.7: αCXCR3-9C5 treatment in untouched C57BL/6 mice – CD4+ Foxp3+ T 
cells 
Untouched C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5, were assessed by flow 
cytometry for splenic lymphocyte populations at day 4 and 8 post i.v. Splenocytes were 
expressed as cell number for (a) CD4+Foxp3+ T cells and (b) CD4+Foxp3+CXCR3+ 
showing binding of free CXCR3, determined via CXCR3-173 binding. Mean+/- SEM 
p<0.01** (n=2-6mice/group). 
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The number of cells expressing free unbound CXCR3 was also found to differ 
significantly for CD4+, CD4+Foxp3+ and CD8+ T cell subsets at day 8 post 
αCXCR3-9C5 administration compared to day 4 post treatment. The number of cells 
expressing free CXCR3 was found to be significantly decreased at day 4 compared to 
day 8 post treatment, suggesting loss of αCXCR3-9C5 binding and recovery of free 
unbound CXCR3 at 8 days post treatment (figure 4.6b, 4.7b, 4.8b).  
Analysis of CD4+ and CD8+ effector (CD44
high
, CD62L
low
), memory (CD44
high
, 
CD62L
high
) and naïve (CD44
low
, CD62L
high
) T cell subsets at day 8 following 
treatment with αCXCR3-9C5 was also performed compared to untreated controls 
(figure 4.9a & b). No difference was seen between groups for CD4+ T cells. Of note, 
changes in CD4+CXCR3+ frequency seen at day 4 were not maintained to day 8 
post-treatment (figure 4.6b) and as such although no change in CD4+ T cell subsets 
are evident at day 8 controls (figure 4.9a), changes may still exist at day 4 post-
treatment. At day 8 following treatment with αCXCR3-9C5 a decrease in the number 
of CD8+ memory T cells was evident compared to untreated controls, although this 
was found to be non-significant. Of note analysis of percentage CD8+ memory T 
cells did show a significant decrease in CD8+ memory T cells for αCXCR3-9C5 
compared to controls.  
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Figure 4.9:  αCXCR3-9C5 treatment in untouched C57BL/6 mice – T cell activation 
Untouched C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5, were assessed by flow 
cytometry for splenic lymphocyte populations at day 8 post i.v. Splenocytes were expressed 
as cell number for (a) CD4+ and (b) CD8+ effector (CD44highCD62Llow), memory 
(CD44highCD62Lhigh), and naïve (CD44lowCD62Lhigh) subsets and their respective levels of free 
CXCR3 determined via CXCR3-173 binding. Mean+/- SEM p<0.05*, p<0.01**, (n=5-
6mice/group). 
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Analysis of the number of cells expressing free unbound CXCR3, via CXCR3-173 
binding for effector and memory CD8+ T cells showed significantly reduced free 
CXCR3 following αCXCR3-9C5 treatment compared to controls (figure 4.9b). 
These same analyses were then performed in islet allograft recipients treated with 
αCXCR3-9C5 compared to control islet allograft transplant recipient mice. 
Splenocytes were examined for changes in both number and frequency of CD4+, 
CD4+Foxp3+ and CD8+ T cells and their respective number and frequency of cells 
expressing free CXCR3 at day 4 and 8 post injection and transplant in these mice 
(figure 4.10-4.13).  
As no change in raw cell counts was evident for islet allograft recipient splenocytes 
collected at day 4 post-transplant and αCXCR3-9C5 treatment, changes in number 
and frequency of T cell populations and their respective CXCR3 expression were 
consistent. No change in the number or frequency of CD4+, CD4+Foxp3+ or CD8+ 
T cells was evident at day 4 following αCXCR3-9C5 treatment compared to control 
islet allograft recipients (figure 4.10a, 4.11a and 4.12a).  
The proportion of cells expressing free unbound CXCR3 were reduced for both 
number and frequency of CD4+, CD4+Foxp3+ and CD8+ T cells at day 4 post 
αCXCR3-9C5 administration compared to controls, although due to small group size 
this was non-significant (figure 4.10c & d, 4.11c & d, 4.12c & d).  
Differences in 8 day raw cell counts for islet allograft recipients (figure 4.5) resulted 
in inconsistent changes between groups for number and frequency of splenocyte T 
cell subsets. Due to the decreased raw cell counts for control islet allograft recipients 
the number of CD4+, CD4+Foxp3+ and CD8+ T cells were decreased compared to 
αCXCR3-9C5 treated islet allograft recipients (figure 4.10-4.12a). In comparison the 
frequency of CD4+, CD4+Foxp3+ and CD8+ T cells were not different (figure 4.10-
4.12b) for αCXCR3-9C5 treated islet allograft recipients compared to controls.  
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This difference in raw cell counts also obscured any change in the proportion of cells 
compared to controls. While analysis of cell number for CD4+, CD4+Foxp3+ and 
CD8+ T cells showed little change in the number of cells expressing free CXCR3 
(figure 4.10c, 4.11c, 4.12c) a decreased frequency of cells expressing free CXCR3 is 
evident for αCXCR3-9C5 treated islet allograft recipients compared to controls for 
each subset (figure 4.10d, 4.11d, 4.12d). Due to small group size these changes were 
non-significant. 
Control islet allograft recipient mice showed an upregulation in the frequency of 
cells expressing free CXCR3 from day 4 to day 8 post-transplant for CD4+, 
CD4+Foxp3+ and CD8+ T cell frequency, as seen in Figure 4.4 (figure 4.10d, 4.11d, 
4.12d). This same trend was evident for αCXCR3-9C5 treated transplant recipients 
from day 4 to day 8 with increased free unbound CXCR3 for CD4+, CD4+Foxp3+ 
and CD8+ T cells for both number and frequency, compared to controls (figure 4.10c 
& d, 4.11c & d, 4.12c & d). This trend was similar to that seen in naïve mice (figure 
4.1, 4.2, 4.6, 4.7 & 4.8), suggesting a partial loss of αCXCR3-9C5 binding to 
CXCR3 by day 8 post αCXCR3-9C5 administration. 
Figure 4.10: αCXCR3-9C5 treatment in transplanted C57BL/6 mice – CD4+ T cells 
C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5 received a BALB/c islet allograft under 
the kidney capsule followed by flow cytometry for splenic lymphocyte populations at day 4 
and 8 post i.v. and allograft. Controls did not receive αCXCR3-9C5 treatment. Splenocytes 
were expressed as cell number (a & c) or frequency (b & d) for CD4+ T cells (a & b) and 
showing their respective binding of free CXCR3 (c & d), determined via CXCR3-173 binding. 
Mean+/-SEM (n=2-4mice/group) 
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CD4+ and CD8+ effector (CD44
high
, CD62L
low
), memory (CD44
high
, CD62L
high
) and 
naïve (CD44
low
, CD62L
high
) T cell subsets were also analysed at day 8 following islet 
transplant and treatment with αCXCR3-9C5 compared to control islet transplant 
Figure 4.12: αCXCR3-9C5 treatment in transplanted C57BL/6 mice – CD8+ T cells 
C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5 received a BALB/c islet allograft 
under the kidney capsule followed by flow cytometry for splenic lymphocyte populations 
at day 4 and 8 post i.v. and allograft. Controls did not receive αCXCR3-9C5 treatment. 
Splenocytes were expressed as cell number (a & c) or frequency (b & d) for CD8+ T cells (a 
& b) and showing their respective binding of free CXCR3 (c & d), determined via CXCR3-
173 binding. Mean+/-SEM (n=2-4mice/group) 
 
Figure 4.11: αCXCR3-9C5 treatment in transplanted C57BL/6 mice – CD4+Foxp3+ T 
cells 
C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5 received a BALB/c islet allograft under 
the kidney capsule followed by flow cytometry for splenic lymphocyte populations at day 4 
and 8 post i.v. and allograft. Controls did not receive αCXCR3-9C5 treatment. Splenocytes 
were expressed as cell number (a & c) or frequency (b & d) for CD4+Foxp3+ T cells (a & b) 
and showing their respective binding of free CXCR3 (c & d), determined via CXCR3-173 
binding. Mean+/-SEM (n=2-4mice/group) 
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recipients (figure 4.13). A reduced number of CD4 and CD8 effector, memory and 
naïve cell subsets were evident due to reduced absolute raw cell counts in untreated 8 
day allograft transplant recipients (figure 4.13a & c). However, these changes were 
not reflected in cell frequencies, where a non-significant reduction in total CD8 
effector and memory T cells was evident in αCXCR3-9C5 treated mice compared to 
control islet allograft recipients (figure 4.13b & d). In addition following αCXCR3-
9C5 treatment a trend towards a reduced frequency of free CXCR3 on CD4 effector 
and memory and CD8 effector, memory and naïve T cells was also evident, 
compared to control expression (figure 4.13b & d). Due to small group size these 
changes were non-significant. 
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Figure 4.13: αCXCR3-9C5 treatment in transplanted C57BL/6 mice – T cell 
activation 
C57BL/6 mice, treated i.v. with 2mg/kg αCXCR3-9C5 received a BALB/c islet allograft 
under the kidney capsule followed by flow cytometry for splenic lymphocyte populations 
at day 8 post i.v. and allograft. Splenocytes were expressed as cell number (a & c) or 
frequency (b & d) for CD4+ or CD8+ effector (CD44highCD62Llow), memory 
(CD44highCD62Lhigh), and naïve (CD44lowCD62Llow) T cell subsets and showing their 
respective binding of free CXCR3, determined via CXCR3-173 binding. Mean+/- SEM 
(n=2-4mice/group) 
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Effector and memory T cell subsets are important mediators of inflammation and 
allograft rejection
21,270-272
. Due to the reductions in CD8+ effector and memory 
splenocyte populations of untouched and allograft recipients at POD 8 we assessed 
changes in markers of T cell activation, CD44 and CD62L. Representative FACS 
plots of CD8+ T cells from the spleens of untouched or islet allograft transplant 
recipients (figure 4.14ai & bi) at POD 8 show increased memory and effector subsets 
for control mice compared to mice treated with 2mg/kg αCXCR3-9C5 (figure 4.14aii 
& bii).  
Representative histograms of the activation markers CD44 (figure 4.14a & biii) and 
CD62L (figure 4.14a & b iv) are also shown for control mice (black unfilled) or 
those treated with αCXCR3-9C5 (grey shaded). The addition of αCXCR3-9C5 
resulted in no change in CD62L expression, however a substantial decrease in the 
expression of CD44
high 
CD8+ T cells compared to untreated controls was observed 
for both untouched and islet allograft recipient mice.  
 
 
  
 
 
Figure 4.14: Altered activation of naïve and allogeneic C57BL/6 splenocytes 
Representative FACS plots of CD8+ effector (CD44highCD62Llow), memory 
(CD44highCD62Lhigh), and naïve (CD44lowCD62Llow) subsets from either (a) 
untouched/untransplanted or (b) islet allograft recipient mice for (i) untreated 
controls or (ii) αCXCR3-9C5 treated (2mg/kg i.v.) mice at 8 days post-transplant 
and/or αCXCR3-9C5. Representative histograms of (iii) CD44 and (iv) CD62L are also 
shown for mice treated with αCXCR3-9C5 (grey shaded) or untreated controls 
(unfilled black) (n=2-4mice/group) 
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The decreased CD8+CD44
high
 expression found in these mice resulted in a reduction 
in CD44+CD8+ T cells at day 8 for both untouched and islet allograft recipient mice 
following treatment with αCXCR3-9C5 when compared to untreated controls (figure 
4.15b). This change was non-significant due to small group size. No change was seen 
for CD4+ CD44 expression. When frequency of CD8+ T cells were analysed a slight 
decrease was evident for both untouched and allograft recipients treated with 
αCXCR3-9C5 compared to controls (figure 4.15a). 
C
D
4
+
C
D
8
+
0
1 0
2 0
3 0
%
 C
D
4
4
+
 T
 c
e
ll
s
T ra n sp la n t  C X C R 3 -9 C 5
T ra n s p la n t c o n tro l
U n to u c h e d  C X C R 3 -9 C 5
U n to u c h e d  c o n tro l
0
5
1 0
1 5
%
 C
D
8
+
 T
 c
e
ll
s
a b
 
 
 
 
 
 
 
αCXCR3-9C5 Prolongs C57BL/6 Islet Allograft Survival  
Using this initial characterisation it was determined that regular administration of 
αCXCR3-9C5 once per 7 days at a concentration of 2mg/mL would maintain 
expression of free unbound CXCR3 at a low level. We then further investigated the 
effect this antagonism of the CXCR3 receptor had on islet allograft survival.  
Transplantation of BALB/c to C57BL/6 islet allografts were performed and mice 
were treated with one of 4 regimens. These were either; 2mg/kg i.v. Isotype control 
antibody or 2mg/kg i.v. αCXCR3-9C5 antibody once per week or a combination of 
Isotype or αCXCR3-9C5 antibody with sub-therapeutic doses of the 
immunosuppressant rapamycin, at 0.1mg/kg, i.p., every day for the first week 
Figure 4.15: Altered CD44 expression of untouched and transplanted C57BL/6 
splenocytes  
Untouched or islet allograft recipient mice were treated with 2mg/kg αCXCR3-9C5 i.v. 
or untreated as controls and analysed by flow cytometry at day 8 post-transplant/i.v. 
for frequency of (a) CD8+ T cells or (b) expression of CD44high CD4+ and CD8+ T cells. 
Mean+/- SEM (n=2-4 mice/group) 
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following transplant
260
 (see figure 4.3). Mice were then monitored for the onset of 
hyperglycaemia, indicative of allograft rejection. 
 
 
 
 
 
 
 
Rejection of islet allografts occurred in all recipients treated with isotype control 
antibody by POD 24 with a median survival time (MST) of 22 days. However, 
treatment of mice with αCXCR3-9C5 resulted in a significant prolongation of 
allograft survival with MST of 31 days and permanent engraftment (>100days) in 1 
out of 7 mice. When rapamycin was given in combination with αCXCR3-9C5 50% 
of mice showed long term islet allograft survival with a MST of 81.5 days (figure 
4.16). In contrast to those mice treated with a combination of αCXCR3-9C5 and 
rapamycin, treatment of mice with isotype and rapamycin resulted in a MST of 40 
days and did not show any long-term allograft survival. Although treatment with 
rapamycin improved allograft survival compared to mice treated with isotype alone 
this change was not significant. 
 
Figure 4.16: Allogeneic C57BL/6 Islet Transplant  
Kaplan-Meier survival curve of C57BL/6 (H2b) recipient mice, transplanted under the 
kidney capsule with BALB/c (H2d) islet allografts. Mice received either; isotype antibody 
(1/week, 2mg/kg, i.v. for 9 weeks)(●), αCXCR3-9C5 mAb (1/week, 2mg/kg, i.v. for 9 
weeks)(■), or combined Isotype + rapamycin (1x/day, 0.1mg/kg, i.p. for 7 days)(▼) or 
αCXCR3-9C5 + rapamycin (1x/day, 0.1mg/kg, i.p. for 7 days)(♦) from the morning of 
allograft . Mice were monitored a loss of euglycaemia indicating loss of allograft. Mean+/- 
SEM p<0.05* (n=4-7 mice/group).  
 
 
Isotype vs. αCXCR3 p= 0.0291* 
Isotype+Rapa vs. αCXCR3+Rapa p=0.087 
αCXCR3 vs. αCXCR3+Rapa p=0.3309 
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αCXCR3-9C5 and Rapamycin Therapy Preserve Islet Allograft Architecture 
Examination of islet allograft pathology taken from long term (>POD 100) surviving 
grafts from mice treated with a combination of αCXCR3-9C5 and rapamycin, was 
then performed. Staining for H&E and insulin revealed a preserved islet architecture 
and strong insulin labelling with isolated pockets of mononuclear cell infiltration 
restricted to the edges of the graft (figure 4.17a). Due to the role of regulatory T cells 
in allograft survival
144,273-275
, characterised by their expression of the Foxp3 
transcription factor, we next examined Foxp3+ T cells within the graft. Consequently 
we found robust staining (brown) within the observed pockets of immune infiltrate at 
the edge of the long term surviving islet allografts (figure 4.17b).  
  
 
 
 
 
 
 
Figure 4.17: Long-term surviving allograft pathology  
Representative histology of long-term surviving (POD>100) islet allografts from mice 
treated with 2mg/kg αCXCR3-9C5 mAb (i.v. 1x/week for 9 weeks) + 0.1mg/kg rapamycin 
(i.p. 1x/day for 7 days) POD>100. (a) Hematoxylin & Eosin staining (H&E), Insulin 
staining (INS) (brown) and (b) Foxp3+ cell staining (brown). Flow cytometric analysis of 
CD4+Foxp3+ T cells as % of total lymphocytes for untouched controls (o), αCXCR3-9C5 + 
rapamycin (as above, POD>100) (♦) and αCXCR3-9C5 alone (POD>100) (■) measured in 
spleen, thymus and blood. Individual values of each mouse represented. p<0.05 *  
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In addition to the presence of Foxp3+ cells at the graft site, we found an increased 
frequency of CD4+Foxp3+ Tregs within the spleens of long term surviving islet 
allograft recipients (Figure 4.17c). The frequency of Foxp3+ regulatory T cells 
isolated from the spleens of long-term surviving mice treated with αCXCR3-9C5 and 
rapamycin was significantly greater, ~1.05% of total lymphocytes, than that seen for 
untreated control C57BL/6 mice, which had not received an allograft, ~0.625% of 
total lymphocytes. The individual long-term surviving αCXCR3-9C5 treated mouse 
showed a similarly elevated regulatory T cell population as that seen in αCXCR3-
9C5 and rapamycin treated mice. No change was seen in the thymus or blood of 
these mice compared to controls (figure 4.17c). 
 
A role for Regulatory T cells in αCXCR3-9C5 and Rapamycin treated Islet 
Allograft survival 
Next to establish whether regulatory T cells played a role in promoting allograft 
survival in this model we employed strategies to deplete T cells from our allograft 
models. Firstly we performed islet allografts, as previously described, followed by 
weekly treatments with isotype or αCXCR3-9C5 antibody. In addition one group 
received αCXCR3-9C5 in combination with an anti-CD25 depleting antibody 
(PC61). This effectively removes the CD4+CD25+Foxp3+ T cell fraction by starving 
them of IL-2, necessary for Treg survival
261
. As previously described mice treated 
with isotype had a MST of 22 days, while αCXCR3-9C5 treatment resulted in a MST 
31 days. However, in mice treated with PC61 the beneficial effects of αCXCR3-9C5 
on graft survival were lost, resulting in a MST of 26 days (figure 4.18a).  
Next, to further elucidate this role of Tregs, an in vivo cell transfer model was used 
(figure 4.18b). RAG-/- recipient mice firstly received a BALB/c islet allograft 
followed by transfer of T cells from either untreated control mice or long term 
surviving islet allograft recipient mice (treated with αCXCR3-9C5 and rapamycin). 
Transferred T cells were either whole T cells (figure 4.18c) or CD25 depleted T cells   
(CD25-), lacking CD4+CD25+Foxp3+ T cells (figure 4.18d). In support of previous 
findings the transfer of whole T cells from long-term surviving mice resulted in 
prolongation of allograft survival in RAG-/- mice compared to T cells from controls. 
These results were non-significant due to small group size (figure 4.18c). Transfer of 
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CD25 depleted cells on the other hand resulted in a complete loss of this 
prolongation compared to control T cell transfer (figure 4.18d). This supports a role 
for CD4+CD25+Foxp3+ Tregs in the maintenance of αCXCR3-9C5 induced long 
term allograft survival. 
 
 
 
 
 
 
 
 
 
Figure 4.18: A role for Regulatory T cells in αCXCR3-9C5 allograft survival 
(a) Kaplan-Meier survival curve of BALB/c islet (H2d) allografts transplanted under the 
kidney capsule of C57BL/6 (H2b) recipient mice treated i.v. with 2mg/kg Isotype mAb 
(●), 2mg/kg αCXCR3-9C5 mAb (■)(1x/week for 9 weeks) or 2mg/kg αCXCR3-9C5 mAb 
in combination with the αCD25 mAb PC61 (depletes CD25+ cells) ( ). (n>3mice/group) 
(b) Schematic of T cell transfer experiments for RAG-/- mice which received BALB/c islet 
allograft followed by adoptive T cell transfer from long-term surviving αCXCR3-9C5 and 
rapamycin treated mice or untouched controls. Transfer experiment mice received T cell 
transfer of either (c) whole T cells or (d) CD25- T cells. (n=2-3mice/group) 
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Summary & Conclusions 
The chemokine receptor CXCR3 has a well-established role in mediating chemotaxis 
of T cells to sites of inflammation and as such has been shown to undergo 
upregulation under conditions of inflammation
22,185,194
. Here we show that in 
agreement with previous literature, upon receipt of an islet allograft, stimulating an 
inflammatory response, the proportion of cells expressing CXCR3 was upregulated 
from basal levels on CD4+, Treg and CD8+ T cell subsets (figure 4.4). In addition 
administration of our novel αCXCR3-9C5 antibody resulted in a reduced ability of 
CXCR3-173 mAb to bind to the CXCR3 receptor. We interpret this to indicate 
receptor occupancy by αCXCR3-9C5, acting as a receptor antagonist, and possibly 
affecting the ability of chemokines, CXCL9, CXCL10 and CXCL11 to bind CXCR3 
and mediate biological functions e.g. chemotaxis.  
Doses of αCXCR3-9C5 between 1-10mg/kg were found to be equally efficacious at 
blocking CXCR3-173 binding for up to 8 days for CD4+ T cells and for over 10days 
for CD4+Foxp3+ Treg and CD8+ T cells (figure 4.1 & 4.2). From this, a once 
weekly 2mg/kg αCXCR3-9C5 dose was chosen for use in further experiments. In the 
spleens of both un-transplanted and allograft recipient mice the proportion of cells 
expressing free CXCR3 on T cell subsets was reduced at day 4 following treatment 
with αCXCR3-9C5 with partial or complete recovery of free, unbound CXCR3 by 
day 8, validating findings in peripheral blood (figure 4.6-4.13).  
Importantly a reduction in absolute number of whole splenocytes for islet allograft 
recipient mice at day 8 was noted, which affected determination of real changes in 
the lymphocyte populations in the spleens (figure 4.5) For this reason both cell 
number and frequencies were displayed for islet allograft splenocyte analyses (figure 
4.10-4.13). A number of possible explanations for this exist, such as immune cell 
migration from the spleen to the graft site. However, this experiment was performed 
using STZ to induce diabetes with a previous paper showing lymphopenia post STZ 
administration
276
. The difference between groups then may result from slightly 
longer time from STZ administration to transplant or differential effects between 
mice and for this reason and due to small group size future studies will involve 
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repetition of this experiment using alloxan rather than STZ to eliminate this 
possibility.    
Investigation of the effect of αCXCR3-9C5 on activation of T cells revealed that 
both the proportion of CD4+ and CD8+ naïve, memory and effector T cells 
expressing free CXCR3 were reduced. Although only CD8+ T cells showed a 
marked decrease in the total memory and effector T cell populations compared to 
untreated mice (figure 4.9 & 4.13). This reduction, seen in both un-transplanted and 
allograft recipients, resulted from a decrease in CD44
high 
CD8+ T cells (figure 4.14). 
No significant change in the frequency of CD8+ T cells between αCXCR3-9C5 
treated and control groups were evident (figure 4.15). It is difficult to determine if in 
this case depletion is occurring as this population accounts for only a 1-1.5% change 
in total CD8+ T cells as a frequency of lymphocytes with variability and a small 
group size. This may indicate depletion or natural variability and as such repetition 
with larger group number may assist in determination if the change in CD44
high
 
CD8+ T cells was a result of depletion of memory/effector subsets, or a reduction in 
expression of the activation marker CD44. 
The role of CXCR3 in allograft rejection is well-established in humans, xenografts 
and in mouse models
180,182,200,216,239-243,252
. Here we provide further evidence of the 
essential role of CXCR3 in allograft rejection and for the efficacy of αCXCR3-9C5 
treatment of mice. Treatment of mice with αCXCR3-9C5 alone or in combination 
with low doses of the immunosuppressant rapamycin resulted in a significant 
prolongation of functioning islet allograft survival (figure 4.16). In addition 15% of 
αCXCR3-9C5 treated and 50% of αCXCR3-9C5 and rapamycin treated mice 
exhibited functional islet allografts for over 100 days. Islet allograft pathology also 
displayed preserved islet morphology with no lymphocytes found within the graft 
site and concurrently showed a robust staining with insulin, indicating well-
functioning grafts (figure 4.17). The limited immune infiltrate present at these grafts 
was encircled by Foxp3+ regulatory T cells. These Treg were found in significant 
frequencies in the spleens of long term surviving mice and were found to be partially 
responsible for the prolonged allograft survival in αCXCR3-9C5 treated mice, as 
determined by PC61 treatment and T cell transfer experiments (figure 4.18a). For 
controls tissue from younger 6-8 week old un-manipulated C57BL/6 mice were 
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compared to treated long-term surviving allograft recipient mice (figure 4.17c). 
These controls were chosen due to the logistical and ethical issues involving use of 
aged controls. Of note previous literature indicates that an age related increase in 
Treg frequency occurs between 16 and 40 weeks of age in C57BL/6 mice, which 
may account for this change
277,278
. However, while literature suggests that this 
increase can be seen throughout the periphery, our data shows a significant increase 
in Treg frequency only in the spleens of treated mice and no significant change 
within the blood. In order to rule out this age related increase in Treg as a potential 
confounding factor, it would be interesting to repeat this experiment using age 
matched controls. 
Interestingly a similar pattern of infiltration was shown in a recent article focusing on 
the role of CXCR3 in viral infection. This paper indicated that while CXCR3 
knockout CD8+ T cells were able to migrate to sites of infection they were less likely 
to penetrate regions of heavy infection, hesitating at the perimeter of the infected 
area. CXCR3 knockout CD8+ T cells were also significantly more motile with an 
impaired ability to maintain contact with infected cells
220
. It is possible that 
αCXCR3-9C5 treatment may also impair contact dependent interactions resulting in 
reduced allograft destruction and greater peripheral lymphocyte localisation, 
restricted to small pockets at the periphery of the graft but not within the allograft.  
From this we conclude that αCXCR3-9C5 is able to antagonise the CXCR3 receptor 
resulting in reduced free CXCR3 chemokine receptor and a reduction in activation 
marker CD44. Reduced frequencies of CD44
high
 effector and memory CD8+ T cell 
subsets were also evident as a result of altered CD44 expression. In addition 
αCXCR3-9C5 appears to work synergistically with rapamycin to enhance islet 
allograft survival, likely through promoting regulatory and inhibiting effector T 
cells
279
.  
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Chapter 5. αCXCR3-9C5 in the NOD Autoimmune 
Diabetic Model 
Type 1 diabetes is an autoimmune disease characterised by progressive loss of islet 
beta cells until onset of overt diabetes. For a number of individuals maintenance of 
euglycaemia with insulin administration is inadequate to prevent hyper- and 
hypoglycaemic episodes. In these individuals with variable blood glucose or with 
hypoglycaemic unawareness islet or pancreas transplant may be recommended
98,100-
102
. For this reason we next investigated the role of αCXCR3-9C5 mAb in models of 
type 1 diabetes. 
To do this we determined the effect of αCXCR3-9C5 in the NOD mouse model of 
diabetes. The NOD mouse is a model of spontaneous diabetes caused by the 
development of self-directed B and T cells that target and destroy insulin producing 
beta cells. The NOD mouse is a useful model due to the natural development of 
autoimmunity, pancreatic islet infiltration and loss of euglycaemia, similar to that 
seen in the human disease. However it differs from human T1D as discussed 
previously within the introduction
61,71,72,77
. 
We were interested in this model for a number of reasons; firstly no previous 
literature looks at both the islet allograft and NOD model in the context of 
chemokine therapies within a single study. This will be advantageous if we wish to 
pursue αCXCR3-9C5 in a clinical context for islet transplantation in individuals with 
type 1 diabetes. Moreover such a study may highlight a clinically relevant role of 
αCXCR3-9C5 for use in human islet transplantation. Additionally other models 
looking at CXCR3 in the context of diabetes have given variable results with studies 
in the RIP-LCMV virally induced model showing reduced immune infiltration and 
delayed diabetes onset, while CXCR3-/- NOD mice were shown to have accelerated 
diabetes onset resulting from impaired Treg trafficking into the pancreas
124,217
. Of 
particular interest to us was the result of Yamada et al. who found accelerated 
development of diabetes in CXCR3 deficient NOD mice
217
. A role for CXCR3 in the 
migration of Treg cells into sites of inflammation has been shown for Th1 type 
Tregs, which express CXCR3 under the control of the T-bet transcription factor in a 
number of autoimmune conditions
217,225,226
. Acceleration of diabetes driven by our 
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antibody would make further studies into the efficacy of our antibody in a clinical, 
type 1 diabetes transplantation context unfounded. 
As such it is important to determine whether αCXCR3-9C5 confers protection, with 
delayed diabetes incidence/onset or prolonged islet allograft survival, in the NOD 
mouse model of diabetes. Deleterious effects of αCXCR3-9C5 treatment, such as 
impaired pancreatic Treg infiltration were also investigated. 
Peripheral Immune cell characterisation of CXCR3 Expression  
In order to determine the appropriate dosing regimen in the NOD mouse model 
initial antibody titration experiments were performed, as in C57BL/6 mice. Due to 
the previous finding in chapter 4 that doses of 1-10mg/kg were equally efficacious 
we performed further NOD experiments with 1mg/kg αCXCR3-9C5. NOD mice 
were administered a single i.v. of αCXCR3-9C5 or isotype at 8 weeks of age or 
untouched as controls, followed by FACS analysis of peripheral blood post injection 
on days 2, 4 and 6 to determine changes in peripheral lymphocytes and their 
respective frequency of free CXCR3. 
Flow cytometry revealed minimal binding of CXCR3 by CXCR3-173 on B cells, as 
seen in C57BL/6 samples (figure 4.1a), indicating very low levels of CXCR3 
expression which was not affected by treatment with αCXCR3-9C5(figure 5.1a).  No 
difference in the frequency of total CD4+, Tregs and CD8+ T cells was evident 
between αCXCR3-9C5 treated and isotype or control groups for all time points 
(figure 5.1). However administration of αCXCR3-9C5 was found to significantly 
reduce the frequency of cells expressing free unbound CXCR3, as determined by 
CXCR3-173 binding, for all T cell subsets at day 2 post injection. Reduced CXCR3-
173 binding of CD8+ T cells was also evident at day 4 for αCXCR3-9C5 treated, 
compared to isotype treated T cells. This reduction in the frequency of cells 
expressing free unbound CXCR3 was absent for all T cell subsets by day 6, 
suggesting loss of αCXCR3-9C5 binding (figure 5.1b-d).  
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Figure 5.1: αCXCR3-9C5 Antibody Titrations - NOD 
Analysis of peripheral blood lymphocyte expression of CXCR3, determined using CXCR3-
173 by flow cytometry. Mice were treated with 1mg/kg αCXCR3-9C5 or Isotype antibody 
i.v. on day 0 or untouched as controls for total (a) B cells, (b) CD4+ T cells, (c) Treg and 
(d) CD8+ T cells and on day (i) 2 (n=5-10mice/group) (ii) 4 (n=5-10mice/group), and (iii) 
6 (n=2-3mice/group). Expressed as percent of lymphocytes. Mean+/-SEM p<0.05*, 
p<0.001*** 
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Basal CXCR3 Expression 
Analysis of baseline frequency of free unbound CXCR3 in the spleens of untreated 
NOD mice (figure 5.2; black histogram) compared to isotype stained cells (grey 
histogram) was also performed by flow cytometry for CD4+, CD4+Foxp3+ and 
CD8+ T cells as well as for NK cells (figure 5.2).  
This was performed at 3 different ages: 6 weeks (figure 5.2a), initial onset of mild 
pancreatic infiltration; 12 weeks (figure 5.2b) at which point a significant increase in 
islet infiltration occurs and at 15-25 weeks of age, onset of overt diabetes for 
females, with heavily infiltrated islets and loss of insulin producing beta cells (figure 
5.2c)
77
.  
 
 
 
Figure 5.2: NOD CXCR3 Expression Profiles 
Representative histograms of NOD splenic T (CD4+, CD4+Foxp3+ and CD8+) and NK 
(CD3-NKp46+) cell subsets, showing median for proportion of CXCR3+ staining (%) for 
NOD mice at (a) 6 and (b) 12 weeks of age and (c) at onset of overt diabetes. Isotype 
(grey) compared to Control (black) CXCR3 expression (n=3-7 mice/ group).  
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The median value for the proportion of cells positively staining for CXCR3 on T 
cells, including CD4+, CD4+Foxp3+ Treg and CD8+ T cells, increased from 6 
weeks to 12 weeks of age, peaking at 12 weeks where they either stabilised or 
decreased until the onset of diabetes at 20-25 weeks of age. In contrast proportion of 
cells positively staining for CXCR3 on NK cells was highest at 6 weeks of age with 
reduced expression at 12 weeks and at onset of diabetes at 20-25 weeks of age 
(figure 5.2). This profile would agree with an early innate response by NK cells at 6 
weeks, followed by a more acquired, T cell, response at 12 weeks of age. Mean, 
median and range values are provided in Table 5.1. 
    NOD 6W 
NOD 
12W 
NOD 
Diabetic 
CD4+CXCR3+ Median 4.13 9.98 6.46 
  Mean 4.033333 9.71 8.928571 
  Range 
3.17-
4.13 
6.68-
12.2 
4.86-
19.3 
CD4+Foxp3+ 
CXCR3+ 
Median 8.47 14.65 11.5 
  Mean 9.076667 14.8 14.78143 
  Range 
8.46-
10.3 
14.1-
15.8 
8.72-
31.4 
CD8+CXCR3+ Median 10.5 13.3 13.3 
  Mean 10.31667 13.75 15.65 
  Range 
8.65-
11.8 
12.1-
16.43 
7.05-26 
NK+CXCR3+ Median 51.2 40.85 35 
  Mean 51.83333 39.15 39.48571 
  Range 
41.2-
63.1 
26.8-
48.1 
28.7-56 
  n= 3 4 7 
 
 
 
NOD Insulitis Scoring 
Baseline insulitis was determined in the NOD pancreas using formalin fixed, H&E 
stained sections from 4-6, 9 and 15-16 (diabetic BGL >15mmol/L) week old mice. In 
order to do this we employed an established 0-4 grading system, where grade 0 islets 
have no infiltrate, grade 1 peri-insulitis, grade 2 <25% infiltrate, grade 3 >25% and 
Table 5.1: NOD CXCR3 Expression Profiles  
Mean and median values as well as range of NOD splenic T (CD4+, CD4+Foxp3+ and CD8+) 
and NK (CD3-NKp46+) cell subsets, showing median for proportion of CXCR3+ staining 
(%) for NOD mice at (a) 6 and (b) 12 weeks of age and (c) at onset of overt diabetes (n=3-
7 mice/ group).  
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grade 4 >75% infiltrate
262
. Quantification of insulitis for each age expressed as a 
percent of total islets scored for each group, revealed a progressive increase in 
severity of insulitis as mice aged, as expected from previous literature
77
(figure 5.3).  
 
 
 
 
NOD Diabetes Incidence 
Cumulative diabetes incidence data for our laboratory was also obtained to validate 
NOD diabetes incidence data generated within these studies (figure 5.4). This is 
necessary as the incidence of diabetes within NOD colonies is strongly influenced by 
environmental factors such as diet and microbial infections and is known to vary 
between facilities
75
. Figure 5.4 shows the fraction of normoglycaemic NOD female 
mice over time from birth to 50 weeks of age. Diabetes incidence rates of 60% at 25 
weeks have been previously documented by our facility
280
. 
Figure 5.3: NOD Insulitis Grading 
Representative histological images of H&E stained NOD pancreata, grade 0-4 insulitis scoring; 
grade 0 no infiltrate, grade 1 peri-insulitis, grade 2 <25% infiltrate, grade 3 >25% infiltrate 
and grade 4 >75%/complete infiltration 
Assessment of baseline insulitis in 4-6 week old, 9 week old and 15-16 week old diabetic 
(diabetic BGL >15mmol/L) NOD mice using H&E stained histological sections, expressed as 
percentage of islets scored per grade (>50 Islets scored/group n=3 mice/group). 
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αCXCR3-9C5 does not alter Diabetes Incidence in the NOD mouse 
Following determination of basal expression of CXCR3 (figure 5.2), degree of 
insulitis at different ages (figure 5.3) and the efficacy of a 1mg/kg dose of αCXCR3-
9C5 to bind CXCR3 expressed by NOD peripheral blood lymphocytes (figure 5.1), 
we investigated the effect of long term treatment with αCXCR3-9C5 in the NOD 
mouse. 
For this we established a model involving treatment of mice every 4 days with 
1mg/kg i.v. αCXCR3-9C5 antibody or isotype control antibody, alternatively mice 
were untreated as controls. Mice began treatments from either; 6 weeks of age, where 
6 weeks of age is early in the initial phase of immune infiltration or 8 weeks of age, 
the age at which a 7 fold increase in infiltration of leukocytes occurs in the NOD 
mouse
77
 (figure 5.3). Treatments were continued until euthanasia at 12 weeks of age 
for analysis of pancreatic pathology and changes in lymphocyte populations. 
Alternatively treatment was continued until onset of overt diabetes or 25 weeks of 
age, allowing incidence of diabetes in our model to be determined. Diabetes was 
determined as a blood glucose level (BGL) >15mmol/L on 2 consecutive days 
(figure 5.5). 
Figure 5.4: NOD Diabetes incidence 
Cumulative diabetes incidence data was obtained showing diabetes incidence for NOD 
colonies housed at our facility monitored for BGL>15mmol/L for 2 consecutive days 
which was considered diabetic. Graph shows fraction of mice maintaining 
euglycaemia at each age in weeks. Courtesy of S. T. Grey and E. Marino1 
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Mice were treated until onset of overt diabetes, with initial onset for each group at 
approximately 15 weeks of age. Mice treated from 6 weeks of age with αCXCR3-
9C5 (6W start) were the exception to this trend with a single mouse becoming 
diabetic at 10 weeks of age. A similar incidence of diabetes was also seen for all 
groups with 50-60% of mice diabetic at 25 weeks of age. This revealed no significant 
effect of 1mg/kg αCXCR3-9C5 on the kinetic of diabetes development in the NOD 
mice, regardless of age of initial treatment (figure 5.6).   
To ensure the lack of effect on diabetes incidence was not due to the lower 1mg/kg 
αCXCR3-9C5 dose, compared to that used in allograft experiments, we also 
determined the efficacy of 2mg/kg αCXCR3-9C5 given from 6 weeks of age until 
onset of overt diabetes. No difference in diabetes incidence between mice treated 
with 1mg/kg or 2mg/kg was evident (figure 5.7). 
 
Figure 5.5: Autoimmune NOD Experimental Model 
Overview of experimental model including initial age of treatment (6 or 8 weeks of age) 
with isotype or αCXCR3-9C5 mAb administered 1mg/kg, every 4 days. Mice were 
monitored for onset of hyperglycaemia/diabetes (Incidence Study) or euthanised at 12 
weeks of age to examine pathology (Pathology Study). 
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Figure 5.6: αCXCR3-9C5 does not alter NOD Diabetes incidence 
NOD mice were treated from 6 weeks with 1mg/kg Isotype (  ) or αCXCR3-9C5 antibody 
(  ) or from 8 weeks with Isotype (■) or αCXCR3-9C5 antibody (■) every 4 days or 
untouched as controls (o). Blood glucose levels were monitored for a loss of euglycaemia 
and onset of diabetes, designated as BGL>15mmol/L for 2 consecutive days. Rates of 
diabetes in each group were monitored until 25 weeks of age and expressed as percent 
of normoglycaemic mice per group from 6-25 weeks of age. (n=7-18mice/group) 
Figure 5.7: Equivalent diabetes incidence for 1mg/kg or 2mg/kg αCXCR3-9C5  
NOD mice were treated every 4 days from 6 weeks with 1mg/kg (  ) or 2mg/kg (  ) αCXCR3-9C5 
antibody. Blood glucose levels were monitored for a loss of euglycaemia and onset of diabetes, 
designated as BGL>15mmol/L for 2 consecutive days. Rates of diabetes in each group were 
monitored until 25 weeks of age and expressed as percent of normoglycaemic mice per group from 
6-25 weeks of age. (n=5-13mice/group) 
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αCXCR3-9C5 does not alter Insulitis or Regulatory T cell Migration in the 
NOD mouse 
Although little difference was evident in diabetes incidence for αCXCR3-9C5 treated 
mice, markers of pathology including insulitis and changes in immune cell 
populations were examined due to the role of αCXCR3-9C5 in inhibiting 
chemotaxis. 
In mice treated with 1mg/kg αCXCR3-9C5 from 6 or 8 weeks until 12 weeks of age 
(pre-diabetic) (figure 5.8a), no significant difference in insulitis was seen compared 
to isotype treated mice. This was determined by insulitis grading as shown 
previously (figure 5.3), statistical analysis was performed by comparing the 
percentage of islets with grade 3 and 4 insulitis for each group. Although severity of 
insulitis in pre-diabetic mice was reduced for untreated controls compared to all 
other groups, this change was not significant when comparing severe insulitis 
(combined percent grade 3 and 4) between isotype or αCXCR3-9C5 treated and 
control groups (figure 5.8a).  
 
 
 
 
Figure 5.8: αCXCR3-9C5 does not affect NOD pancreatic insulitis  
Insulitis grading of H&E stained pancreata from NOD mice treated from 6 weeks or 8 
weeks of age with 1mg/kg αCXCR3-9C5 or isotype every 4 days or untreated as controls. 
(a) Insulitis at 12 weeks of age or (b) in diabetic mice graded as; grade 0 no infiltrate, 
grade 1 peri-insulitis, grade 2 <25% infiltrate, grade 3 >25% and grade 4 >75% infiltrate, 
expressed as percentage of islets scored per grade (>40 islets/group, n=3-7mice/group). 
Significance determined for % grade 3+4 insulitis for αCXCR3-9C5 vs. isotype for each age 
matched group was found to be non-significant (paired t-Test). 6-12 W = 0.5490, 8-12W 
=0.0894, 6-diabetic = 0.2823, 8-diabetic = 0.6792. 
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Further, mice treated with 1mg/kg αCXCR3-9C5 from either 6 or 8 weeks of age 
until onset of overt diabetes showed no significant difference in insulitis compared to 
isotype treated or control mice (figure 5.8b). 
Regulatory T cells play an important role in restraining progression of effector cell 
mediated destruction in the NOD pancreas
281
. Due to the previously described role of 
CXCR3 in recruitment of Foxp3+ Treg into the pancreas during diabetes in the NOD 
model
217
 we examined Treg infiltration into the pre-diabetic NOD pancreas. 
Foxp3 positively stained cells within the NOD pancreas were enumerated from 
histological sections of pancreata harvested from mice treated with 1mg/kg 
αCXCR3-9C5 or isotype antibody from 6 or 8 weeks until 12 weeks of age or 
untreated controls. Representative histological images of pre-diabetic NOD islets, 
grade 3, are shown with Foxp3+ stained cells in brown for Isotype and αCXCR3-
9C5 treated mice (figure 5.9a).  
Few Foxp3+ T cells were found within the exocrine tissue and as such only Foxp3 
positively stained cells associated with islet infiltrate were counted. Cells were 
enumerated for 3 non-contiguous sections of pancreas and the average number of 
Foxp3+ cells counted per islet for each mouse were expressed as individual data 
points (figure 5.9b). Infiltration of Foxp3 positively stained cells did not show 
significant differences when comparing αCXCR3-9C5 and respective isotype 
antibody treated groups or untreated controls for mice treated either from 6 or 8 
weeks of age. The frequency of Foxp3+ staining was also found to generally be 
higher for islets with more severe insulitis. However, considerable variation in the 
average number of Foxp3+ cells within mice from each group exists.  
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αCXCR3-9C5 reduces CXCR3 but not CD44 expression in the NOD mouse 
Due to the well characterised role of CXCR3 in mediating immune cell migration, 
lymphocyte populations in these NOD mice were also investigated
3,22,23
. Assessment 
of the frequency of cells expressing free CXCR3, through binding of CXCR3-173 
antibody, and changes in overall cell populations within the spleen, distal lymph 
node (dLN) and pancreatic LN (pLN) were performed using flow cytometry. Pre-
diabetic NOD mice treated from 6 or 8 weeks of age with 1mg/kg αCXCR3-9C5 or 
Figure 5.9: αCXCR3-9C5 does not affect NOD pancreatic regulatory T cell Infiltrate 
(a) Representative Immunohistochemistry of Foxp3+ stained sections of Isotype and 
αCXCR3-9C5 treated pre-diabetic (12 week old) NOD pancreas. Foxp3+ stained cells, shown 
in brown.  
(b) Foxp3+ regulatory T cell quantification as average Foxp3+ cells per islet for 3 non-
contiguous sections of pancreas for each NOD mouse, treated from 6 weeks or 8 weeks of 
age with 1mg/kg αCXCR3-9C5 or isotype every 4 days until 12 weeks of age or untreated 
as controls. Each data point represents average number of Foxp3+ cells per islet for each 
mouse. (n=4-5 mice/group) 
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Isotype every 4 days, until 12 weeks of age or untreated as controls were euthanised 
and tissues harvested for flow cytometry. 
Lymphocytes were analysed for T cell subsets; CD4+, CD4+CD25+Foxp3+, 
CD4+CD25-Foxp3+ or CD8+ T cells and for NK cells. No difference in the total 
number of any cell population for mice treated with αCXCR3-9C5 was evident in the 
spleen, dLN and pLN compared to controls (figure 5.10 & 5.11). 
Pre-diabetic mice treated with αCXCR3-9C5 from 6 weeks of age showed no 
apparent difference in expression of free CXCR3 for CD4+, CD4+CD25+Foxp3+ 
(Treg) T cells or for NK cells in any of the tissues examined, compared to isotype 
controls. Differences in free unbound CXCR3 were evident in the spleen and pLN 
for CD4+CD25-Foxp3+ Treg (figure 5.10b & f) and in the spleen for CD8+ T cells 
(figure 5.11a) for mice treated from 6 weeks with αCXCR3-9C5 compared to isotype 
controls although due to low group number these were not significant. 
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Figure 5.10: Pre-diabetic NOD αCXCR3 Treatment – CD4+ T cell & CD4+Foxp3+ T cell 
analysis 
NOD mice treated from 6 or 8 weeks of age with 1mg/kg Isotype (grey triangles 6weeks or 
squares 8 weeks) or αCXCR3-9C5 antibody (black triangles  6weeks or squares 8 weeks) every 4 
days or untouched as controls (white circles) until 12 weeks of age. CD4 T cells and their 
respective CXCR3 expression, determined via CXCR3-173 binding, were determined in the (a) 
spleen, (b) distal LN and (c) pancreatic LN. Treg (Foxp3+CD25+ and Foxp3+CD25-) cells and 
their respective CXCR3 expression, determined via CXCR3-173 binding, was assessed in the (d) 
spleen, (e) distal LN and (f) pancreatic LN. Results are expressed as total number of 
lymphocytes (n=2-4mice/group) 
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Figure 5.11: Pre-diabetic NOD αCXCR3 Treatment – CD8+ T cell & NK cell analysis 
NOD mice treated from 6 or 8 weeks of age with 1mg/kg grey triangles 6weeks or squares 8 
weeks) or αCXCR3-9C5 antibody (black triangles 6weeks or squares 8 weeks) every 4 days or 
untouched as controls (white circles) until 12 weeks of age. CD8 T cells and their respective 
CXCR3 expression, determined via CXCR3-173 binding, were determined in the (a) spleen, (b) 
distal LN and (c) pancreatic LN. NK cells and their respective CXCR3 expression, determined 
via CXCR3-173 binding, was determined in the (d) spleen, (e) distal LN and (f) pancreatic LN. 
Results are expressed as total number of lymphocytes (n=2-4mice/group) 
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Mice treated from 8 weeks of age with αCXCR3-9C5 showed reduced free CXCR3 
on CD4+ and CD4+CD25+Foxp3+ cells in the spleen (figure 5.10a & b) and for 
CD4+CD25-Foxp3+ cells in the spleen and dLN (figure 5.10b & d), compared to 
respective isotype controls. In addition free, unbound CXCR3 was reduced for CD8+ 
T cells in the spleen (figure 5.11a) and for NK cells in the spleen and dLN (figure 
5.11d & e) for mice treated from 8 weeks of age with αCXCR3-9C5 compared to 
isotype controls. These changes were non-significant due to small group size. 
Finally, due to changes in CD44 expression seen in C57BL/6 naïve mice and 
BALB/c to C57BL/6 islet allograft model, we tested if αCXCR3-9C5 treatment in 
the NOD model would produce a similar change. Analysis of CD44 expression and 
expression of free CXCR3 in the spleens of NOD mice treated with 1mg/kg 
αCXCR3-9C5 (grey shaded, figure 5.12) from 6 weeks of age was compared to 
splenocytes from both isotype and control (black figure 5.12) treated mice. As shown 
previously (chapter 4, figure 4.4) a reduction in CXCR3-173 binding was evident for 
αCXCR3-9C5 treated mice compared to control or isotype treated mice, however 
their respective CD44 expression was not different. This indicates a differential 
effect of αCXCR3-9C5 in the C57BL/6 allograft model compared to that seen in the 
NOD model and may offer an explanation as to the beneficial effects seen in the 
allograft but not the autoimmune NOD model.  
 
 
Figure 5.12: Unaltered activation of NOD 
splenocytes 
Representative histograms of CD4+ and 
CD8+ T cell CXCR3 and CD44 expression 
for pre-diabetic NOD mice treated from 6 
weeks of age with 1mg/kg αCXCR3-9C5 i.v. 
(grey shaded) or isotype controls (black). 
αCXCR3-9C5 in the NOD Islet Allograft Model 
 
103 
 
Summary & Conclusions  
Here we studied the effect of αCXCR3-9C5 in a mouse model of autoimmune 
diabetes due to the role of CXCR3 in migration of immune cells to sites of 
inflammation
3,22
. CXCR3 and its ligands are also upregulated within the serum of 
individuals with type 1 diabetes
214,228-231,233,282
. Finally we were interested in the 
effect of our anti-CXCR3 antibody in this model due to the variable effects of 
inhibiting CXCR3 in previous literature
124,217
.   
In NOD mice validation of diabetes incidence rates is important as diabetes 
incidence is strongly influenced by environment (diet and microbial infections) and 
thus diabetes incidence in the NOD is known to vary between facilities
75
. Diabetes 
incidence in our NOD colony was consistent with previous literature with 50-60% of 
our NOD cohort showing overt diabetes by 25 weeks of age. Incidence rates of 60% 
at 25 weeks have been previously documented by our facility
280
. 
Here we found that treatment with αCXCR3-9C5 had no ameliorating or detrimental 
effect on the incidence or onset of diabetes in NOD mice. This is in contrast to 
previous studies in the NOD mouse showing an accelerated onset of diabetes 
following genetic deletion of CXCR3. 
Within the NOD mouse we have shown that αCXCR3-9C5 does not alter disease 
outcomes with respect to the ability of cells to migrate into the pancreas, pancreatic 
LN, distal LN or spleen of treated compared to control mice. This was evident 
through unaltered insulitis for pre-diabetic and diabetic NOD mice, as well as a lack 
of changes in T and NK cell populations within primary and secondary lymphoid 
tissues. In particular no change in the ability of Foxp3+ regulatory T cells to infiltrate 
the pancreas was evident. This is in stark contrast to results of Yamada et al., which 
showed the CXCR3-/- NOD mice had impaired pancreatic infiltration by Foxp3+ 
regulatory T cells. This difference in Foxp3+ cell accumulation may explain the 
differential effects seen between our study and results for CXCR3-/- NOD mice
217
. 
Of note, studies by Yamada et al. showed a very low diabetes incidence of 20-25% at 
25 weeks of age indicating a low disease penetrance within these transgenic mice. 
This may indicate that the breeding of this transgenic line altered the genetics of the 
NOD mice which predispose to diabetes development and as such may not be a good 
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model of diabetes. Together our results show treatment with αCXCR3-9C5is safe for 
use in the autoimmune NOD mouse model of type 1 diabetes. 
Interestingly although basal expression of free CXCR3 in T cell subsets were seen to 
increase from 6 to 12 weeks of age, expression remained below that seen in C57BL/6 
islet allograft recipient mice. These results, as well as the lack of effect of αCXCR3-
9C5 administration on immune cell infiltration of the pancreas or CD44 expression 
suggest that CXCR3 may be dispensable for development of autoimmune diabetes in 
the NOD mouse model. Additionally these results may indicate involvement of other 
chemokine signalling pathways in the pathogenesis of diabetes in the NOD model, 
such as CCR2 and CCR5
283,284
.   
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Chapter 6. αCXCR3-9C5 in the NOD Islet Allograft Model 
Unlike results found in a previous study showing an acceleration of diabetes in a 
CXCR3 knockout NOD mouse
217
, we showed no deleterious or beneficial effect of 
our αCXCR3-9C5 antibody in the autoimmune NOD mouse model. However we 
have shown a clear prolongation of MHC mismatched islet allograft survival upon 
treatment with our αCXCR3-9C5 antibody. For this reason we proceeded to test the 
efficacy of the antibody in a model of MHC mismatched islet allograft (BALB/c, 
H2
d
) into diabetic NOD mice (H2
g7
, BGL 8-19mmol/L). Islet allograft is used 
clinically to treat patients with unmanageable autoimmune diabetes, which involves a 
combined autoimmune and allogeneic immune response, both of which are present in 
this mouse model. 
 
 
 
 
 
Figure 6.1: NOD Allogeneic Experimental Model 
Overview of experimental model including monitoring of diabetic NOD mice for 
BGL>7mmol/L followed by receipt of a MHC mismatched BALB/c islet allograft and 
treatment with isotype or αCXCR3-9C5 mAb +/- rapamycin. Mice were monitored for 
onset of hyperglycaemia indicating loss of graft function, see graph of typical BGL over 
the course of rejection. 
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Mice were treated with one of 5 regimens including; 2mg/kg isotype (2) or 
αCXCR3-9C5 (3) antibody once per week, sub-therapeutic Rapamycin 
(0.5mg/kg)(4) once per day for the first 7 days of transplant or a combination of 
2mg/kg αCXCR3-9C5 (1/week) with sub-therapeutic Rapamycin (0.5mg/kg, 1/day 
for 7 days)(5). An untreated control group (1) was also included. Rapamycin was 
administered i.p. and αCXCR3-9C5 or isotype antibody was administered i.v. (figure 
6.1). 
αCXCR3-9C5 Prolongs autoimmune NOD Islet Allograft Survival  
Following transplantation of diabetic NOD mice, untreated control and isotype 
treated mice showed rapid islet allograft rejection, with a MST of 4 and 5 days 
respectively. In comparison allograft survival for mice treated with 2mg/kg 
αCXCR3-9C5 was significantly prolonged with a MST of 8 days and one mouse 
surviving to day 28 post-transplant (figure 6.2).  
Mice treated with rapamycin also showed prolonged allograft survival with a MST of 
11 days compared to control mice. However when low dose rapamycin and 
αCXCR3-9C5 antibody treatments were combined, similarly to that seen for the 
C57BL/6 allografts (chapter 4, figure 4.15), graft survival was substantially 
improved. Mice receiving once weekly αCXCR3-9C5 combined with rapamycin 
once per day for the first week following transplant showed a MST of 35 days with 
long-term survival in 1 out of 5 mice, surviving to day 90 post-transplant (figure 6.2). 
Allograft survival was determined as the number of post-operative days maintaining 
euglycaemia before onset of hyperglycaemia (BGL>15mmol/L for 2 consecutive 
days) indicating loss of the islet allograft (figure 6.3).  
An additional group of pre-diabetic NOD mice received a variation of the combined 
αCXCR3-9C5 and rapamycin therapy to determine if this altered regimen could 
improve graft survival. These mice received a BALB/c islet allograft, as above, and 
treatment from the day of allograft with 2mg/kg αCXCR3-9C5 1/week and 0.5mg/kg 
rapamycin, 1 per day for 1 week followed by treatment every 2
nd
 day for 1 week (2 
weeks total). 
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Islet allografts were lost, as determined by onset of hyperglycaemia, at day 6, 7 and 
17 for these mice (figure 6.4, black diamonds). However two mice treated with this 
regimen survived >75days, but upon nephrectomy failed to become hyperglycaemic 
(figure 6.4, white diamonds). This indicates that the graft was not the source of 
insulin in these mice suggesting maintenance of pancreatic beta cell function. Mice 
were followed for 10 days post nephrectomy to confirm this result followed by 
euthanasia and collection of tissues for histology and flow cytometry to discern the 
mechanism behind this allograft independent long-term survival. Lack of residual 
islet mass in the kidney was confirmed by H&E staining with only mild infiltrate and 
no islet structures remaining (figure 6.5). 
Figure 6.2: αCXCR3-9C5 Prolongs NOD Islet Allograft Survival 
Kaplan-Meier survival curves of BALB/c (H2d) islet graft transplant into diabetic NOD 
(H2g7) recipients (BGL 8-19mmol/L). Recipients were left untreated or treated with 
Isotype (2mg/kg, 1/week, i.v.), αCXCR3-9C5 antibody (2mg/kg, 1/week, i.v.), rapamycin 
(0.5mg/kg, 1/day for 7 days i.p.) or a combination of αCXCR3-9C5 (2mg/kg, 1/week) 
with sub-therapeutic rapamycin (0.5mg/kg, 1/day for 7 days). Allograft survival was 
determined as the number of post-operative days maintaining euglycaemia before onset 
of hyperglycaemia (BGL>15mmol/L, >2 days) indicating loss of allograft. p<0.05* for 
αCXCR3-9C5 vs. Isotype (n=4-6mice/group). 
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Figure 6.3: αCXCR3-9C5 NOD Islet Allograft  
Blood glucose levels of NOD recipients of BALB/c (H2d) islet allograft from the day of 
transplant until loss of allograft (BGL> 15mmol/L) for mice treated with (a) untreated 
control, (b) Isotype (2mg/kg, 1/week, i.v.), (c) αCXCR3-9C5 antibody (2mg/kg, 1/week, 
i.v.), (d) rapamycin (0.5mg/kg for 7 days i.p.) (e) αCXCR3-9C5 (2mg/kg, 1/week) + 
rapamycin (0.5mg/kg, 1/day, 7days) (n=3-5mice/group) 
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Figure 6.4: αCXCR3-9C5 NOD Islet Allograft Long-term survival  
Blood glucose levels of NOD recipients of BALB/c (H2d) islet allograft from the day of 
transplant for mice treated with αCXCR3-9C5 (2mg/kg, 1/week) + rapamycin (0.5mg/kg, 
1/day, 7days + 1 every 2 days for 7days). Islet allograft recipients monitored until loss of 
allograft (BGL> 15mmol/L)(black) or maintained euglycaemia and received nephrectomy 
at day >75 (white) (n=5mice) 
 
Figure 6.5. αCXCR3-9C5 NOD Islet Allograft Long-term survival shows minimal islet 
insulin staining 
Kidney and pancreas histology from 2 NOD recipients of BALB/c (H2d) islet allograft, 
treated with αCXCR3-9C5 (2mg/kg, 1/week) + rapamycin (0.5mg/kg, 1/day, 7days + 1 
every 2 days for 7days) which maintained euglycaemia following nephrectomy. H&E 
stained sections of kidney, H&E and Insulin stained sections of pancreatic islets and insulin 
staining of acinar tissue containing insulin positively stained cells. 
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Curiously no significant change in the proportions of T cell or NK cell subsets were 
detected through flow cytometry in the spleen, dLN or pLN (data not shown). In 
addition, although islets were found within the pancreas of these mice showing minor 
if any infiltrate, islets showed very little insulin staining (figure 6.5). However we 
did identify regions of acinar tissue, which stained positive for insulin and appeared 
to have residual beta cells post islet destruction. This pattern of recovery of 
euglycaemia in NOD mice post combined immunomodulation and islet allograft has 
been shown previously and may offer an explanation as to these results, see summary 
& conclusions
285-288
. 
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Summary & Conclusions  
Previous literature looking at the role of CXCR3 in models of islet allograft rejection 
have yet to examine the effects of deletion or antibody blockade in a combined 
model of islet allograft transplant into diabetic NOD mice. As a result of the efficacy 
and safety shown for our αCXCR3-9C5 mAb in islet allograft (chapter 4) and 
diabetes models (chapter 5), respectively, we examined the effect of our antibody in 
a model of islet allograft into diabetic NOD mice.  
Here we show for the first time efficacy of an anti-CXCR3 antibody therapy in a 
mouse model of diabetic islet allograft. Similarly to that seen in the C57BL/6 islet 
allograft recipients (chapter 4, figure 4.15), NOD mice showed prolonged graft 
survival upon treatment with αCXCR3-9C5 with a synergistic effect observed when 
treated in combination with low-dose rapamycin. Further both αCXCR3-9C5 
treatments, alone or in combination with low-dose rapamycin, lead to a small 
proportion of islet allograft recipients exhibiting significantly longer survival. 
Together we show the potential of αCXCR3-9C5 treatment for use as part of a 
combination immunosuppressive therapy for use in islet allograft recipients with type 
1 diabetes. 
Of note we have also shown recovery of euglycaemia for two NOD islet allograft 
recipients, which received a combination of αCXCR3-9C5 and rapamycin. Although 
BGLs of these mice were below 15mmol/L at transplant, NOD mice would be 
expected to proceed to onset of overt diabetes due to autoimmune destruction of 
residual pancreatic beta cell mass. However here we show that these mice, upon 
receipt of an islet allograft, maintained euglycaemia for over 75 days but did not 
become hyperglycaemic upon islet graft removal via nephrectomy. Previous papers 
showing immunomodulation with complete Freunds adjuvant (CFA) and islet 
allograft transplantation of diabetic NOD recipients have reported a similar 
phenomenon. These papers attributed euglycaemia post nephrectomy to regeneration 
or maintenance of residual beta cell mass with one paper suggesting CFA and islet 
allograft transplant skewed the balance of beta cell autoimmune destruction and beta 
cell replication toward replication resulting in recovery of euglycaemia
285-288
. Further 
as with results found in our mice Suri et al. indicated that although mice maintained 
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euglycaemia, few islets were present (6% or less) and only some were insulin 
positive
286
.  
This phenomenon has also been found to occur in humans. In a single case study of 
an individual with type 1 diabetes who had received a whole pancreas transplant, 
islets were found to be insulin negative, however single insulin positive cells were 
found within the native pancreas suggestive of beta cell regeneration
289
. Further a 
previous study by Liu et al. investigated the role of immunosuppression combined 
with islet or whole pancreas transplant in patients with type 1 diabetes, showing a 
small but detectable amount of C-peptide was produced by the native pancreas a 
number of years after transplant
290
.  
Although this occurred in only a small subset of mice in our study it suggests that in 
addition to prolongation of survival of islet allografts, combined immunomodulation 
with low dose rapamycin and αCXCR3-9C5 antibody may promote survival and 
replication of residual beta cell mass allowing maintenance of euglycaemia and this 
may also be applicable in humans although further investigation of this result is 
required
285-288
.  
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Chapter 7. Clarifying the Role of αCXCR3-9C5 
Finally of interest to us was the mechanism behind the effects of αCXCR3-9C5 in 
models of islet transplant. Previous studies on CXCR3 mAbs have focused primarily 
on disease outcomes with little examination of molecular mechanism. In vivo mixed 
lymphocyte reactions (MLR) were performed using transfer of CFSE labelled whole 
splenocytes from naïve C57BL/6 mice into sub-lethally irradiated BALB/c mice. 
Mice were also administered 2mg/kg i.v. αCXCR3-9C5 or untreated as controls. The 
spleens of these mice were then harvested 72 hours later and analysed by flow 
cytometry for changes in proliferation and activation markers, particularly for CD44 
expression. CD44 is a marker of T cell development and activation with a high 
expression on effector and memory T cell subsets. CD44 is also involved in cell-cell 
interactions, adhesion and migration of activated cells
291
.  
Firstly proliferation of both CD4 and CD8 T cells was evident from CFSE dilution 
with the right-most peak showing un-proliferated cells and successive peaks showing 
generation of proliferated cells (figure 7.1a & 7.2a). Activation of proliferated cells, 
indicated by up-regulation of CD44 expression and downregulation of CD62L 
expression in proliferated compared to un-proliferated cells, was also evident. No 
difference was evident in CD4+ or CD8+ T cell proliferation or expression of 
CXCR3 or CD62L for both proliferated and non-proliferated cells for αCXCR3-9C5 
treated (grey shaded histogram) compared to cells from control mice (black unfilled 
histogram) (figure 7.1a & 7.2a). Expression of CD4+CD44, CD44 MFI and CD4+ T 
cell subsets (CD44-CD62L+, CD44+CD62L+, CD44+CD62L) was also not different 
for αCXCR3-9C5 treated cells compared to controls (black unfilled histogram), for 
proliferated and non-proliferated T cells (figure 7.1a, b, c). 
In contrast CD8+ T cells treated with αCXCR3-9C5 (grey shaded histogram, figure 
7.2a), showed a significantly reduced expression of CD44, similar to that seen in the 
C57BL/6 allograft model (chapter 4, figure 4.13), compared to untreated controls 
(black unfilled histogram, figure 7.2a). This was particularly evident in non-
proliferated cells with reduced CD44 MFI compared to controls (figure 7.2b). 
Further when the frequency of CD8+ memory (CD44+CD62L+) T cells was 
examined following αCXCR3-9C5 treatment, a reduced frequency of non-
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proliferated memory CD8+ T cells was evident compared to untreated control cells 
(figure 7.2d).  
 
 
Figure 7.1: αCXCR3-9C5 treatment does not alter CD4+ T cell proliferation or 
activation  
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Figure 7.1: αCXCR3-9C5 treatment does not alter CD4+ T cell proliferation or 
activation  
Analysis of CD4+ T cell proliferation and activation from sublethally irradiated BALB/c 
recipients of C57BL/6 CFSE labelled splenocytes, treated with 2mg/kg αCXCR3-9C5 or 
controls at 72hours post cell transfer. a) Representative histograms of CFSE proliferation 
and activation markers (CXCR3, CD62L and CD44) and b) Mean fluorescence intensity 
(MFI) for CD44 expression for proliferated and non-proliferated cells: αCXCR3-9C5 treated 
(grey shaded histogram) or control mice (black, unfilled histogram). c) Representative 
FACS plots of mean frequencies for CD4+ T cell subsets (CD44-CD62L+, CD44+CD62L+, 
CD44+CD62L-) for non-proliferated and proliferated αCXCR3-9C5 treated and control T 
cells and d) frequencies of CD4+ T cell subsets from c)  (n=4/group for 2 repeat 
experiments). 
Figure 7.2: αCXCR3-9C5 treatment alters expression of CD8+ CD44high T cells 
Analysis of CD8+ T cell proliferation and activation from sublethally irradiated BALB/c 
recipients of C57BL/6 CFSE labelled splenocytes, treated with 2mg/kg αCXCR3-9C5 or 
controls at 72hours post cell transfer. a) Representative histograms of CFSE proliferation 
and activation markers (CXCR3, CD62L and CD44) and b) Mean fluorescence intensity 
(MFI) for CD44 expression for proliferated and non-proliferated cells from αCXCR3-9C5 
treated (grey shaded) or control mice (black, unfilled). c) Representative FACS plots 
displaying mean frequencies for CD8+ T cell subsets (CD44-CD62L+, CD44+CD62L+, 
CD44+CD62L-) for non-proliferated and proliferated αCXCR3-9C5 treated and control T 
cells and d) frequencies of CD8+ T cell subsets from c)  (n=4/group for 2 repeat 
experiments). 
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Figure 7.2: αCXCR3-9C5 treatment alters expression of CD8+ CD44high T cells 
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Summary & Conclusions 
Here we show a role of CXCR3 in regulating expression of CD44 on CD8+ but not 
CD4+ T cells. Use of in vivo MLR revealed reduced CD44 expression without 
affecting CD62L expression or the ability of these cells to proliferate following 
αCXCR3-9C5 treatment. Interestingly mice administered with αCXCR3-9C5 
antibody showed no difference in CXCR3 expression at 72hours post i.v. compared 
to untreated control expression. This may result from a high turnover of the CXCR3 
receptor under conditions of alloantigen stimulation, which involves receptor 
degradation and de novo synthesis of new receptor for surface expression
292
.  
While a greater proportion of cells which have proliferated express CD44, compared 
to those cells which are undivided, the effect of blockade of CXCR3 via αCXCR3-
9C5 treatment appears to preferentially affect CD44 expression on non-proliferated 
CD8+ T cells (figure 7.2a). These untreated, undivided CD44 high CD8+ T cells 
may represent a subset of undivided, naive cells, which are becoming activated and 
will go on to proliferate and differentiate into memory and effector T cell subsets.  
The effect on CD8+ T cell CD44 expression appears to particularly affect non-
proliferated CD8+CD44+CD62L+ memory T cells. The reduction in non-
proliferated CD44 high CD8+ T cells also appears to cause a non-significant 
decrease in the frequency of CD8+ memory (CD44+CD62L+) cells. This may result 
through a reduced frequency of activated parent cells, which subsequently divide into 
this memory subset. In the context of allograft immune response this reduction in 
CD44 expression resulted in decreased frequencies of effector and memory CD8+ T 
cells. CD44 expression also plays an important role in T cell migration to sites of 
infection or injury and reduced expression may impede migration and activation of 
these cells. Together this reduction in CD8+CD44+ T cells, presumably memory or 
effector CD8 T cells, likely contributed to the prolonged islet allograft survival seen 
upon treatment with αCXCR3-9C5 (figure 4.16). 
This may highlight an important clinical application for αCXCR3-9C5 antibody 
targeting CD8+ memory T cells, which are poorly targeted by current 
immunosuppressive therapies
244,293-296
. These cells are instrumental in the allograft 
rejection response with CD8+ memory T cells found to infiltrate and produce IFN-γ 
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within the first 24 hours following transplant. IFN-γ then stimulates donor 
chemokine release, CXCL9 and CXCL10, recruiting effector T cells to the allograft 
and promoting rejection
213,244,272
. Although this memory subset plays a critical role in 
allograft rejection, these cells display unique cell surface markers and costimulatory 
requirements, as well as distinct trafficking and activation profiles
297
. As such naïve 
T cells are effectively depleted using ATG or aletuzumab and their activation and 
proliferation blocked by co-stimulation blockade therapies, such as anti-CTLA4, 
anti-CD40L and anti-CD154 antibodies, while memory T cells are resistant to these 
immunosuppressive therapies
244,293-296
. Additionally, non-allograft specific, viral 
memory responses have been found to impede allograft tolerance induction, which 
were also co-stimulation blockade resistant
298
. 
Interestingly a marker common to CD8+ effector, central memory and effector 
memory T cells is the up-regulated expression of CXCR3, which presents an 
appealing therapeutic target for each of these cell types involved in mediating the 
allograft rejection response
299-301
. 
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Chapter 8. Discussion 
Overview  
The major aim of our studies was to delineate the function of a novel anti-CXCR3 
monoclonal antibody, which targets a conserved epitope of CXCR3 found in a 
number of species including mice and humans. Due to prior studies showing efficacy 
of CXCR3 deletion and blockade in models of allograft transplantation
200,216
 we 
investigated the role of our αCXCR3-9C5 mAb in a MHC mismatched islet 
transplant. In addition islet allograft transplantation is used clinically in individuals 
with type 1 diabetes. This application warranted further investigation into the 
efficacy of αCXCR3-9C5 as a rejection prophylaxis in mouse models of islet 
allograft transplantation into diabetic autoimmune NOD recipients, as well as in a 
model of spontaneous autoimmune diabetes alone.  
This thesis explores the efficacy of αCXCR3-9C5 mediated blockade of CXCR3 
signalling for the prolongation of allograft survival in both autoimmune and non-
autoimmune mouse models. However within the NOD model of autoimmune type 1 
diabetes, we found no effect of antagonism of CXCR3 using our αCXCR3-9C5 mAb 
suggesting the effect is specific to the allogeneic, but not the autoimmune response. 
Allograft Transplantation 
Several studies have highlighted a strong correlation between increased expression of 
CXCR3 and its chemokine ligands with processes of human allograft rejection, as 
well as T1D
178-180,182,214,228,229,302
. In support of those findings our data also highlight 
an important role for CXCR3 mediated signalling in the allograft rejection response. 
This has been show previously in heart, lung, skin and islet allograft models. In all 
those studies, including ours, blockade of CXCR3 reduced the recruitment of 
immune cells to the graft site, resulting in a significant delay in allograft loss (figure 
4.16, 4.17)
200,213,216,245-247,252
.  
Here we show that similarly to other islet allograft studies antagonism of CXCR3 
signalling resulted in a prolonged islet allograft survival
216,252
.  We also found that 
within long-term surviving islet allografts, which showed preserved islet architecture 
and strong insulin staining, only minimal immune infiltrate was present. This 
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infiltrate was restricted to the graft periphery, suggesting impaired immune cell 
infiltration. Previous literature has highlighted the importance of CXCR3 signalling 
in immune cell migration, with inhibition of this signalling pathway by antibody 
blockade or gene silencing, decreasing infiltration and inflammation within the graft 
and resulting in enhanced allograft survival
200,213,216
. Further investigation of the 
ability of immune cells to infiltrate the graft in the acute response following 
treatment with αCXCR3-9C5 will provide further evidence to confirm a role for 
αCXCR3-9C5 in impaired immune cell recruitment to the graft.  
T cell Activation & Regulatory T Cells 
While the majority of previous studies exclusively investigated the impact of CXCR3 
blockade on chemotaxis
200,216,252
, we have also examined a possible role for altered T 
cell activation or regulatory T cell accumulation in the enhanced survival of islet 
allografts. Interestingly, although a role for CXCR3 mediated T cell activation has 
been described previously it has yet to be investigated within models of allograft 
rejection
192,219,299
. CXCR3 was previously shown to be involved in immune cell 
activation and proliferation in a model of type 1 IFN induced T cell stimulation. 
CXCR3 mediated signals induced the up-regulation of activation markers CD25 and 
CD69 on CD8 T cells, as well as promoting CD8 T cell proliferation, particularly for 
CD44
low 
CD8+ T cells
192
.  
We show here that αCXCR3-9C5 mediated antagonism of CXCR3 signalling in un-
transplanted and islet allograft recipients as well as under conditions of in vivo MLR, 
resulted in a decreased proportion of CD8+ T cells with high CD44 expression. This 
resulted in a significantly reduced number of CD8 effector and memory T cells, both 
important contributors to the allograft rejection response
244,270-272
. Although a role for 
CXCR3 in CD44 expression has not yet been shown it is possible that CXCR3 
signalling may directly or indirectly affect T cell activation and CD44 expression. 
Moreover other studies have shown a critical role for CXCR3 in the co-localisation 
of T cells and DC within the splenic marginal zone, as well as the ability to form 
long-lasting cell-cell interactions with virally infected cells
220,303
. Antagonism of 
CXCR3 may therefore result in altered T cell activation that could account for the 
decreased CD44 expression seen. This co-localisation and activation has been shown 
to favour CD8+ T cell expression of cytotoxic markers, perforin and granzyme 
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B
219,221
. Although we have yet to investigate the phenotype or function of our 
αCXCR3-9C5 treated CD8+ T cells it is possible that they may also show reduced 
cytotoxicity, contributing to graft survival.  
In addition to a role in T cell activation our results suggest that the improved survival 
of αCXCR3-9C5 treated islet allograft recipient mice is also dependent on 
CD4+CD25+Foxp3+ regulatory T cells. These regulatory T cells have been well 
characterised within the allograft immune responses to confer protection and limit 
graft destruction
144,273,275
, and as such altered function of these cells was of interest. 
We found high numbers of Foxp3+ cells within the spleen and graft site of long-term 
surviving allograft recipients treated with αCXCR3-9C5 alone or in combination 
with low dose rapamycin. The involvement of CD25+Foxp3+ T cells is further 
supported by the loss of prolonged islet allograft survival in αCXCR3-9C5 treated 
mice upon co-treatment with a CD25 depleting antibody (PC61). Finally, cell 
transfer experiments from long-term surviving mice show improved islet allograft 
survival in the presence of CD25+ T cells compared to those mice transferred CD25 
depleted T cells.   
 
Use of the CD25 depleting antibody (PC61) has been previously shown to effectively 
deplete the CD4+CD25+Foxp3+ population of regulatory T cells, with up to 90% 
depletion for 2-3 weeks post-injection
261
. This allows the protective role of Treg in 
the allograft immune response to be determined. A limitation to this method 
however, is the elimination of CD25+ cells, which are not Tregs and likely to play 
roles within the allograft immune response. This is particularly true for recently 
activated T cells expressing CD25
304
. An alternative method of eliminating Treg 
cells uses the transgenic DEREG mouse (depletion of regulatory T cells), expressing 
the diphtheria toxin (DT) receptor under the control of the Foxp3 locus, and 
providing selective depletion of Foxp3+ Treg
305,306
. Future studies may further 
clarify the roles of Tregs in this model using a more specific approach, such as the 
DREG mouse. 
Of note the clinically used immunosuppressive agent used in these studies, 
rapamycin, has been shown to differentially affect effector and regulatory T cells. 
Rapamycin has been shown to promote the induction of regulatory T cells while 
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blocking activation and proliferation of effector T cells
279,307
. As a result, we propose 
that the effects of rapamycin synergise with the impaired chemotaxis and activation 
of T cells driven by αCXCR3-9C5, leading to enhanced regulatory and impaired 
effector and memory T cell responses; resulting in enhanced islet allograft survival. 
We also show that treatment of mice with αCXCR3-9C5 alone is able to 
significantly prolong islet allograft survival and cause long-term survival in a small 
proportion of these mice, with a notable increase in regulatory T cells. This 
represents a novel mechanism by which CXCR3 may affect activation of the 
allograft immune response and will be investigated further in future experiments. 
Allograft transplantation in the NOD mouse 
The role of CXCR3 blockade in the clinically applicable model of islet allograft 
transplantation into a recipient with pre-established autoimmune T1D has not yet be 
characterised in the literature. To do this we employed islet allograft into the NOD 
mouse model of type 1 diabetes. Due to the involvement of both autoimmune and 
alloimmune response within this model the kinetic of rejection in isotype or control 
treated mice was significantly faster than that of the non-autoimmune allograft 
model.  Upon investigation of the efficacy of our novel αCXCR3-9C5 antibody 
within this model, a single antibody administration was found to significantly 
prolong survival of the allograft. Additionally, as seen in the non-autoimmune 
allograft model, a synergistic effect was seen when αCXCR3-9C5 was administered 
in combination with low dose rapamycin, further enhancing islet allograft survival. 
Together this shows promise for clinical application of αCXCR3-9C5 within the 
context of islet allograft transplantation into autoimmune recipients with T1D.  
The NOD Mouse 
Given the combined autoimmune and alloimmune nature of this NOD islet allograft 
transplant model and previous literature on accelerated disease in CXCR3-/- NOD 
mice, the effect of αCXCR3-9C5 within an autoimmune diabetes model alone was of 
interest. Within autoimmune models of type 1 diabetes the role of CXCR3 is less 
well characterised. Virally induced models using the RIP-LCMV system (Chapter 1, 
animal models) initially showed a substantial role of CXCR3 for the recruitment of 
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immune cells into the pancreas
124
. However, further characterisation of this model 
using both deletion and antibody blockade of CXCR3 and its chemokine CXCL10 
though suggest that the CXCR3 signalling axis contributes only minimally to viral 
induced diabetes and suggests redundancy within the chemokine system may account 
for this difference
124,236
. The spontaneous onset model of diabetes using the NOD 
mouse has also shown differential effects when targeting the CXCR3 signalling 
pathway. Firstly CXCL10, which is produced by the islets themselves, has been 
shown to inhibit beta cell proliferation through CXCR3 independent auto/paracrine 
signalling
66,235
. As such, inhibition of CXCL10 was found to reduce diabetes 
incidence. However, upon CXCR3 deletion in a NOD mouse model, diabetes onset 
was found to be accelerated. This was attributed to an inability of CD4+Foxp3+ 
regulatory T cells to traffic from the pancreatic lymph node into the pancreas
217
. 
Investigation using antibody blockade rather than complete deletion of the CXCR3 
receptor has not previously been examined. We show here for the first time that use 
of antibody mediated blockade of CXCR3 signalling within the NOD mouse model 
has no effect on the onset or incidence of diabetes in our model. Furthermore no 
change in the frequency of immune cells, including Foxp3+ Treg cells were seen in 
the spleen, distal or pancreatic lymph nodes; in αCXCR3-9C5 treated mice compared 
to controls. Nor was the ability of immune cells or Foxp3+ T cells to infiltrate the 
pancreas different. 
Results seen for Yamada et al. using CXCR3 deficient NOD mice differ significantly 
from those found using our αCXCR3-9C5 antibody. This differential effect of 
transient antibody blockade compared to complete deletion is not unique, as seen in 
studies on CTLA-4, a critical negative regulator of T cell activation. Mouse studies 
using genetic deletion of the CTLA-4 gene showed high levels of lymphocyte 
accumulation within lymphoid and non-lymphoid tissues including the heart, which 
showed myocardial lesions. These mice died at 3-4weeks of age, likely due to this 
myocarditis and uncontrolled T cell activation
259
. In contrast use of CTLA-4-Ig 
antibody blockade has shown considerable benefit for the treatment of tumours and 
is now used in human trials. CTLA-4 antibodies (e.g. ipilimumab) used in cancer, 
function through loss of the CTLA-4 co-inhibitory signal, enhancing co-stimulatory 
signalling of T cells and the resulting anti-tumour response. This antibody mediated 
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blockade has relatively minor symptoms compared to those seen for CTLA-4 
knockout mice
256-258
. From this it is evident that although previous literature shows a 
deleterious role for CXCR3 deletion in the NOD mouse this does not preclude the 
therapeutic potential of an anti-CXCR3 antibody. In this case we show safety of 
αCXCR3-9C5 in a mouse model of diabetes with potential for use in an islet 
transplant context. 
Conclusion 
In conclusion we have characterised a novel αCXCR3-9C5 monoclonal antibody 
within models of islet allograft and autoimmune type 1 diabetes. Our findings 
support a role for CXCR3 signalling within the allograft immune response as 
previously described.  We also establish that CXCR3 signalling in this model 
participates in additional, previously uncharacterised, functions involved in T cell 
activation and regulatory T cell activity. We have also shown safety and efficacy for 
use of αCXCR3-9C5 in models of autoimmune diabetes and islet allograft, 
respectively, in the NOD mouse model. This is important due to inconsistency and 
potentially detrimental effects seen within previous literature as to the effects of 
CXCR3 inhibition within this model of T1D. Further, prior to this study investigation 
of the role of CXCR3 blockade in a combined autoimmune islet allograft model had 
not been performed.  
We propose that αCXCR3-9C5 may be a viable option for use clinically in islet 
transplantation into individuals with type 1 diabetes. Following islet allograft, in both 
the non-autoimmune C57BL/6 and in the autoimmune NOD mouse, αCXCR3-9C5 
treatment shows a considerable benefit in prolonging allograft survival. Further, in 
contrast to previous studies, blockade of CXCR3 signalling using this antibody does 
not aggravate the autoimmune pathophysiology of the NOD mouse. Additionally due 
to the conserved nature of the epitope of CXCR3 which αCXCR3-9C5 targets, there 
is potential for efficient translation of the antibody into the clinic, by humanising the 
antibody. This study supports further investigation into the use of αCXCR3-9C5 as a 
more targeted therapeutic strategy, with potentially reduced toxicity or side effects 
than conventional immunosuppression, for use as part of a combination therapy in 
clinical islet allograft.                   
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